{"f415c477bac80d18eec2b6775efd8d660a7688ba": [["To successfully infect, replicate, and persist in the host, viruses have evolved numerous strategies to take control of multiple cellular processes, including those that target transmembrane (TM) signal transduction mediated by immune receptors.", [["cellular", "ANATOMY", 129, 137], ["transmembrane", "ANATOMY", 177, 190], ["cellular", "CELL", 129, 137], ["transmembrane", "CELLULAR_COMPONENT", 177, 190], ["TM", "GENE_OR_GENE_PRODUCT", 192, 194], ["immune receptors", "GENE_OR_GENE_PRODUCT", 228, 244], ["TM", "PROTEIN", 192, 194], ["immune receptors", "PROTEIN", 228, 244], ["viruses", "PROBLEM", 60, 67], ["multiple cellular processes", "PROBLEM", 120, 147], ["target transmembrane (TM) signal transduction", "TREATMENT", 170, 215], ["infect", "OBSERVATION", 16, 22], ["multiple", "OBSERVATION_MODIFIER", 120, 128], ["cellular processes", "OBSERVATION", 129, 147]]], ["Despite tremendous advancement in recent years, the exact molecular mechanisms underlying these critical points in viral pathogenesis remain unknown.", [["tremendous advancement", "TREATMENT", 8, 30], ["viral pathogenesis", "PROBLEM", 115, 133], ["tremendous", "OBSERVATION_MODIFIER", 8, 18], ["viral pathogenesis", "OBSERVATION", 115, 133]]], ["In this Opinion, based on a novel model of immune signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, I suggest specific mechanisms used by different viruses such as human immunodeficiency virus (HIV), cytomegalovirus (CMV), severe acute respiratory syndrome coronavirus (SARS-CoV), herpesvirus saimiri (HVS), human herpesvirus 6 (HHV-6), etc., to modulate the host immune response mediated by members of the family of multichain immune recognition receptors (MIRRs).", [["human immunodeficiency virus (HIV), cytomegalovirus (CMV)", "DISEASE", 181, 238], ["acute respiratory syndrome coronavirus", "DISEASE", 247, 285], ["SARS-CoV), herpesvirus saimiri (HVS)", "DISEASE", 287, 323], ["human immunodeficiency virus", "ORGANISM", 181, 209], ["HIV", "ORGANISM", 211, 214], ["cytomegalovirus", "ORGANISM", 217, 232], ["CMV", "ORGANISM", 234, 237], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 240, 285], ["SARS-CoV", "ORGANISM", 287, 295], ["herpesvirus saimiri", "ORGANISM", 298, 317], ["HVS", "ORGANISM", 319, 322], ["human herpesvirus 6", "ORGANISM", 325, 344], ["HHV-6", "ORGANISM", 346, 351], ["multichain immune recognition receptors", "GENE_OR_GENE_PRODUCT", 434, 473], ["MIRRs", "GENE_OR_GENE_PRODUCT", 475, 480], ["multichain immune recognition receptors", "PROTEIN", 434, 473], ["MIRRs", "PROTEIN", 475, 480], ["human immunodeficiency virus (HIV", "SPECIES", 181, 214], ["herpesvirus saimiri", "SPECIES", 298, 317], ["human", "SPECIES", 325, 330], ["herpesvirus", "SPECIES", 331, 342], ["HHV-6", "SPECIES", 346, 351], ["human immunodeficiency virus", "SPECIES", 181, 209], ["HIV", "SPECIES", 211, 214], ["CMV", "SPECIES", 234, 237], ["severe acute respiratory syndrome coronavirus", "SPECIES", 240, 285], ["SARS-CoV", "SPECIES", 287, 295], ["herpesvirus saimiri", "SPECIES", 298, 317], ["HVS", "SPECIES", 319, 322], ["human herpesvirus 6 (HHV-6", "SPECIES", 325, 351], ["immune signaling", "PROBLEM", 43, 59], ["different viruses", "PROBLEM", 155, 172], ["human immunodeficiency virus", "PROBLEM", 181, 209], ["HIV)", "PROBLEM", 211, 215], ["cytomegalovirus (CMV)", "PROBLEM", 217, 238], ["severe acute respiratory syndrome coronavirus (SARS-CoV)", "PROBLEM", 240, 296], ["herpesvirus saimiri (HVS", "PROBLEM", 298, 322], ["human herpesvirus", "PROBLEM", 325, 342], ["HHV", "TEST", 346, 349], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["respiratory syndrome coronavirus", "OBSERVATION", 253, 285]]], ["I also demonstrate how the SCHOOL model, together with the lessons learned from viral pathogenesis, can be used practically for rational drug design and the development of new therapies for immune disorders.", [["immune disorders", "DISEASE", 190, 206], ["viral pathogenesis", "PROBLEM", 80, 98], ["rational drug design", "TREATMENT", 128, 148], ["new therapies", "TREATMENT", 172, 185], ["immune disorders", "PROBLEM", 190, 206]]]], "7b430982b2fc7bb7b3e56ad2b58bb42a431985f6": [["IntroductionBioaerosols, which are aerosols of biological origin, may include intact microorganisms and/or parts or products of organisms [1] .", [["IntroductionBioaerosols", "TREATMENT", 0, 23], ["intact microorganisms", "PROBLEM", 78, 99], ["organisms", "PROBLEM", 128, 137]]], ["Among them, airborne viruses, bacteria, and fungi have been investigated actively because airborne pathogens are readily transmitted by airflow and can cause a variety of diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD), influenza, and severe acute respiratory syndrome (SARS) [2] [3] [4] [5] .IntroductionOver the last several decades, much effort has been devoted to develop efficient bioaerosol control methods and devices, including thermal methods [6] [7] [8] , ultraviolet irradiation [9] [10] [11] , antimicrobial filters [12, 13] , and titanium dioxide catalysis [14, 15] .", [["pulmonary", "ANATOMY", 238, 247], ["allergic rhinitis", "DISEASE", 191, 208], ["asthma", "DISEASE", 210, 216], ["chronic obstructive pulmonary disease", "DISEASE", 218, 255], ["COPD", "DISEASE", 257, 261], ["influenza", "DISEASE", 264, 273], ["acute respiratory syndrome", "DISEASE", 286, 312], ["SARS", "DISEASE", 314, 318], ["ultraviolet", "CHEMICAL", 510, 521], ["titanium dioxide", "CHEMICAL", 587, 603], ["titanium dioxide", "CHEMICAL", 587, 603], ["pulmonary", "ORGAN", 238, 247], ["2] [3] [4] [5]", "SIMPLE_CHEMICAL", 321, 335], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 496, 507], ["[9] [10] [11]", "SIMPLE_CHEMICAL", 534, 547], ["[12, 13]", "SIMPLE_CHEMICAL", 572, 580], ["titanium dioxide", "SIMPLE_CHEMICAL", 587, 603], ["airborne viruses", "PROBLEM", 12, 28], ["bacteria", "PROBLEM", 30, 38], ["fungi", "PROBLEM", 44, 49], ["airborne pathogens", "PROBLEM", 90, 108], ["a variety of diseases", "PROBLEM", 158, 179], ["allergic rhinitis", "PROBLEM", 191, 208], ["asthma", "PROBLEM", 210, 216], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 218, 262], ["influenza", "PROBLEM", 264, 273], ["severe acute respiratory syndrome", "PROBLEM", 279, 312], ["efficient bioaerosol control methods", "TREATMENT", 420, 456], ["thermal methods", "TREATMENT", 480, 495], ["ultraviolet irradiation", "TREATMENT", 510, 533], ["antimicrobial filters", "TREATMENT", 550, 571], ["titanium dioxide catalysis", "TREATMENT", 587, 613], ["airborne viruses", "OBSERVATION", 12, 28], ["diseases", "OBSERVATION", 171, 179], ["allergic rhinitis", "OBSERVATION", 191, 208], ["asthma", "OBSERVATION", 210, 216], ["chronic", "OBSERVATION_MODIFIER", 218, 225], ["obstructive", "OBSERVATION_MODIFIER", 226, 237], ["pulmonary", "ANATOMY", 238, 247], ["disease", "OBSERVATION", 248, 255], ["COPD", "OBSERVATION", 257, 261], ["severe", "OBSERVATION_MODIFIER", 279, 285], ["acute", "OBSERVATION_MODIFIER", 286, 291], ["respiratory syndrome", "OBSERVATION", 292, 312]]], ["Among these, antimicrobial air filtration technologies are considered promising because they are easily applied to conventional air-conditioning systems.", [["antimicrobial air filtration technologies", "TREATMENT", 13, 54]]], ["Previous studies have shown that air filtration technologies employing antimicrobial inorganic nanoparticles are effective in controlling bacterial aerosols.", [["inorganic nanoparticles", "CHEMICAL", 85, 108], ["antimicrobial inorganic nanoparticles", "SIMPLE_CHEMICAL", 71, 108], ["Previous studies", "TEST", 0, 16], ["air filtration technologies", "TREATMENT", 33, 60], ["antimicrobial inorganic nanoparticles", "TREATMENT", 71, 108], ["air filtration", "OBSERVATION", 33, 47], ["bacterial aerosols", "OBSERVATION", 138, 156]]], ["The antimicrobial efficacies of such systems depend on the exposure time, particle size, and concentration [16, 17] .", [["such systems", "PROBLEM", 32, 44], ["antimicrobial efficacies", "OBSERVATION", 4, 28], ["size", "OBSERVATION_MODIFIER", 83, 87]]], ["In particular, silver (Ag) nanoparticles are antimicrobial agents with a broad antimicrobial spectrum.", [["silver", "CHEMICAL", 15, 21], ["Ag", "CHEMICAL", 23, 25], ["silver", "CHEMICAL", 15, 21], ["Ag", "CHEMICAL", 23, 25], ["silver (Ag) nanoparticles", "SIMPLE_CHEMICAL", 15, 40], ["silver (Ag) nanoparticles", "TREATMENT", 15, 40], ["antimicrobial agents", "TREATMENT", 45, 65], ["a broad antimicrobial spectrum", "TREATMENT", 71, 101]]], ["Ag nanoparticles damage bacterial cell membranes and induce metabolic changes by decreasing enzyme activity [18, 19] .", [["cell membranes", "ANATOMY", 34, 48], ["Ag", "CHEMICAL", 0, 2], ["Ag", "CHEMICAL", 0, 2], ["Ag nanoparticles", "SIMPLE_CHEMICAL", 0, 16], ["bacterial cell", "CELL", 24, 38], ["membranes", "CELLULAR_COMPONENT", 39, 48], ["Ag nanoparticles damage bacterial cell membranes", "PROBLEM", 0, 48], ["induce metabolic changes", "PROBLEM", 53, 77], ["decreasing enzyme activity", "PROBLEM", 81, 107], ["nanoparticles damage", "OBSERVATION", 3, 23], ["bacterial cell membranes", "OBSERVATION", 24, 48], ["metabolic changes", "OBSERVATION", 60, 77], ["decreasing", "OBSERVATION_MODIFIER", 81, 91]]], ["Due to the outstanding antimicrobial activity of these materials, they have been extensively studied and applied in a variety of fields including indoor air quality (IAQ) and human health, air filtration, clothing manufacturing, electronics, food processing, cosmetics, and medical devices [20, 21] .", [["human", "ORGANISM", 175, 180], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["air filtration", "TREATMENT", 189, 203], ["clothing manufacturing", "TREATMENT", 205, 227], ["air filtration", "OBSERVATION", 189, 203]]], ["Similarly, copper (Cu) nanoparticles are widely known as antimicrobial substances.", [["copper", "CHEMICAL", 11, 17], ["Cu", "CHEMICAL", 19, 21], ["copper", "CHEMICAL", 11, 17], ["Cu", "CHEMICAL", 19, 21], ["copper (Cu) nanoparticles", "SIMPLE_CHEMICAL", 11, 36], ["copper (Cu) nanoparticles", "TREATMENT", 11, 36], ["antimicrobial substances", "TREATMENT", 57, 81], ["antimicrobial substances", "OBSERVATION", 57, 81]]], ["Previous studies showed that Staphylococcus aureus, Escherichia coli, Bacillus subtilis, Klebsiella pneumoniae, and Pseudomonas aeruginosa are sensitive to Cu nanoparticles [22] .", [["Staphylococcus aureus", "DISEASE", 29, 50], ["Cu", "CHEMICAL", 156, 158], ["Cu", "CHEMICAL", 156, 158], ["Staphylococcus aureus", "ORGANISM", 29, 50], ["Escherichia coli", "ORGANISM", 52, 68], ["Bacillus subtilis", "ORGANISM", 70, 87], ["Klebsiella pneumoniae", "ORGANISM", 89, 110], ["Pseudomonas aeruginosa", "ORGANISM", 116, 138], ["Cu nanoparticles", "SIMPLE_CHEMICAL", 156, 172], ["Staphylococcus aureus", "SPECIES", 29, 50], ["Escherichia coli", "SPECIES", 52, 68], ["Bacillus subtilis", "SPECIES", 70, 87], ["Klebsiella pneumoniae", "SPECIES", 89, 110], ["Pseudomonas aeruginosa", "SPECIES", 116, 138], ["Staphylococcus aureus", "SPECIES", 29, 50], ["Escherichia coli", "SPECIES", 52, 68], ["Bacillus subtilis", "SPECIES", 70, 87], ["Klebsiella pneumoniae", "SPECIES", 89, 110], ["Pseudomonas aeruginosa", "SPECIES", 116, 138], ["Previous studies", "TEST", 0, 16], ["Staphylococcus aureus", "PROBLEM", 29, 50], ["Escherichia coli", "PROBLEM", 52, 68], ["Bacillus subtilis", "PROBLEM", 70, 87], ["Klebsiella pneumoniae", "PROBLEM", 89, 110], ["Pseudomonas aeruginosa", "PROBLEM", 116, 138], ["Staphylococcus aureus", "OBSERVATION", 29, 50], ["Escherichia coli", "OBSERVATION", 52, 68], ["Klebsiella pneumoniae", "OBSERVATION", 89, 110]]], ["Carbon nanotubes (CNTs) have also been applied to the control of water quality and IAQ.", [["Carbon nanotubes", "CHEMICAL", 0, 16], ["CNTs", "CHEMICAL", 18, 22], ["Carbon", "CHEMICAL", 0, 6], ["Carbon nanotubes", "SIMPLE_CHEMICAL", 0, 16], ["IAQ", "SIMPLE_CHEMICAL", 83, 86], ["Carbon nanotubes (CNTs", "TREATMENT", 0, 22]]], ["In their aquatic dispersion, CNTs showed strong antimicrobial activities as the reduction in bacterial viability reached a maximum of~6 log, and in combination with Ag nanoparticles enhanced the antimicrobial activity of air filters.", [["CNTs", "CHEMICAL", 29, 33], ["Ag", "CHEMICAL", 165, 167], ["Ag", "CHEMICAL", 165, 167], ["CNTs", "SIMPLE_CHEMICAL", 29, 33], ["Ag nanoparticles", "SIMPLE_CHEMICAL", 165, 181], ["strong antimicrobial activities", "PROBLEM", 41, 72], ["bacterial viability", "PROBLEM", 93, 112], ["Ag nanoparticles", "TREATMENT", 165, 181], ["air filters", "TREATMENT", 221, 232], ["aquatic dispersion", "OBSERVATION", 9, 27], ["strong", "OBSERVATION_MODIFIER", 41, 47], ["antimicrobial activities", "OBSERVATION", 48, 72], ["reduction", "OBSERVATION_MODIFIER", 80, 89], ["bacterial viability", "OBSERVATION", 93, 112], ["antimicrobial activity", "OBSERVATION", 195, 217], ["air filters", "OBSERVATION", 221, 232]]], ["CNTs in direct contact with bacterial cells induce membrane damage and subsequent cell death.", [["cells", "ANATOMY", 38, 43], ["membrane", "ANATOMY", 51, 59], ["cell", "ANATOMY", 82, 86], ["CNTs", "CHEMICAL", 0, 4], ["death", "DISEASE", 87, 92], ["CNTs", "SIMPLE_CHEMICAL", 0, 4], ["cells", "CELL", 38, 43], ["membrane", "CELLULAR_COMPONENT", 51, 59], ["cell", "CELL", 82, 86], ["bacterial cells", "CELL_TYPE", 28, 43], ["bacterial cells", "PROBLEM", 28, 43], ["membrane damage", "PROBLEM", 51, 66], ["subsequent cell death", "PROBLEM", 71, 92], ["membrane damage", "OBSERVATION", 51, 66], ["cell death", "OBSERVATION", 82, 92]]], ["Single-walled CNTs are more toxic to bacteria than multi-walled CNTs [23] [24] [25] .IntroductionDespite these advantages, inorganic nanoparticles [26, 27] can exert adverse effects on health [28] [29] [30] .", [["multi-walled CNTs", "CHEMICAL", 51, 68], ["inorganic nanoparticles [26, 27]", "CHEMICAL", 123, 155], ["Single-walled CNTs", "SIMPLE_CHEMICAL", 0, 18], ["multi-walled CNTs [23] [24] [25]", "SIMPLE_CHEMICAL", 51, 83], ["inorganic nanoparticles", "SIMPLE_CHEMICAL", 123, 146], ["Single-walled CNTs", "TREATMENT", 0, 18], ["multi-walled CNTs", "TEST", 51, 68], ["inorganic nanoparticles", "TREATMENT", 123, 146], ["more toxic", "OBSERVATION_MODIFIER", 23, 33]]], ["Previous studies have indicated that Ag nanoparticles are toxic to mammalian cells and certain organs because of transcutaneous penetration of the particles.", [["cells", "ANATOMY", 77, 82], ["organs", "ANATOMY", 95, 101], ["Ag", "CHEMICAL", 37, 39], ["Ag", "CHEMICAL", 37, 39], ["Ag nanoparticles", "SIMPLE_CHEMICAL", 37, 53], ["mammalian cells", "CELL", 67, 82], ["organs", "ORGAN", 95, 101], ["mammalian cells", "CELL_TYPE", 67, 82], ["Previous studies", "TEST", 0, 16], ["Ag nanoparticles", "PROBLEM", 37, 53], ["toxic to mammalian cells", "PROBLEM", 58, 82], ["transcutaneous penetration of the particles", "PROBLEM", 113, 156]]], ["Copper oxide nanoparticles induce DNA damage and oxidative stress in cells [31] [32] [33] [34] .", [["cells", "ANATOMY", 69, 74], ["Copper oxide", "CHEMICAL", 0, 12], ["Copper oxide", "CHEMICAL", 0, 12], ["Copper oxide nanoparticles", "SIMPLE_CHEMICAL", 0, 26], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["cells", "CELL", 69, 74], ["Copper oxide nanoparticles", "TREATMENT", 0, 26], ["DNA damage", "PROBLEM", 34, 44], ["oxidative stress in cells", "PROBLEM", 49, 74]]], ["Various toxicity mechanisms for CNTs have been reported, including the interruption of transmembrane electron transfer, penetration of the cell envelope, and oxidation of cell components [35, 36] .", [["transmembrane", "ANATOMY", 87, 100], ["cell", "ANATOMY", 139, 143], ["cell", "ANATOMY", 171, 175], ["toxicity", "DISEASE", 8, 16], ["CNTs", "SIMPLE_CHEMICAL", 32, 36], ["cell", "CELL", 139, 143], ["cell", "CELL", 171, 175], ["Various toxicity mechanisms", "PROBLEM", 0, 27], ["transmembrane electron transfer", "TREATMENT", 87, 118], ["the cell envelope", "TREATMENT", 135, 152]]], ["Moreover, long-term exposure or inhalation of these nanoparticles can lead to a reduction in respiratory functions [37, 38] .IntroductionTo overcome these disadvantages, alternative air filtration technologies employing natural antimicrobial materials have been proposed [39] [40] [41] .", [["respiratory", "ANATOMY", 93, 104], ["[39] [40] [41]", "SIMPLE_CHEMICAL", 271, 285], ["long-term exposure", "TREATMENT", 10, 28], ["these nanoparticles", "TREATMENT", 46, 65], ["a reduction in respiratory functions", "PROBLEM", 78, 114], ["these disadvantages", "TREATMENT", 149, 168], ["alternative air filtration technologies", "TREATMENT", 170, 209], ["natural antimicrobial materials", "TREATMENT", 220, 251], ["reduction", "OBSERVATION_MODIFIER", 80, 89], ["respiratory functions", "OBSERVATION", 93, 114]]], ["Natural products, such as plant extracts, are typically less toxic relative to inorganic antimicrobial materials [42] .", [["extracts", "ANATOMY", 32, 40], ["Natural products", "TREATMENT", 0, 16], ["inorganic antimicrobial materials", "TREATMENT", 79, 112]]], ["Natural-product nanoparticles consist of multiple compounds with various chemical properties.", [["Natural-product nanoparticles", "TREATMENT", 0, 29], ["multiple", "OBSERVATION_MODIFIER", 41, 49], ["compounds", "OBSERVATION", 50, 59]]], ["Depending on the extract and the nature of the material, these properties can include antibiotic activities such as anti-inflammatory, antiviral, and/or antimicrobial effects [43] [44] [45] [46] .", [["extract", "ANATOMY", 17, 24], ["[43] [44] [45] [46]", "SIMPLE_CHEMICAL", 175, 194], ["antibiotic activities", "TREATMENT", 86, 107], ["anti-inflammatory, antiviral", "TREATMENT", 116, 144], ["antimicrobial effects", "TREATMENT", 153, 174]]], ["Many natural antimicrobial products have been discovered, including extracts from Ratibida latipalearis, Teloxys graveolens, Dodonaea viscosa, Hyptis albida, Melaleuca alternifolia (tea tree oil), and Sophora flavescens [47] [48] [49] [50] .", [["extracts", "ANATOMY", 68, 76], ["oil", "ANATOMY", 191, 194], ["extracts", "ORGANISM_SUBSTANCE", 68, 76], ["Ratibida latipalearis", "ORGANISM", 82, 103], ["Teloxys graveolens", "ORGANISM", 105, 123], ["Dodonaea viscosa", "ORGANISM", 125, 141], ["Hyptis albida", "ORGANISM", 143, 156], ["Melaleuca alternifolia", "ORGANISM", 158, 180], ["tea tree oil", "ORGANISM", 182, 194], ["Sophora flavescens", "ORGANISM", 201, 219], ["[47] [48] [49] [50]", "SIMPLE_CHEMICAL", 220, 239], ["Ratibida latipalearis", "SPECIES", 82, 103], ["Teloxys graveolens", "SPECIES", 105, 123], ["Dodonaea viscosa", "SPECIES", 125, 141], ["Hyptis albida", "SPECIES", 143, 156], ["Melaleuca alternifolia", "SPECIES", 158, 180], ["tea", "SPECIES", 182, 185], ["Sophora flavescens", "SPECIES", 201, 219], ["Ratibida latipalearis", "SPECIES", 82, 103], ["Teloxys graveolens", "SPECIES", 105, 123], ["Dodonaea viscosa", "SPECIES", 125, 141], ["Hyptis albida", "SPECIES", 143, 156], ["Melaleuca alternifolia (tea tree oil)", "SPECIES", 158, 195], ["Sophora flavescens", "SPECIES", 201, 219], ["Many natural antimicrobial products", "TREATMENT", 0, 35], ["antimicrobial products", "OBSERVATION", 13, 35]]], ["In addition, various chemical compounds contained in natural products have been shown to control bacterial metabolism.", [["various chemical compounds", "PROBLEM", 13, 39], ["natural products", "TREATMENT", 53, 69], ["bacterial metabolism", "PROBLEM", 97, 117], ["various", "OBSERVATION_MODIFIER", 13, 20], ["chemical compounds", "OBSERVATION", 21, 39], ["bacterial metabolism", "OBSERVATION", 97, 117]]], ["Recently, reports detailing the control of bacterial aerosols using natural-product nanoparticles have shown that extracted essential oils can reduce bacterial loads when applied to contaminated ventilation systems [51] .", [["oils", "ANATOMY", 134, 138], ["bacterial aerosols", "TREATMENT", 43, 61], ["natural-product nanoparticles", "TREATMENT", 68, 97], ["bacterial loads", "PROBLEM", 150, 165]]], ["Air filters coated with tea tree oil inactivated~99% of bacteria on their surface within 2-8 min.", [["tea tree oil", "ANATOMY", 24, 36], ["surface", "ANATOMY", 74, 81], ["tea tree", "CHEMICAL", 24, 32], ["tea", "ORGANISM", 24, 27], ["oil", "ORGANISM_SUBSTANCE", 33, 36], ["Air filters", "TREATMENT", 0, 11], ["tea tree oil", "TREATMENT", 24, 36], ["bacteria", "PROBLEM", 56, 64]]], ["Filters coated with S. flavescens nanoparticles inactivated >91% of bacteria within 2 min [12, 41, 51] .IntroductionIn this study, a Euscaphis japonica extract was used to produce natural-product nanoparticles that were deposited onto air filters.", [["Euscaphis japonica extract", "CHEMICAL", 133, 159], ["S. flavescens", "ORGANISM", 20, 33], ["Euscaphis japonica", "ORGANISM", 133, 151], ["nanoparticles", "SIMPLE_CHEMICAL", 196, 209], ["S. flavescens", "SPECIES", 20, 33], ["Euscaphis japonica", "SPECIES", 133, 151], ["S. flavescens", "SPECIES", 20, 33], ["Euscaphis japonica", "SPECIES", 133, 151], ["Filters coated", "TREATMENT", 0, 14], ["S. flavescens nanoparticles", "TEST", 20, 47], ["bacteria", "PROBLEM", 68, 76], ["this study", "TEST", 119, 129], ["a Euscaphis japonica extract", "TREATMENT", 131, 159], ["natural-product nanoparticles", "TREATMENT", 180, 209], ["air filters", "OBSERVATION", 235, 246]]], ["Extracts of E. japonica, a tree grown in Northeastern Asia, are an ingredient in traditional herbal medicines used primarily to treat inflammation [52] .", [["Extracts", "ANATOMY", 0, 8], ["inflammation", "DISEASE", 134, 146], ["Extracts", "ORGANISM_SUBSTANCE", 0, 8], ["E. japonica", "ORGANISM", 12, 23], ["E. japonica", "SPECIES", 12, 23], ["E. japonica", "SPECIES", 12, 23], ["traditional herbal medicines", "TREATMENT", 81, 109], ["inflammation", "PROBLEM", 134, 146], ["E. japonica", "OBSERVATION_MODIFIER", 12, 23], ["tree", "OBSERVATION_MODIFIER", 27, 31]]], ["Several antibiotic activities of E. japonica have been reported, including anti-fibrotic [53] , antiproliferative, and antimutagenic activities [54] .", [["E. japonica", "ORGANISM", 33, 44], ["E. japonica", "SPECIES", 33, 44], ["E. japonica", "SPECIES", 33, 44], ["Several antibiotic activities", "TREATMENT", 0, 29], ["E. japonica", "PROBLEM", 33, 44], ["antiproliferative", "TREATMENT", 96, 113]]], ["However, the antimicrobial activity of E. japonica when used in an air filtration system has not been reported.", [["E. japonica", "ORGANISM", 39, 50], ["E. japonica", "SPECIES", 39, 50], ["E. japonica", "SPECIES", 39, 50], ["E. japonica", "PROBLEM", 39, 50], ["an air filtration system", "TREATMENT", 64, 88], ["antimicrobial activity", "OBSERVATION", 13, 35], ["air", "OBSERVATION", 67, 70]]], ["E. japonica nanoparticles were produced by a nebulization-thermal drying process [55, 56] .", [["E. japonica", "ORGANISM", 0, 11], ["nanoparticles", "ORGANISM", 12, 25], ["E. japonica", "SPECIES", 0, 11], ["E. japonica", "SPECIES", 0, 11], ["E. japonica nanoparticles", "TREATMENT", 0, 25], ["a nebulization-thermal drying process", "TREATMENT", 43, 80], ["japonica nanoparticles", "OBSERVATION", 3, 25]]], ["The characteristics of E. japonica nanoparticle-coated filters were evaluated in terms of filtration efficiency, pressure drop, and antimicrobial activity under various particle deposition conditions.", [["E. japonica", "ORGANISM", 23, 34], ["E. japonica", "SPECIES", 23, 34], ["E. japonica", "SPECIES", 23, 34], ["E. japonica nanoparticle", "TREATMENT", 23, 47], ["coated filters", "TREATMENT", 48, 62], ["filtration efficiency", "PROBLEM", 90, 111], ["pressure drop", "PROBLEM", 113, 126], ["antimicrobial activity", "TREATMENT", 132, 154], ["various particle deposition conditions", "TREATMENT", 161, 199], ["filtration efficiency", "OBSERVATION", 90, 111], ["pressure drop", "OBSERVATION", 113, 126], ["antimicrobial activity", "OBSERVATION", 132, 154], ["particle deposition", "OBSERVATION", 169, 188]]], ["Additionally, the major components of the extract were analyzed using high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI/MS/MS) and the cytotoxicity of E. japonica was compared with that of a soluble nickel compound (SNC), a known human carcinogen.Materials and MethodsPreparation of Euscaphis japonica methanolic extract powder E. japonica was purchased from a plant extract bank at the Korea Research Institute of Bioscience & Biotechnology (KRIBB), dried at room temperature, and pulverized in a blender.", [["extract", "ANATOMY", 42, 49], ["nickel", "CHEMICAL", 247, 253], ["SNC", "CHEMICAL", 264, 267], ["Euscaphis japonica methanolic extract", "CHEMICAL", 331, 368], ["nickel", "CHEMICAL", 247, 253], ["E. japonica", "ORGANISM", 199, 210], ["nickel compound", "SIMPLE_CHEMICAL", 247, 262], ["SNC", "SIMPLE_CHEMICAL", 264, 267], ["human", "ORGANISM", 278, 283], ["Euscaphis japonica", "ORGANISM", 331, 349], ["E. japonica", "ORGANISM", 376, 387], ["E. japonica", "SPECIES", 199, 210], ["human", "SPECIES", 278, 283], ["Euscaphis japonica", "SPECIES", 331, 349], ["E. japonica", "SPECIES", 376, 387], ["E. japonica", "SPECIES", 199, 210], ["human", "SPECIES", 278, 283], ["Euscaphis japonica", "SPECIES", 331, 349], ["E. japonica", "SPECIES", 376, 387], ["high-performance liquid chromatography", "TEST", 70, 108], ["tandem mass spectrometry", "TEST", 133, 157], ["HPLC", "TEST", 159, 163], ["MS", "PROBLEM", 168, 170], ["MS", "PROBLEM", 171, 173], ["the cytotoxicity of E. japonica", "PROBLEM", 179, 210], ["a soluble nickel compound", "PROBLEM", 237, 262], ["a known human carcinogen", "PROBLEM", 270, 294], ["Materials", "TREATMENT", 295, 304], ["MethodsPreparation", "TREATMENT", 309, 327], ["Euscaphis japonica methanolic extract powder", "TREATMENT", 331, 375], ["major", "OBSERVATION_MODIFIER", 18, 23], ["carcinogen", "OBSERVATION", 284, 294]]], ["Pulverized E. japonica was extracted with methanol (106,009; Merck KGaA, Darmstadt, Germany) and sonicated for 3 days.", [["methanol", "CHEMICAL", 42, 50], ["methanol", "CHEMICAL", 42, 50], ["E. japonica", "ORGANISM", 11, 22], ["methanol", "SIMPLE_CHEMICAL", 42, 50], ["E. japonica", "SPECIES", 11, 22], ["E. japonica", "SPECIES", 11, 22], ["methanol", "TREATMENT", 42, 50], ["japonica", "ANATOMY", 14, 22]]], ["The extracts were passed through nonfluorescent cotton filters (0.45 \u03bcm pore size, 13 mm filter diameter; Smartpor GHP syringe filter, Woongki Science, Seoul, Republic of Korea) and concentrated in vacuo to yield the methanol extract.", [["extracts", "ANATOMY", 4, 12], ["pore", "ANATOMY", 72, 76], ["methanol", "CHEMICAL", 217, 225], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["The extracts", "TREATMENT", 0, 12], ["nonfluorescent cotton filters", "TREATMENT", 33, 62], ["0.45 \u03bcm pore size", "TREATMENT", 64, 81], ["13 mm filter diameter", "TREATMENT", 83, 104], ["Smartpor GHP syringe filter", "TREATMENT", 106, 133], ["the methanol extract", "TREATMENT", 213, 233], ["13 mm", "OBSERVATION_MODIFIER", 83, 88]]], ["After concentration, the extract was lyophilized for 24 h and the resulting E. japonica extract powder was stored at 5\u00b0C.Preparation of E. japonica nanoparticle-coated filtersAntimicrobial filters were coated with E. japonica nanoparticles.", [["extract", "ANATOMY", 25, 32], ["E. japonica", "ORGANISM", 76, 87], ["E. japonica", "ORGANISM", 136, 147], ["E. japonica", "ORGANISM", 214, 225], ["E. japonica", "SPECIES", 76, 87], ["E. japonica", "SPECIES", 136, 147], ["E. japonica", "SPECIES", 214, 225], ["E. japonica", "SPECIES", 76, 87], ["E. japonica", "SPECIES", 136, 147], ["E. japonica", "SPECIES", 214, 225], ["the extract", "TREATMENT", 21, 32], ["the resulting E. japonica extract powder", "TREATMENT", 62, 102], ["E. japonica nanoparticle-coated filters", "TREATMENT", 136, 175], ["Antimicrobial filters", "TREATMENT", 175, 196], ["E. japonica nanoparticles", "TREATMENT", 214, 239], ["japonica nanoparticles", "OBSERVATION", 217, 239]]], ["Then 0.25 g of E. japonica extract powder was dissolved in 40 mL of methanol and filtered through a 0.45-\u03bcm cellulose acetate membrane filter (National Scientific Co., Rockwood, TN, USA) to remove insoluble residues.", [["E. japonica extract", "CHEMICAL", 15, 34], ["cellulose acetate", "CHEMICAL", 108, 125], ["methanol", "CHEMICAL", 68, 76], ["acetate", "CHEMICAL", 118, 125], ["E. japonica", "ORGANISM", 15, 26], ["methanol", "SIMPLE_CHEMICAL", 68, 76], ["E. japonica", "SPECIES", 15, 26], ["E. japonica", "SPECIES", 15, 26], ["E. japonica extract powder", "TREATMENT", 15, 41], ["methanol", "TREATMENT", 68, 76], ["a 0.45-\u03bcm cellulose acetate membrane filter", "TREATMENT", 98, 141], ["insoluble residues", "PROBLEM", 197, 215]]], ["Fig 1 (A) shows the experimental setup for the fabrication of nanoparticle-coated filters.", [["the experimental setup", "TREATMENT", 16, 38], ["the fabrication of nanoparticle-coated filters", "TREATMENT", 43, 89], ["coated filters", "OBSERVATION", 75, 89]]], ["Twenty milliliters of the above E. japonica solution was poured into a one-jet Collison nebulizer (BGI Inc., Waltham, MA, USA).", [["E. japonica", "ORGANISM", 32, 43], ["E. japonica", "SPECIES", 32, 43], ["E. japonica", "SPECIES", 32, 43], ["the above E. japonica solution", "TREATMENT", 22, 52], ["a one-jet Collison nebulizer", "TREATMENT", 69, 97]]], ["The nebulizer was supplied with 1 L/min of HEPAfiltered air under 1 psig.", [["The nebulizer", "TREATMENT", 0, 13], ["HEPAfiltered air", "TREATMENT", 43, 59]]], ["The resulting E. japonica aerosol was passed through an activated carbon absorber, mixed with 9 L/min of clean and dry air, and passed through a thermal glass quartz tube heater to remove methanol.", [["methanol", "CHEMICAL", 188, 196], ["carbon", "CHEMICAL", 66, 72], ["quartz", "CHEMICAL", 159, 165], ["methanol", "CHEMICAL", 188, 196], ["E. japonica", "ORGANISM", 14, 25], ["methanol", "SIMPLE_CHEMICAL", 188, 196], ["E. japonica", "SPECIES", 14, 25], ["E. japonica", "SPECIES", 14, 25], ["The resulting E. japonica aerosol", "TREATMENT", 0, 33], ["an activated carbon absorber", "TREATMENT", 53, 81], ["clean and dry air", "TREATMENT", 105, 122], ["a thermal glass quartz tube heater", "TREATMENT", 143, 177], ["methanol", "TREATMENT", 188, 196], ["carbon absorber", "OBSERVATION", 66, 81], ["dry air", "OBSERVATION", 115, 122], ["quartz tube", "OBSERVATION", 159, 170]]], ["The size and number concentration of the fabricated natural-product nanoparticles were measured using a wide-range particle spectrometer (WPS-100XP; MSP Co., Minneapolis, MN, USA) calibrated to a size range of 10-10,000 nm.", [["the fabricated natural-product nanoparticles", "TREATMENT", 37, 81], ["WPS", "TEST", 138, 141], ["size", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 13, 19], ["concentration", "OBSERVATION_MODIFIER", 20, 33], ["natural", "OBSERVATION_MODIFIER", 52, 59], ["nanoparticles", "OBSERVATION_MODIFIER", 68, 81], ["size", "OBSERVATION_MODIFIER", 196, 200]]], ["The particle morphology was examined using a scanning electron microscope (200 NANO SEM; FEI Co., Hillsboro, OR, USA).", [["a scanning electron microscope", "TEST", 43, 73]]], ["The fabricated natural-product nanoparticles were continuously deposited onto polyurethane resin fiber filters (Clean & Science Co., Ltd., Seoul, Republic of Korea) (fiber diameter: 10-20 \u03bcm; thickness: 0.3 mm; and packing density: 33%).Test bacteriaStaphylococcus epidermidis (Korean Collection for Type Cultures KCTC 1917; Biological Resource Center, Republic of Korea) and Micrococcus luteus (KCTC 9856) were used as the test bacteria in this study.", [["KCTC 9856", "CHEMICAL", 396, 405], ["polyurethane", "CHEMICAL", 78, 90], ["nanoparticles", "SIMPLE_CHEMICAL", 31, 44], ["bacteriaStaphylococcus epidermidis", "ORGANISM", 242, 276], ["Micrococcus luteus", "ORGANISM", 376, 394], ["KCTC 9856", "CELL", 396, 405], ["bacteriaStaphylococcus epidermidis", "SPECIES", 242, 276], ["Micrococcus luteus", "SPECIES", 376, 394], ["bacteriaStaphylococcus epidermidis", "SPECIES", 242, 276], ["Micrococcus luteus", "SPECIES", 376, 394], ["The fabricated natural-product nanoparticles", "TREATMENT", 0, 44], ["polyurethane resin fiber filters", "TREATMENT", 78, 110], ["thickness", "TEST", 192, 201], ["packing density", "TEST", 215, 230], ["Test bacteriaStaphylococcus epidermidis", "PROBLEM", 237, 276], ["Korean Collection", "TEST", 278, 295], ["Type Cultures", "TEST", 300, 313], ["Micrococcus luteus", "PROBLEM", 376, 394], ["the test bacteria", "TEST", 420, 437], ["this study", "TEST", 441, 451], ["fiber filters", "OBSERVATION", 97, 110], ["epidermidis", "OBSERVATION", 265, 276], ["Micrococcus luteus", "ANATOMY", 376, 394]]], ["Gram-positive bacteria are widely used in bioaerosol research [57] and are common in indoor environments and on human skin [58, 59] .", [["skin", "ANATOMY", 118, 122], ["Gram-", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 112, 117], ["skin", "ORGAN", 118, 122], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["Gram-positive bacteria", "PROBLEM", 0, 22], ["positive", "OBSERVATION_MODIFIER", 5, 13], ["bacteria", "OBSERVATION", 14, 22], ["skin", "ANATOMY", 118, 122]]], ["The bacteria were incubated in a nutrient broth medium (Becton Dickinson, Franklin Lakes, NJ, USA) at 37\u00b0C. When the optical density of the bacterial suspension reached~0.8 at 600 nm, the bacteria were harvested by centrifugation and washed three times with distilled water.", [["The bacteria", "PROBLEM", 0, 12], ["the bacterial suspension", "TREATMENT", 136, 160], ["the bacteria", "PROBLEM", 184, 196], ["bacteria", "OBSERVATION_MODIFIER", 4, 12], ["bacterial", "OBSERVATION_MODIFIER", 140, 149], ["suspension", "OBSERVATION_MODIFIER", 150, 160], ["bacteria", "OBSERVATION_MODIFIER", 188, 196]]], ["The concentration of the resulting suspension was~10 8 colony forming units (CFU)/mL.", [["the resulting suspension", "TREATMENT", 21, 45]]], ["One milliliter of the bacterial suspension was mixed with 19 mL of distilled water and loaded into a six-jet Collison nebulizer (BGI Inc.).", [["the bacterial suspension", "TREATMENT", 18, 42], ["distilled water", "TREATMENT", 67, 82], ["a six-jet Collison nebulizer", "TREATMENT", 99, 127], ["bacterial suspension", "OBSERVATION", 22, 42]]], ["Fig 1 (B) shows a schematic diagram of the apparatus used to measure the filtration efficiency, pressure drop, and antimicrobial activity of the coated filters.", [["the filtration efficiency", "TREATMENT", 69, 94], ["pressure drop", "PROBLEM", 96, 109], ["antimicrobial activity", "TREATMENT", 115, 137], ["the coated filters", "TREATMENT", 141, 159], ["filtration efficiency", "OBSERVATION", 73, 94], ["pressure", "OBSERVATION_MODIFIER", 96, 104], ["drop", "OBSERVATION_MODIFIER", 105, 109], ["antimicrobial activity", "OBSERVATION", 115, 137], ["coated filters", "OBSERVATION", 145, 159]]], ["Droplets containing test bacteria were sprayed using a six-jet Collison nebulizer supplied with a 5 L/min airflow under 1 psig.", [["Droplets containing test bacteria", "PROBLEM", 0, 33], ["a six-jet Collison nebulizer", "TREATMENT", 53, 81]]], ["Moisture was removed from the droplets by passing through a diffusion dryer, and the bacterial aerosols were introduced onto the surface of the filter medium.", [["surface", "ANATOMY", 129, 136], ["Moisture", "TREATMENT", 0, 8], ["a diffusion dryer", "TREATMENT", 58, 75], ["the bacterial aerosols", "TREATMENT", 81, 103], ["the filter medium", "TREATMENT", 140, 157], ["bacterial aerosols", "OBSERVATION", 85, 103], ["filter medium", "OBSERVATION", 144, 157]]], ["The particle size and concentration of bacterial aerosols were measured with an aerodynamic particle sizer (APS model 3321; TSI, Inc., Shoreview, MN, USA) at both the inlet and outlet of the filter holder.", [["bacterial aerosols", "PROBLEM", 39, 57], ["an aerodynamic particle sizer", "TEST", 77, 106], ["APS model", "TEST", 108, 117], ["TSI", "TEST", 124, 127], ["the filter holder", "TREATMENT", 187, 204], ["particle", "OBSERVATION_MODIFIER", 4, 12], ["size", "OBSERVATION_MODIFIER", 13, 17], ["concentration", "OBSERVATION_MODIFIER", 22, 35], ["bacterial aerosols", "OBSERVATION", 39, 57], ["aerodynamic", "OBSERVATION", 80, 91], ["particle sizer", "OBSERVATION", 92, 106], ["inlet", "ANATOMY_MODIFIER", 167, 172], ["outlet", "OBSERVATION", 177, 183], ["filter holder", "OBSERVATION", 191, 204]]], ["Filtration efficiencies of the coated filters were calculated using the following equation:Filtration efficiency and pressure dropwhere C inlet and C outlet represent the particle concentrations (particles/cm 3 air ) of the bacterial aerosol at the inlet and outlet of the filter, respectively.", [["Filtration efficiencies", "TREATMENT", 0, 23], ["the coated filters", "TREATMENT", 27, 45], ["Filtration efficiency", "TREATMENT", 91, 112], ["pressure dropwhere C inlet and C outlet", "TREATMENT", 117, 156], ["the particle concentrations (particles/cm 3 air", "TREATMENT", 167, 214], ["the bacterial aerosol at the inlet and outlet of the filter", "TREATMENT", 220, 279], ["coated filters", "OBSERVATION", 31, 45], ["outlet", "ANATOMY_MODIFIER", 150, 156], ["particle concentrations", "OBSERVATION", 171, 194], ["bacterial aerosol", "OBSERVATION", 224, 241], ["inlet", "ANATOMY_MODIFIER", 249, 254], ["outlet", "ANATOMY_MODIFIER", 259, 265], ["filter", "OBSERVATION", 273, 279]]], ["The pressure drops of the coated filters were measured using a micromanometer (FC012; Furness Control, Ltd., Bexhill, UK).Antimicrobial testsThe bacterial aerosols were deposited onto the filters for~3 min.", [["The pressure drops", "TREATMENT", 0, 18], ["the coated filters", "TREATMENT", 22, 40], ["a micromanometer (FC012", "TREATMENT", 61, 84], ["Furness Control", "TREATMENT", 86, 101], ["Antimicrobial tests", "TEST", 122, 141], ["The bacterial aerosols", "TREATMENT", 141, 163], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["drops", "OBSERVATION_MODIFIER", 13, 18], ["coated filters", "OBSERVATION", 26, 40], ["bacterial aerosols", "OBSERVATION", 145, 163]]], ["After a contact time of 10 min, the filters were placed in 5 mL (V extraction ) of phosphate-buffered saline (PBS) containing 0.01% Tween 80 and sonicated for 10 min to transfer the bacteria from the filters to the PBS solution.", [["phosphate-buffered", "CHEMICAL", 83, 101], ["phosphate", "CHEMICAL", 83, 92], ["Tween 80", "CHEMICAL", 132, 140], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 83, 108], ["the filters", "TREATMENT", 32, 43], ["V extraction", "TREATMENT", 65, 77], ["phosphate-buffered saline (PBS)", "TREATMENT", 83, 114], ["the PBS solution", "TREATMENT", 211, 227]]], ["The resulting bacterial suspension was serially diluted onto plates of nutrient agar (Becton Dickinson) and incubated at 37\u00b0C for 24 h.", [["The resulting bacterial suspension", "TREATMENT", 0, 34], ["bacterial suspension", "OBSERVATION", 14, 34]]], ["The colonies that grew on the plates were counted.", [["colonies", "ANATOMY", 4, 12], ["the plates", "TEST", 26, 36], ["colonies", "OBSERVATION", 4, 12]]], ["Bacterial inactivation efficiency was calculated as follows:Antimicrobial testsRatio of bacterial inactivationAntimicrobial testswhere ABCF is the active proportion of bacteria from the control filter and ABAF is the active proportion of bacteria from the antimicrobial filter; CFU control and CFU antimicrobial are the concentrations (CFU/mL) of active bacterial suspensions produced from the control and antimicrobial filters, respectively; and N is the concentration of bacteria (particles/mL) in the extraction suspension that was plated onto agar.", [["ABAF", "CHEMICAL", 205, 209], ["ABAF", "SIMPLE_CHEMICAL", 205, 209], ["Bacterial inactivation efficiency", "PROBLEM", 0, 33], ["Antimicrobial testsRatio", "TREATMENT", 60, 84], ["bacterial inactivation", "TREATMENT", 88, 110], ["bacteria", "PROBLEM", 168, 176], ["the control filter", "TREATMENT", 182, 200], ["ABAF", "TREATMENT", 205, 209], ["bacteria", "PROBLEM", 238, 246], ["the antimicrobial filter", "TREATMENT", 252, 276], ["CFU control", "TREATMENT", 278, 289], ["CFU antimicrobial", "TREATMENT", 294, 311], ["active bacterial suspensions", "PROBLEM", 347, 375], ["antimicrobial filters", "TREATMENT", 406, 427], ["bacteria (particles/mL", "TREATMENT", 473, 495], ["the extraction suspension", "TREATMENT", 500, 525], ["inactivation efficiency", "OBSERVATION", 10, 33], ["bacterial inactivation", "OBSERVATION", 88, 110], ["active", "OBSERVATION_MODIFIER", 147, 153], ["bacteria", "OBSERVATION", 168, 176], ["active", "OBSERVATION_MODIFIER", 217, 223], ["bacteria", "OBSERVATION", 238, 246], ["antimicrobial filter", "OBSERVATION", 256, 276], ["active", "OBSERVATION_MODIFIER", 347, 353], ["bacterial suspensions", "OBSERVATION", 354, 375], ["antimicrobial filters", "OBSERVATION", 406, 427]]], ["Q sampling is the total airflow sampling volume and z extraction is the physical extraction efficiency of the filter for bacteria, which is defined as the ratio of the number of particles transferred from the filter to the extraction liquid to the number of particles removed from the airflow using the filter.", [["the total airflow sampling volume", "TREATMENT", 14, 47], ["z extraction", "TREATMENT", 52, 64], ["the filter", "TREATMENT", 106, 116], ["bacteria", "PROBLEM", 121, 129], ["the filter", "TREATMENT", 205, 215], ["the extraction liquid", "TREATMENT", 219, 240], ["the filter", "TREATMENT", 299, 309], ["filter", "OBSERVATION", 110, 116], ["particles", "OBSERVATION", 258, 267], ["airflow", "OBSERVATION", 285, 292], ["filter", "OBSERVATION", 303, 309]]], ["In this study, we assumed that the physical extraction efficiency for bacterial particles from all filters was identical.Chemical analysis of the E. japonica extractIdentification of the major chemical compounds in the E. japonica extract was performed using an HPLC-ESI/MS device (Thermo Fisher Scientific Inc., San Jose, CA) equipped with an ACCELA photodiode array detector (PDA), an autosampler, a quaternary pump, and an LCQ FLEET ion trap with an electrospray ionization source.", [["extract", "ANATOMY", 231, 238], ["E. japonica", "ORGANISM", 146, 157], ["E. japonica", "ORGANISM", 219, 230], ["E. japonica", "SPECIES", 146, 157], ["E. japonica", "SPECIES", 219, 230], ["E. japonica", "SPECIES", 146, 157], ["E. japonica", "SPECIES", 219, 230], ["this study", "TEST", 3, 13], ["the physical extraction efficiency", "PROBLEM", 31, 65], ["bacterial particles", "PROBLEM", 70, 89], ["all filters", "TREATMENT", 95, 106], ["Chemical analysis", "TEST", 121, 138], ["the E. japonica extract", "TREATMENT", 142, 165], ["an HPLC", "TEST", 259, 266], ["ESI/MS device", "TREATMENT", 267, 280], ["an ACCELA photodiode array detector", "TREATMENT", 341, 376], ["an autosampler", "TREATMENT", 384, 398], ["a quaternary pump", "TREATMENT", 400, 417], ["an LCQ FLEET ion trap", "TREATMENT", 423, 444], ["an electrospray ionization source", "TREATMENT", 450, 483], ["chemical compounds", "OBSERVATION", 193, 211]]], ["The Thermo Xcalibur software (version 2.1) was used for data acquisition and processing.", [["data acquisition", "TEST", 56, 72]]], ["The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B In vitro cytotoxicity of E. japonica nanoparticles A549 human lung adenocarcinoma cancer cells and HEL 299 human lung fibroblasts were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and the cells were maintained in a 5% CO 2 humidified atmosphere at 37\u00b0C. Eagle's minimum essential medium (EMEM; ATCC) was used to support the HEL 299 cells and RPMI-1640 (Hyclone, Logan, UT, USA) was used for A549 cultivation.", [["A549", "ANATOMY", 167, 171], ["lung adenocarcinoma cancer cells", "ANATOMY", 178, 210], ["HEL", "ANATOMY", 215, 218], ["lung fibroblasts", "ANATOMY", 229, 245], ["cells", "ANATOMY", 337, 342], ["HEL 299 cells", "ANATOMY", 473, 486], ["A549", "ANATOMY", 540, 544], ["formic acid", "CHEMICAL", 35, 46], ["solvent A", "CHEMICAL", 57, 66], ["formic acid", "CHEMICAL", 77, 88], ["acetonitrile", "CHEMICAL", 92, 104], ["lung adenocarcinoma cancer", "DISEASE", 178, 204], ["RPMI-1640", "CHEMICAL", 491, 500], ["formic acid", "CHEMICAL", 35, 46], ["formic acid", "CHEMICAL", 77, 88], ["acetonitrile", "CHEMICAL", 92, 104], ["CO", "CHEMICAL", 367, 369], ["formic acid", "SIMPLE_CHEMICAL", 35, 46], ["water", "SIMPLE_CHEMICAL", 50, 55], ["formic acid", "SIMPLE_CHEMICAL", 77, 88], ["acetonitrile", "SIMPLE_CHEMICAL", 92, 104], ["E. japonica", "ORGANISM", 141, 152], ["human", "ORGANISM", 172, 177], ["lung adenocarcinoma cancer cells", "CELL", 178, 210], ["HEL 299", "CELL", 215, 222], ["human", "ORGANISM", 223, 228], ["lung fibroblasts", "CELL", 229, 245], ["cells", "CELL", 337, 342], ["HEL 299 cells", "CELL", 473, 486], ["RPMI-1640", "CELL", 491, 500], ["Hyclone", "ORGANISM_SUBSTANCE", 502, 509], ["A549", "CELL", 540, 544], ["A549 human lung adenocarcinoma cancer cells", "CELL_LINE", 167, 210], ["HEL 299 human lung fibroblasts", "CELL_LINE", 215, 245], ["HEL 299 cells", "CELL_LINE", 473, 486], ["E. japonica", "SPECIES", 141, 152], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 223, 228], ["E. japonica", "SPECIES", 141, 152], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 223, 228], ["ATCC", "SPECIES", 303, 307], ["0.1% formic acid in water (solvent A)", "TREATMENT", 30, 67], ["formic acid in acetonitrile (solvent B", "TREATMENT", 77, 115], ["vitro cytotoxicity", "TREATMENT", 119, 137], ["E. japonica nanoparticles", "TREATMENT", 141, 166], ["human lung adenocarcinoma cancer cells", "PROBLEM", 172, 210], ["HEL", "TEST", 215, 218], ["human lung fibroblasts", "PROBLEM", 223, 245], ["RPMI", "TEST", 491, 495], ["A549 cultivation", "TREATMENT", 540, 556], ["lung", "ANATOMY", 178, 182], ["adenocarcinoma cancer", "OBSERVATION", 183, 204], ["lung", "ANATOMY", 229, 233], ["fibroblasts", "OBSERVATION", 234, 245]]], ["These cells were supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin and 100 \u03bcg/mL streptomycin.", [["cells", "ANATOMY", 6, 11], ["fetal bovine serum", "ANATOMY", 45, 63], ["FBS", "ANATOMY", 65, 68], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 105, 117], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 105, 117], ["cells", "CELL", 6, 11], ["bovine", "ORGANISM", 51, 57], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["FBS", "ORGANISM_SUBSTANCE", 65, 68], ["penicillin", "SIMPLE_CHEMICAL", 80, 90], ["streptomycin", "SIMPLE_CHEMICAL", 105, 117], ["bovine", "SPECIES", 51, 57], ["bovine", "SPECIES", 51, 57], ["fetal bovine serum (FBS", "TREATMENT", 45, 68], ["penicillin", "TREATMENT", 80, 90], ["streptomycin", "TREATMENT", 105, 117]]], ["Cell viability upon exposure to E. japonica extract was evaluated using an EZ-Cytox cell viability assay kit (Daeil Lab Service, Ltd., Seoul, Republic of Korea) according to the manufacturer's instructions.", [["Cell", "ANATOMY", 0, 4], ["extract", "ANATOMY", 44, 51], ["cell", "ANATOMY", 84, 88], ["E. japonica extract", "CHEMICAL", 32, 51], ["Cell", "CELL", 0, 4], ["E. japonica", "ORGANISM", 32, 43], ["Cytox cell", "CELL", 78, 88], ["E. japonica", "SPECIES", 32, 43], ["E. japonica", "SPECIES", 32, 43], ["Cell viability", "PROBLEM", 0, 14], ["an EZ", "TEST", 72, 77]]], ["Cells (1 \u00d7 10 4 cells/well) were plated in 96-well plates, incubated at 37\u00b0C for 24 h, and given a fresh change of medium containing E. japonica extract at the indicated concentration for 48 h.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 16, 21], ["extract", "ANATOMY", 145, 152], ["E. japonica extract", "CHEMICAL", 133, 152], ["Cells", "CELL", 0, 5], ["cells", "CELL", 16, 21], ["E. japonica", "ORGANISM", 133, 144], ["E. japonica", "SPECIES", 133, 144], ["E. japonica", "SPECIES", 133, 144], ["Cells", "TEST", 0, 5], ["a fresh change of medium containing E. japonica extract", "TREATMENT", 97, 152]]], ["At the end of the incubation, 10 \u03bcL of EZ-Cytox solution was added to the well and incubated for at least 1 more hour.", [["EZ-Cytox", "CHEMICAL", 39, 47], ["EZ-Cytox", "CHEMICAL", 39, 47], ["EZ-Cytox", "SIMPLE_CHEMICAL", 39, 47], ["EZ-Cytox solution", "TREATMENT", 39, 56]]], ["The absorbance at 450 nm was measured using a Synergy HT Multi-microplate reader (BioTek Instruments, Winooski, VT, USA).", [["The absorbance", "PROBLEM", 0, 14], ["a Synergy HT Multi-microplate reader (BioTek Instruments", "TREATMENT", 44, 100], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["Data were expressed as cell growth percentages relative to the controls (cells treated with dimethyl sulfoxide (DMSO) only) for each extract concentration.Statistical analysesCorrelation coefficients, linear regressions, and t-statistics of experimental data were calculated using the SPSS statistical software, version 12.0 (SPSS, Inc., Chicago, IL, USA).Results and DiscussionAs shown in Fig 2 (A) , nebulization and thermal drying produced natural-product nanoparticles with a wide size distribution, ranging from a few to several hundred nanometers in diameter.", [["cell", "ANATOMY", 23, 27], ["cells", "ANATOMY", 73, 78], ["extract", "ANATOMY", 133, 140], ["dimethyl sulfoxide", "CHEMICAL", 92, 110], ["DMSO", "CHEMICAL", 112, 116], ["dimethyl sulfoxide", "CHEMICAL", 92, 110], ["DMSO", "CHEMICAL", 112, 116], ["cell", "CELL", 23, 27], ["cells", "CELL", 73, 78], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 92, 110], ["DMSO", "SIMPLE_CHEMICAL", 112, 116], ["cell growth percentages", "TEST", 23, 46], ["dimethyl sulfoxide (DMSO)", "TREATMENT", 92, 117], ["Statistical analysesCorrelation coefficients", "TEST", 155, 199], ["linear regressions", "PROBLEM", 201, 219], ["experimental data", "TEST", 241, 258], ["the SPSS statistical software", "TEST", 281, 310], ["version", "TEST", 312, 319], ["SPSS", "TEST", 326, 330], ["nebulization", "TREATMENT", 402, 414], ["thermal drying", "TREATMENT", 419, 433], ["natural-product nanoparticles", "TREATMENT", 443, 472], ["linear", "OBSERVATION_MODIFIER", 201, 207], ["wide", "OBSERVATION_MODIFIER", 480, 484], ["size", "OBSERVATION_MODIFIER", 485, 489], ["distribution", "OBSERVATION_MODIFIER", 490, 502], ["ranging", "OBSERVATION_MODIFIER", 504, 511], ["diameter", "OBSERVATION_MODIFIER", 556, 564]]], ["The distribution is best represented by a monomodal curve with a peak diameter of 75.16 nm, a geometric mean diameter (GMD) of 75.82 nm, and geometric standard deviation (GMD) of 1.217.", [["a monomodal curve", "TEST", 40, 57], ["a peak diameter", "TEST", 63, 78], ["a geometric mean diameter", "TEST", 92, 117], ["geometric standard deviation (GMD)", "PROBLEM", 141, 175], ["peak", "OBSERVATION_MODIFIER", 65, 69], ["diameter", "OBSERVATION_MODIFIER", 70, 78], ["geometric", "OBSERVATION_MODIFIER", 94, 103], ["mean", "OBSERVATION_MODIFIER", 104, 108], ["diameter", "OBSERVATION_MODIFIER", 109, 117], ["geometric", "OBSERVATION_MODIFIER", 141, 150], ["standard deviation", "OBSERVATION", 151, 169]]], ["The particles generated from methanol showed a broad size distribution, and compared to size distribution and concentration of natural-product nanoparticles, the particles generated from methanol were trivial (<3%).", [["methanol", "CHEMICAL", 29, 37], ["methanol", "CHEMICAL", 187, 195], ["methanol", "CHEMICAL", 29, 37], ["methanol", "CHEMICAL", 187, 195], ["methanol", "SIMPLE_CHEMICAL", 29, 37], ["natural-product nanoparticles", "SIMPLE_CHEMICAL", 127, 156], ["methanol", "SIMPLE_CHEMICAL", 187, 195], ["a broad size distribution", "PROBLEM", 45, 70], ["natural-product nanoparticles", "TREATMENT", 127, 156], ["broad", "OBSERVATION_MODIFIER", 47, 52], ["size", "OBSERVATION_MODIFIER", 53, 57], ["distribution", "OBSERVATION_MODIFIER", 58, 70], ["size", "OBSERVATION_MODIFIER", 88, 92], ["distribution", "OBSERVATION_MODIFIER", 93, 105], ["concentration", "OBSERVATION_MODIFIER", 110, 123], ["product nanoparticles", "OBSERVATION", 135, 156]]], ["The deposition efficiency of these particles is shown in Fig 2 (B) .", [["The deposition efficiency of these particles", "PROBLEM", 0, 44], ["deposition", "OBSERVATION_MODIFIER", 4, 14], ["efficiency", "OBSERVATION_MODIFIER", 15, 25], ["particles", "OBSERVATION_MODIFIER", 35, 44]]], ["More than 98% of particles with diameters less than 43 nm and greater than 277 nm were deposited onto the control filter.", [["diameters", "TEST", 32, 41], ["the control filter", "TREATMENT", 102, 120], ["diameters", "OBSERVATION_MODIFIER", 32, 41]]], ["The deposition efficiency of particles between 43 and 277 nm was lower.", [["The deposition efficiency of particles", "PROBLEM", 0, 38], ["deposition", "OBSERVATION_MODIFIER", 4, 14], ["efficiency", "OBSERVATION_MODIFIER", 15, 25], ["particles", "OBSERVATION_MODIFIER", 29, 38]]], ["The lowest deposition efficiency on the control filter was 85.3% for particles 92 nm in diameter.", [["The lowest deposition efficiency", "PROBLEM", 0, 32], ["the control filter", "TREATMENT", 36, 54], ["lowest", "OBSERVATION_MODIFIER", 4, 10], ["deposition", "OBSERVATION_MODIFIER", 11, 21], ["efficiency", "OBSERVATION_MODIFIER", 22, 32], ["diameter", "OBSERVATION_MODIFIER", 88, 96]]], ["The relatively low deposition efficiency observed for particles between 43 and 277 nm results from the mechanism of particle filtration.", [["The relatively low deposition efficiency", "PROBLEM", 0, 40], ["particle filtration", "PROBLEM", 116, 135], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["low", "OBSERVATION_MODIFIER", 15, 18], ["deposition efficiency", "OBSERVATION", 19, 40], ["particle filtration", "OBSERVATION", 116, 135]]], ["Particles with midrange diameters were too large for diffusion filtration and too small for impaction and interception mechanisms [1] .", [["Particles", "ANATOMY", 0, 9], ["midrange diameters", "TEST", 15, 33], ["diffusion filtration", "TREATMENT", 53, 73], ["impaction", "PROBLEM", 92, 101], ["midrange diameters", "OBSERVATION_MODIFIER", 15, 33], ["large", "OBSERVATION_MODIFIER", 43, 48], ["too small", "OBSERVATION_MODIFIER", 78, 87]]], ["SEM micrographs show spherical and polydisperse naturalproduct nanoparticles on the filter fibers (Fig 2 (B) ).", [["SEM micrographs", "TEST", 0, 15], ["spherical and polydisperse naturalproduct nanoparticles", "PROBLEM", 21, 76], ["the filter fibers", "TREATMENT", 80, 97], ["spherical", "OBSERVATION_MODIFIER", 21, 30], ["polydisperse", "OBSERVATION_MODIFIER", 35, 47], ["naturalproduct nanoparticles", "OBSERVATION", 48, 76]]], ["The quantity of deposited material was determined by weighing the filters before and after particle deposition using a microbalance (Mettler MT5; Mettler-Toledo International, Inc., Seoul, Republic of Korea).", [["deposited material", "PROBLEM", 16, 34], ["a microbalance (Mettler MT5", "TREATMENT", 117, 144], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["deposited material", "OBSERVATION", 16, 34]]], ["The weight of the particles deposited on the filter surface ranged from~590 to 1150 \u03bcg/cm 2 filter (590, 855, and 1150 \u03bcg/cm 2 filter correspond to deposition times of 3, 6, and 9 min, respectively).", [["filter surface", "ANATOMY", 45, 59], ["the filter surface", "TREATMENT", 41, 59], ["filter", "OBSERVATION", 45, 51]]], ["Fig 3 shows that pressure drop across the filter increased linearly from 1.1 to 13.4 mmH 2 O as the quantity of deposited nanoparticles increased (y = 1.37x + 1.94, r 2 = 0.9857, p <0.05) [60] .", [["Fig", "TEST", 0, 3], ["pressure drop", "PROBLEM", 17, 30], ["the filter", "TEST", 38, 48], ["deposited nanoparticles", "TEST", 112, 135], ["pressure", "OBSERVATION_MODIFIER", 17, 25], ["drop", "OBSERVATION_MODIFIER", 26, 30], ["filter", "OBSERVATION", 42, 48], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["linearly", "OBSERVATION_MODIFIER", 59, 67], ["nanoparticles", "OBSERVATION_MODIFIER", 122, 135], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["Filtration efficiencies were tested using S. epidermidis and M. luteus aerosols.", [["S. epidermidis", "ORGANISM", 42, 56], ["M. luteus", "ORGANISM", 61, 70], ["S. epidermidis", "SPECIES", 42, 56], ["M. luteus", "SPECIES", 61, 70], ["S. epidermidis", "SPECIES", 42, 56], ["M. luteus", "SPECIES", 61, 70], ["Filtration efficiencies", "TREATMENT", 0, 23], ["S. epidermidis", "PROBLEM", 42, 56], ["M. luteus aerosols", "PROBLEM", 61, 79], ["epidermidis", "OBSERVATION", 45, 56], ["luteus aerosols", "OBSERVATION", 64, 79]]], ["As shown in Table 1 , the test bacteria concentrations were~278 (S. epidermidis) and~234 particle/cm 3 (M. luteus), respectively.", [["S. epidermidis", "ORGANISM", 65, 79], ["S. epidermidis", "SPECIES", 65, 79], ["M. luteus", "SPECIES", 104, 113], ["S. epidermidis", "SPECIES", 65, 79], ["M. luteus", "SPECIES", 104, 113], ["the test bacteria concentrations", "TEST", 22, 54], ["S. epidermidis", "TEST", 65, 79]]], ["The distribution of the S. epidermidis aerosol was a monomodal curve with a peak diameter of~0.84 \u03bcm, a GMD of~0.81 \u03bcm, and a GSD of~1.22 (S1 Fig, Table 1 ).", [["S. epidermidis", "ORGANISM", 24, 38], ["GMD", "PROTEIN", 104, 107], ["S. epidermidis", "SPECIES", 24, 38], ["S. epidermidis", "SPECIES", 24, 38], ["the S. epidermidis aerosol", "TREATMENT", 20, 46], ["a monomodal curve", "TEST", 51, 68], ["a peak diameter", "TEST", 74, 89], ["a GMD", "TEST", 102, 107], ["a GSD", "TEST", 124, 129], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["epidermidis aerosol", "OBSERVATION", 27, 46], ["peak", "OBSERVATION_MODIFIER", 76, 80], ["diameter", "OBSERVATION_MODIFIER", 81, 89]]], ["Although the shape of size distribution curve of the M. luteus aerosol was similar to that of S. epidermidis aerosol, the M. luteus particles were larger than those of S. epidermidis (S1 Fig).", [["M. luteus", "ORGANISM", 53, 62], ["S. epidermidis aerosol", "ORGANISM", 94, 116], ["M. luteus particles", "ORGANISM", 122, 141], ["S. epidermidis", "ORGANISM", 168, 182], ["M. luteus", "SPECIES", 53, 62], ["S. epidermidis", "SPECIES", 94, 108], ["M. luteus", "SPECIES", 122, 131], ["S. epidermidis", "SPECIES", 168, 182], ["M. luteus", "SPECIES", 53, 62], ["S. epidermidis", "SPECIES", 94, 108], ["M. luteus", "SPECIES", 122, 131], ["S. epidermidis", "SPECIES", 168, 182], ["the M. luteus aerosol", "TREATMENT", 49, 70], ["S. epidermidis aerosol", "TREATMENT", 94, 116], ["the M. luteus particles", "TEST", 118, 141], ["S. epidermidis", "PROBLEM", 168, 182], ["shape", "OBSERVATION_MODIFIER", 13, 18], ["size", "OBSERVATION_MODIFIER", 22, 26], ["distribution", "OBSERVATION_MODIFIER", 27, 39], ["curve", "OBSERVATION_MODIFIER", 40, 45], ["luteus aerosol", "OBSERVATION", 56, 70], ["luteus", "OBSERVATION_MODIFIER", 125, 131], ["particles", "OBSERVATION_MODIFIER", 132, 141], ["larger", "OBSERVATION_MODIFIER", 147, 153], ["epidermidis", "OBSERVATION", 171, 182]]], ["No statistically significant difference was observed between the filtration efficiencies of filters that had been coated for 3 and 9 min (p >0.05).", [["the filtration efficiencies of filters", "TREATMENT", 61, 99], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["difference", "OBSERVATION", 29, 39], ["filtration efficiencies", "OBSERVATION", 65, 88], ["filters", "OBSERVATION", 92, 99]]], ["However, because of the dissimilar size distributions of the two bacterial aerosols, filtration efficiencies of the two species were slightly different (p <0.05):~97% for S. epidermidis and 95% for M. luteus.", [["S. epidermidis", "DISEASE", 171, 185], ["S. epidermidis", "ORGANISM", 171, 185], ["M. luteus", "ORGANISM", 198, 207], ["S. epidermidis", "SPECIES", 171, 185], ["M. luteus", "SPECIES", 198, 207], ["S. epidermidis", "SPECIES", 171, 185], ["M. luteus", "SPECIES", 198, 207], ["the two bacterial aerosols", "TREATMENT", 57, 83], ["filtration efficiencies", "TREATMENT", 85, 108], ["the two species", "PROBLEM", 112, 127], ["S. epidermidis", "PROBLEM", 171, 185], ["M. luteus", "PROBLEM", 198, 207], ["dissimilar", "OBSERVATION_MODIFIER", 24, 34], ["size", "OBSERVATION_MODIFIER", 35, 39], ["distributions", "OBSERVATION_MODIFIER", 40, 53], ["bacterial aerosols", "OBSERVATION", 65, 83], ["filtration efficiencies", "OBSERVATION", 85, 108], ["two", "OBSERVATION_MODIFIER", 116, 119], ["species", "OBSERVATION_MODIFIER", 120, 127], ["slightly", "OBSERVATION_MODIFIER", 133, 141], ["different", "OBSERVATION_MODIFIER", 142, 151], ["epidermidis", "OBSERVATION", 174, 185], ["luteus", "ANATOMY", 201, 207]]], ["Also, note that flat panel-type filters were used in these tests to estimate the effects of natural-product nanoparticles.", [["flat panel", "TEST", 16, 26], ["type filters", "TREATMENT", 27, 39], ["these tests", "TEST", 53, 64], ["natural-product nanoparticles", "TREATMENT", 92, 121]]], ["Real-world applications would typically employ folded filters to increase the filtration area and decrease the pressure drop.Results and DiscussionAs shown in Fig 4, the inactivation efficiencies of antimicrobial filters increased for both bacteria with increasing nanoparticle deposition time (M. luteus: r 2 = 0.9612, S. epidermidis: r 2 = 0.9959, p <0.05).", [["nanoparticle", "CHEMICAL", 265, 277], ["S. epidermidis", "ORGANISM", 320, 334], ["M. luteus", "SPECIES", 295, 304], ["S. epidermidis", "SPECIES", 320, 334], ["M. luteus", "SPECIES", 295, 304], ["S. epidermidis", "SPECIES", 320, 334], ["folded filters", "TREATMENT", 47, 61], ["the filtration area", "TREATMENT", 74, 93], ["the pressure drop", "PROBLEM", 107, 124], ["the inactivation efficiencies", "TREATMENT", 166, 195], ["antimicrobial filters", "TREATMENT", 199, 220], ["both bacteria", "PROBLEM", 235, 248], ["increasing nanoparticle deposition time", "PROBLEM", 254, 293], ["M. luteus", "TEST", 295, 304], ["S. epidermidis", "TEST", 320, 334], ["decrease", "OBSERVATION_MODIFIER", 98, 106], ["pressure drop", "OBSERVATION", 111, 124], ["antimicrobial filters", "OBSERVATION", 199, 220], ["epidermidis", "OBSERVATION", 323, 334]]], ["Approximately 61, 73, and 82% of the M. luteus aerosols were inactivated on filters that had been coated for 3, 6 and 9 min, respectively, while the corresponding values were88, and~94% with S. epidermidis.", [["M. luteus", "ORGANISM", 37, 46], ["S. epidermidis", "ORGANISM", 191, 205], ["M. luteus", "SPECIES", 37, 46], ["S. epidermidis", "SPECIES", 191, 205], ["M. luteus", "SPECIES", 37, 46], ["S. epidermidis", "SPECIES", 191, 205], ["the M. luteus aerosols", "TEST", 33, 55], ["filters", "TREATMENT", 76, 83], ["S. epidermidis", "PROBLEM", 191, 205], ["epidermidis", "OBSERVATION", 194, 205]]], ["M. luteus was more resistant to the E. japonica extract than S. epidermidis under all conditions (p <0.05), with a maximum difference of 17%.", [["M. luteus", "ORGANISM", 0, 9], ["E. japonica", "ORGANISM", 36, 47], ["S. epidermidis", "ORGANISM", 61, 75], ["M. luteus", "SPECIES", 0, 9], ["E. japonica", "SPECIES", 36, 47], ["S. epidermidis", "SPECIES", 61, 75], ["M. luteus", "SPECIES", 0, 9], ["E. japonica", "SPECIES", 36, 47], ["S. epidermidis", "SPECIES", 61, 75], ["M. luteus", "PROBLEM", 0, 9], ["S. epidermidis", "PROBLEM", 61, 75], ["luteus", "OBSERVATION", 3, 9], ["more resistant", "OBSERVATION_MODIFIER", 14, 28], ["japonica extract", "OBSERVATION_MODIFIER", 39, 55], ["epidermidis", "OBSERVATION", 64, 75]]], ["Although both M. luteus and S. epidermidis are Gram-positive bacteria, M. luteus is more suited to survive in extreme and/or nutrient-poor environments over extended periods of time [61] .", [["M. luteus", "ORGANISM", 14, 23], ["S. epidermidis", "ORGANISM", 28, 42], ["Gram-", "GENE_OR_GENE_PRODUCT", 47, 52], ["M. luteus", "ORGANISM", 71, 80], ["M. luteus", "SPECIES", 14, 23], ["S. epidermidis", "SPECIES", 28, 42], ["M. luteus", "SPECIES", 71, 80], ["M. luteus", "SPECIES", 14, 23], ["S. epidermidis", "SPECIES", 28, 42], ["M. luteus", "SPECIES", 71, 80], ["both M. luteus", "TEST", 9, 23], ["S. epidermidis", "PROBLEM", 28, 42], ["Gram-positive bacteria", "PROBLEM", 47, 69], ["M. luteus", "PROBLEM", 71, 80], ["luteus", "OBSERVATION_MODIFIER", 17, 23], ["epidermidis", "OBSERVATION_MODIFIER", 31, 42], ["bacteria", "OBSERVATION_MODIFIER", 61, 69], ["luteus", "OBSERVATION_MODIFIER", 74, 80]]], ["Similarly, in extreme environments, Micrococcus strains have been shown to exhibit greater resistance to novobiocin than Staphylococcus strains [62] .Results and DiscussionThe major chemical constituents of E. japonica extract were investigated using HPLC.", [["extract", "ANATOMY", 219, 226], ["novobiocin", "CHEMICAL", 105, 115], ["novobiocin", "CHEMICAL", 105, 115], ["Micrococcus strains", "ORGANISM", 36, 55], ["novobiocin", "SIMPLE_CHEMICAL", 105, 115], ["Staphylococcus strains", "ORGANISM", 121, 143], ["E. japonica", "ORGANISM", 207, 218], ["E. japonica", "SPECIES", 207, 218], ["Staphylococcus strains", "SPECIES", 121, 143], ["E. japonica", "SPECIES", 207, 218], ["Micrococcus strains", "PROBLEM", 36, 55], ["novobiocin", "TREATMENT", 105, 115], ["Staphylococcus strains", "PROBLEM", 121, 143], ["E. japonica extract", "TREATMENT", 207, 226]]], ["The results showed that the chromatogram detected at 280 nm contains three major peaks To assess the toxicity of E. japonica, in vitro cytotoxicity tests were conducted using EZ-Cytox cell viability assay kits, the results of which were compared with those of SNCs, which are known to produce genotoxic effects in cells.", [["cell", "ANATOMY", 184, 188], ["SNCs", "ANATOMY", 260, 264], ["cells", "ANATOMY", 314, 319], ["toxicity", "DISEASE", 101, 109], ["EZ", "CHEMICAL", 175, 177], ["E. japonica", "ORGANISM", 113, 124], ["EZ-Cytox cell", "CELL", 175, 188], ["SNCs", "CELL", 260, 264], ["cells", "CELL", 314, 319], ["SNCs", "CELL_TYPE", 260, 264], ["E. japonica", "SPECIES", 113, 124], ["E. japonica", "SPECIES", 113, 124], ["the chromatogram", "TEST", 24, 40], ["the toxicity", "PROBLEM", 97, 109], ["E. japonica", "PROBLEM", 113, 124], ["vitro cytotoxicity tests", "TEST", 129, 153], ["EZ", "TEST", 175, 177], ["SNCs", "TEST", 260, 264], ["genotoxic effects in cells", "PROBLEM", 293, 319], ["peaks", "OBSERVATION_MODIFIER", 81, 86], ["genotoxic effects", "OBSERVATION", 293, 310]]], ["The SNC used in this study is classified as a human carcinogen by the U.S. National Toxicology Program (NTP) and Beraterkreis Toxikologie in Germany [68] although it is a weaker carcinogen than other, insoluble nickel compounds.", [["SNC", "CHEMICAL", 4, 7], ["nickel", "CHEMICAL", 211, 217], ["nickel", "CHEMICAL", 211, 217], ["human", "ORGANISM", 46, 51], ["nickel compounds", "SIMPLE_CHEMICAL", 211, 227], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["this study", "TEST", 16, 26], ["weaker", "OBSERVATION_MODIFIER", 171, 177], ["carcinogen", "OBSERVATION", 178, 188], ["nickel compounds", "OBSERVATION", 211, 227]]], ["Fig 5 shows the concentration of E. japonica and SNC required to attain 50% inhibition of A549 cancer cells and HEL 299 cells.", [["A549 cancer cells", "ANATOMY", 90, 107], ["HEL 299 cells", "ANATOMY", 112, 125], ["cancer", "DISEASE", 95, 101], ["E. japonica", "ORGANISM", 33, 44], ["A549 cancer cells", "CELL", 90, 107], ["HEL 299 cells", "CELL", 112, 125], ["A549 cancer cells", "CELL_LINE", 90, 107], ["HEL 299 cells", "CELL_LINE", 112, 125], ["E. japonica", "SPECIES", 33, 44], ["E. japonica", "SPECIES", 33, 44], ["E. japonica", "TREATMENT", 33, 44], ["SNC", "TREATMENT", 49, 52], ["A549 cancer cells", "PROBLEM", 90, 107], ["299 cells", "OBSERVATION", 116, 125]]], ["For both cell types, the inhibitory concentration of E. japonica was statistically confirmed to be higher than that of the SNC following 48-h exposures (p <0.05).", [["cell", "ANATOMY", 9, 13], ["cell", "CELL", 9, 13], ["E. japonica", "ORGANISM", 53, 64], ["E. japonica", "SPECIES", 53, 64], ["E. japonica", "SPECIES", 53, 64], ["E. japonica", "PROBLEM", 53, 64], ["cell types", "OBSERVATION", 9, 19], ["higher", "OBSERVATION_MODIFIER", 99, 105]]], ["The required E. japonica concentrations were 137 and 256 \u03bcg/mL, >57% higher than those of the SNC.Results and DiscussionIn addition, the antimicrobial activities of E. japonica and the SNC were casually evaluated using the disk diffusion method.", [["E. japonica", "ORGANISM", 13, 24], ["E. japonica", "ORGANISM", 165, 176], ["SNC", "SIMPLE_CHEMICAL", 185, 188], ["E. japonica", "SPECIES", 13, 24], ["E. japonica", "SPECIES", 165, 176], ["E. japonica", "SPECIES", 13, 24], ["E. japonica", "SPECIES", 165, 176], ["E. japonica concentrations", "TEST", 13, 39], ["the antimicrobial activities", "TEST", 133, 161], ["the SNC", "TREATMENT", 181, 188], ["the disk diffusion method", "TEST", 219, 244]]], ["Approximately 50 mg of E. japonica extract and SNC powders were dissolved in 1 mL of DMSO and distilled water, respectively, and 10 \u03bcL of each suspension was used to soak Whatman filter papers (11-mm diameter; GE Healthcare Life Sciences, Pittsburgh, PA, USA).", [["extract", "ANATOMY", 35, 42], ["E. japonica extract", "CHEMICAL", 23, 42], ["DMSO", "CHEMICAL", 85, 89], ["DMSO", "CHEMICAL", 85, 89], ["E. japonica", "ORGANISM", 23, 34], ["SNC powders", "SIMPLE_CHEMICAL", 47, 58], ["DMSO", "SIMPLE_CHEMICAL", 85, 89], ["E. japonica", "SPECIES", 23, 34], ["E. japonica", "SPECIES", 23, 34], ["E. japonica extract", "TREATMENT", 23, 42], ["SNC powders", "TREATMENT", 47, 58], ["DMSO", "TREATMENT", 85, 89], ["Whatman filter papers", "TREATMENT", 171, 192]]], ["Fig 6 shows the results against S. aureus, Enterococcus hirae, M. luteus, and S. epidermidis.", [["S. aureus", "ORGANISM", 32, 41], ["Enterococcus hirae", "ORGANISM", 43, 61], ["M. luteus", "ORGANISM", 63, 72], ["S. epidermidis", "ORGANISM", 78, 92], ["S. aureus", "SPECIES", 32, 41], ["Enterococcus hirae", "SPECIES", 43, 61], ["M. luteus", "SPECIES", 63, 72], ["S. epidermidis", "SPECIES", 78, 92], ["S. aureus", "SPECIES", 32, 41], ["Enterococcus hirae", "SPECIES", 43, 61], ["M. luteus", "SPECIES", 63, 72], ["S. epidermidis", "SPECIES", 78, 92], ["Fig", "TEST", 0, 3], ["S. aureus", "PROBLEM", 32, 41], ["Enterococcus hirae", "PROBLEM", 43, 61], ["M. luteus", "PROBLEM", 63, 72], ["S. epidermidis", "PROBLEM", 78, 92], ["aureus", "OBSERVATION", 35, 41], ["Enterococcus hirae", "OBSERVATION", 43, 61], ["M. luteus", "OBSERVATION", 63, 72], ["epidermidis", "OBSERVATION", 81, 92]]], ["The antimicrobial activities of E. japonica were similar to those of the SNC against E. hirae and M. luteus (p >0.05), while it was considerably more effective against S. aureus and S. epidermidis with inhibition zones extending to more than twice the radius of those of the SNC (p <0.01) The results in Figs 5 and 6 confirm that E. japonica is less toxic and exhibits stronger antimicrobial activity on some bacteria than the SNC.ConclusionFilters coated with natural E. japonica extract nanoparticles are effective in inactivating bioaerosols.", [["SNC", "CHEMICAL", 73, 76], ["E. japonica", "ORGANISM", 32, 43], ["SNC", "SIMPLE_CHEMICAL", 73, 76], ["E. hirae", "ORGANISM", 85, 93], ["M. luteus", "ORGANISM", 98, 107], ["S. aureus", "ORGANISM", 168, 177], ["S. epidermidis", "ORGANISM", 182, 196], ["E. japonica", "ORGANISM", 330, 341], ["E. japonica", "ORGANISM", 469, 480], ["E. japonica", "SPECIES", 32, 43], ["E. hirae", "SPECIES", 85, 93], ["M. luteus", "SPECIES", 98, 107], ["S. aureus", "SPECIES", 168, 177], ["S. epidermidis", "SPECIES", 182, 196], ["E. japonica", "SPECIES", 330, 341], ["E. japonica", "SPECIES", 469, 480], ["E. japonica", "SPECIES", 32, 43], ["E. hirae", "SPECIES", 85, 93], ["M. luteus", "SPECIES", 98, 107], ["S. aureus", "SPECIES", 168, 177], ["S. epidermidis", "SPECIES", 182, 196], ["E. japonica", "SPECIES", 330, 341], ["E. japonica", "SPECIES", 469, 480], ["E. japonica", "PROBLEM", 32, 43], ["M. luteus", "TEST", 98, 107], ["S. aureus", "PROBLEM", 168, 177], ["S. epidermidis", "PROBLEM", 182, 196], ["inhibition zones", "PROBLEM", 202, 218], ["Figs", "TEST", 304, 308], ["E. japonica", "PROBLEM", 330, 341], ["some bacteria", "PROBLEM", 404, 417], ["ConclusionFilters coated", "TREATMENT", 431, 455], ["natural E. japonica extract nanoparticles", "TREATMENT", 461, 502], ["antimicrobial", "OBSERVATION_MODIFIER", 4, 17], ["aureus", "OBSERVATION", 171, 177], ["epidermidis", "OBSERVATION", 185, 196], ["radius", "ANATOMY_MODIFIER", 252, 258], ["less toxic", "OBSERVATION_MODIFIER", 345, 355], ["stronger", "OBSERVATION_MODIFIER", 369, 377], ["antimicrobial activity", "OBSERVATION_MODIFIER", 378, 400]]], ["The pressure drop and antimicrobial activity of nanoparticle-coated filters increased with increasing nanoparticle deposition time.", [["nanoparticle", "CHEMICAL", 48, 60], ["nanoparticle", "SIMPLE_CHEMICAL", 48, 60], ["nanoparticle", "SIMPLE_CHEMICAL", 102, 114], ["The pressure drop", "TEST", 0, 17], ["antimicrobial activity of nanoparticle-coated filters", "TREATMENT", 22, 75], ["increasing nanoparticle deposition time", "TREATMENT", 91, 130], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["drop", "OBSERVATION_MODIFIER", 13, 17], ["antimicrobial activity", "OBSERVATION", 22, 44], ["increasing", "OBSERVATION_MODIFIER", 91, 101], ["nanoparticle deposition", "OBSERVATION", 102, 125]]], ["HPLC and ESI/MS analyses showed that the major chemical compounds in the E. japonica extract were 1(\u00df)-O-galloyl pedunculagin, quercetin-3-O-glucuronide, and kaempferol-3-O-glucoside.", [["1(\u00df)-O-galloyl pedunculagin", "CHEMICAL", 98, 125], ["quercetin-3-O-glucuronide", "CHEMICAL", 127, 152], ["kaempferol-3-O-glucoside", "CHEMICAL", 158, 182], ["1(\u00df)-O-galloyl pedunculagin", "CHEMICAL", 98, 125], ["quercetin-3-O-glucuronide", "CHEMICAL", 127, 152], ["kaempferol-3-O-glucoside", "CHEMICAL", 158, 182], ["E. japonica", "ORGANISM", 73, 84], ["1(\u00df)-O-galloyl pedunculagin", "SIMPLE_CHEMICAL", 98, 125], ["quercetin-3-O-glucuronide", "SIMPLE_CHEMICAL", 127, 152], ["kaempferol-3-O-glucoside", "SIMPLE_CHEMICAL", 158, 182], ["E. japonica", "SPECIES", 73, 84], ["E. japonica", "SPECIES", 73, 84], ["HPLC", "TEST", 0, 4], ["ESI/MS analyses", "TEST", 9, 24], ["the major chemical compounds", "PROBLEM", 37, 65], ["galloyl pedunculagin", "TREATMENT", 105, 125], ["quercetin", "TEST", 127, 136], ["glucuronide", "TREATMENT", 141, 152], ["kaempferol", "TREATMENT", 158, 168]]], ["The latter two compounds likely play important roles in the inactivation of bacterial aerosols.", [["bacterial aerosols", "TREATMENT", 76, 94], ["bacterial aerosols", "OBSERVATION", 76, 94]]], ["In vitro cytotoxicity and disk diffusion tests showed that E. japonica nanoparticles were less toxic and had stronger antimicrobial activity on some bacterial strains than the SNC, which is classified as a human carcinogen.", [["SNC", "CHEMICAL", 176, 179], ["E. japonica", "ORGANISM", 59, 70], ["nanoparticles", "SIMPLE_CHEMICAL", 71, 84], ["SNC", "SIMPLE_CHEMICAL", 176, 179], ["human", "ORGANISM", 206, 211], ["E. japonica", "SPECIES", 59, 70], ["human", "SPECIES", 206, 211], ["E. japonica", "SPECIES", 59, 70], ["human", "SPECIES", 206, 211], ["vitro cytotoxicity", "TEST", 3, 21], ["disk diffusion tests", "TEST", 26, 46], ["E. japonica nanoparticles", "PROBLEM", 59, 84], ["some bacterial strains", "PROBLEM", 144, 166], ["antimicrobial activity", "OBSERVATION_MODIFIER", 118, 140]]], ["Note that the amount of nanoparticles deposited on a given filter must be optimized for the type of bacterial aerosol.", [["a given filter", "TREATMENT", 51, 65], ["bacterial aerosol", "TREATMENT", 100, 117], ["amount", "OBSERVATION_MODIFIER", 14, 20], ["bacterial aerosol", "OBSERVATION", 100, 117]]], ["The antimicrobial performance of the E. japonica nanoparticle-coated filters depended both on the amount of nanoparticles deposited and the nature of the airborne bacteria.", [["nanoparticle", "CHEMICAL", 49, 61], ["E. japonica", "ORGANISM", 37, 48], ["E. japonica", "SPECIES", 37, 48], ["E. japonica", "SPECIES", 37, 48], ["The antimicrobial performance", "TREATMENT", 0, 29], ["the E. japonica nanoparticle-coated filters", "TREATMENT", 33, 76], ["nanoparticles", "TREATMENT", 108, 121], ["the airborne bacteria", "PROBLEM", 150, 171], ["antimicrobial", "OBSERVATION_MODIFIER", 4, 17], ["airborne bacteria", "OBSERVATION", 154, 171]]], ["Additionally, previous studies showed that major chemical components in a natural product were naturally degraded over time at room temperature [69] and antimicrobial activity and morphologies of natural-product nanoparticles were affected by a variety of environmental factors such as humidity and temperature [40, 70] .", [["natural-product nanoparticles", "SIMPLE_CHEMICAL", 196, 225], ["previous studies", "TEST", 14, 30], ["major chemical components", "PROBLEM", 43, 68], ["antimicrobial activity", "TEST", 153, 175], ["natural-product nanoparticles", "TREATMENT", 196, 225], ["major", "OBSERVATION_MODIFIER", 43, 48], ["chemical", "OBSERVATION_MODIFIER", 49, 57], ["components", "OBSERVATION_MODIFIER", 58, 68]]], ["Thus, the long-term stability and effects of humidity and thermal energy on E. japonica nanoparticles need to be evaluated to estimate the efficiency of nanoparticle-coated filters for real-world applications.", [["E. japonica", "ORGANISM", 76, 87], ["E. japonica", "SPECIES", 76, 87], ["E. japonica", "SPECIES", 76, 87], ["the long-term stability", "PROBLEM", 6, 29], ["humidity", "TREATMENT", 45, 53], ["thermal energy", "TREATMENT", 58, 72], ["E. japonica nanoparticles", "TREATMENT", 76, 101], ["nanoparticle-coated filters", "TREATMENT", 153, 180], ["long-term stability", "OBSERVATION_MODIFIER", 10, 29]]], ["Although the in vitro tests showed that E. japonica is less toxic than the carcinogen, it does not mean that the natural product is harmless to human health.", [["E. japonica", "ORGANISM", 40, 51], ["human", "ORGANISM", 144, 149], ["E. japonica", "SPECIES", 40, 51], ["human", "SPECIES", 144, 149], ["E. japonica", "SPECIES", 40, 51], ["human", "SPECIES", 144, 149], ["the in vitro tests", "TEST", 9, 27], ["E. japonica", "PROBLEM", 40, 51], ["less toxic", "OBSERVATION_MODIFIER", 55, 65]]], ["Thus, additional studies such as in vivo experiments are required.", [["additional studies", "TEST", 6, 24]]], ["Thus, field experiments are required to confirm the applicability of the natural-product nanoparticle-coated filter in a real environment.", [["nanoparticle", "SIMPLE_CHEMICAL", 89, 101], ["the natural-product nanoparticle-coated filter", "TREATMENT", 69, 115], ["coated filter", "OBSERVATION", 102, 115]]], ["We are considering a field experiment of our filters in a future study.", [["our filters", "TREATMENT", 41, 52], ["a future study", "TEST", 56, 70]]], ["This study provides valuable information for the development of an environmentally friendly bioaerosol control system that is suitable for use in indoor environments.", [["This study", "TEST", 0, 10]]]], "ed9bd29d43d2781618f8c3133dd85492af8960ce": [["INTRODUCTIONA/H1N1, more commonly referred to as swine flu, emerged in Mexico in spring 2009 1 and quickly spread across the world through international air travel, 2 infecting hundreds of thousands of people.", [["swine flu", "DISEASE", 49, 58], ["H1N1", "ORGANISM", 14, 18], ["people", "ORGANISM", 202, 208], ["swine flu", "SPECIES", 49, 58], ["people", "SPECIES", 202, 208], ["swine flu", "SPECIES", 49, 58]]], ["Following the approach set out in the UK Department of Health's National framework for responding to an influenza pandemic, 3 enhanced surveillance of cases and their contacts was instituted to minimise the spread of swine flu.", [["influenza pandemic", "DISEASE", 104, 122], ["swine flu", "DISEASE", 217, 226], ["swine", "SPECIES", 217, 222], ["swine flu", "SPECIES", 217, 226], ["an influenza pandemic", "PROBLEM", 101, 122], ["swine flu", "PROBLEM", 217, 226]]], ["Despite this, by May there were increased outbreaks across the UK and around the world, and on 11 June 2009 the WHO revised the alert to phase 6, thus declaring a global influenza pandemic, the first in over four decades.", [["influenza pandemic", "DISEASE", 170, 188], ["a global influenza pandemic", "PROBLEM", 161, 188], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["outbreaks", "OBSERVATION", 42, 51], ["influenza", "OBSERVATION", 170, 179]]], ["During the summer of 2009, predictions from scientists and the then chief medical officer for England, Professor Sir Liam Donaldson, suggested that, as a 'worst case' scenario, 30% of the UK population could be infected by the A/H1N1 virus, with 65 000 killed.", [["UK", "ORGANISM", 188, 190], ["A/H1N1 virus", "ORGANISM", 227, 239], ["H1N1 virus", "SPECIES", 229, 239], ["A/H1N1 virus", "SPECIES", 227, 239], ["the A/H1N1 virus", "PROBLEM", 223, 239], ["infected", "OBSERVATION", 211, 219]]], ["The 'best case' scenario was given as 5% of the population contracting the virus, resulting in 3100 deaths.", [["deaths", "DISEASE", 100, 106], ["the virus", "PROBLEM", 71, 80]]], ["5 Vaccine manufacturers were urgently developing a vaccine in preparation for the worst case and the government secured large quantities to immunise the British population.", [["5 Vaccine manufacturers", "TREATMENT", 0, 23], ["a vaccine", "TREATMENT", 49, 58]]], ["The strategy was to target the vaccination programme at those at greatest risk from A/H1N1, including people with underlying chronic health problems, pregnant women and young children, with a plan to roll it out later to the remaining population.INTRODUCTIONBy the spring of 2010 mortality data demonstrated that swine flu had been less lethal than feared and case death rates compared favourably with previous influenza pandemics, 6 accounting for less than 500 deaths in the UK.", [["chronic health problems", "DISEASE", 125, 148], ["swine flu", "DISEASE", 313, 322], ["death", "DISEASE", 365, 370], ["influenza pandemics", "DISEASE", 411, 430], ["deaths", "DISEASE", 463, 469], ["A/H1N1", "ORGANISM", 84, 90], ["people", "ORGANISM", 102, 108], ["women", "ORGANISM", 159, 164], ["children", "ORGANISM", 175, 183], ["swine", "ORGANISM", 313, 318], ["people", "SPECIES", 102, 108], ["women", "SPECIES", 159, 164], ["children", "SPECIES", 175, 183], ["swine", "SPECIES", 313, 318], ["A/H1N1", "SPECIES", 84, 90], ["swine flu", "SPECIES", 313, 322], ["the vaccination programme", "TREATMENT", 27, 52], ["H1N1", "PROBLEM", 86, 90], ["underlying chronic health problems", "PROBLEM", 114, 148], ["swine flu", "PROBLEM", 313, 322], ["previous influenza pandemics", "PROBLEM", 402, 430], ["chronic", "OBSERVATION_MODIFIER", 125, 132]]], ["7 The large disparity between predicted and actual rates became apparent and rendered a mass vaccination programme unnecessary, leaving the government with millions of doses of surplus vaccines (http://news.bbc.co.uk/ 1/hi/8448080.stm).", [["The large disparity", "PROBLEM", 2, 21], ["a mass vaccination programme", "TREATMENT", 86, 114], ["surplus vaccines", "TREATMENT", 177, 193], ["large", "OBSERVATION_MODIFIER", 6, 11], ["disparity", "OBSERVATION_MODIFIER", 12, 21]]], ["11 These perspectives or 'frames' influence what is included or excluded from stories and can misrepresent the scientific evidence, as was well demonstrated during the measles, mumps and rubella vaccine (MMR) controversy.", [["measles, mumps and rubella", "DISEASE", 168, 194], ["the measles", "PROBLEM", 164, 175], ["mumps", "PROBLEM", 177, 182], ["rubella vaccine", "TREATMENT", 187, 202]]], ["12 They can be influential in how people recall and interpret debates about emerging risks 13 and health behaviours.", [["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40]]], ["14 News coverage of the swine flu pandemic is likely to have influenced public perception and understanding as the media are a key source for health related information.", [["flu pandemic", "DISEASE", 30, 42], ["swine", "ORGANISM", 24, 29], ["swine flu pandemic", "SPECIES", 24, 42], ["swine flu pandemic", "SPECIES", 24, 42]]], ["16 Here we present an analysis of UK newsprint coverage of the swine flu pandemic from March 2009, just before it first emerged in Mexico, to February 2010, some time after it had lost its top news story status, and after the danger of a large peak of virulent cases during the winter flu season seemed to have passed.", [["flu pandemic", "DISEASE", 69, 81], ["swine", "SPECIES", 63, 68], ["UK newsprint coverage", "TREATMENT", 34, 55]]], ["Before commencing this research we were involved in conducting research examining UK public perceptions of the swine flu pandemic.", [["flu pandemic", "DISEASE", 117, 129], ["swine", "ORGANISM", 111, 116], ["swine flu", "SPECIES", 111, 120], ["the swine flu pandemic", "PROBLEM", 107, 129]]], ["17 This focus group study suggested that there was a sense among some people that the swine flu pandemic had been exaggerated by the media, leading us to hypothesise that the media had over-hyped the pandemic.", [["flu pandemic", "DISEASE", 92, 104], ["people", "ORGANISM", 70, 76], ["swine", "ORGANISM", 86, 91], ["people", "SPECIES", 70, 76], ["swine", "SPECIES", 86, 91], ["This focus group study", "TEST", 3, 25], ["the swine flu pandemic", "PROBLEM", 82, 104]]], ["To our knowledge this is the first in-depth examination of the UK newspapers' framing of the threat from the 2009e10 swine flu pandemic. .", [["flu pandemic", "DISEASE", 123, 135], ["swine", "SPECIES", 117, 122]]], ["We selected this timeframe to encompass a one year period from the initial emergence of A/H1N1 in Mexico 1 to the period when swine flu was no longer a top news story status.", [["swine", "SPECIES", 126, 131], ["A/H1N1", "SPECIES", 88, 94], ["swine flu", "SPECIES", 126, 135]]], ["Relevant articles from the eight target publications were identified using the electronic database LexisNexis, adopting the search terms 'swine flu' or 'H1N1' in 'All Text'.", [["swine", "SPECIES", 138, 143], ["swine flu", "SPECIES", 138, 147], ["the electronic database LexisNexis", "TREATMENT", 75, 109]]], ["All 5647 articles were exported into Word files.", [["Word files", "DNA", 37, 47]]], ["The first criterion was that A/H1N1 was the primary focus of article, given the very large number of articles initially identified.", [["A/H1N1", "ORGANISM", 29, 35], ["A/H1N1", "SPECIES", 29, 35], ["A/H1N1", "PROBLEM", 29, 35], ["very", "OBSERVATION_MODIFIER", 80, 84], ["large", "OBSERVATION_MODIFIER", 85, 90], ["number", "OBSERVATION_MODIFIER", 91, 97]]], ["This was defined as A/H1N1 being the primary topic of more than 50% of the article.", [["A/H1N1", "SPECIES", 20, 26], ["H1N1", "PROBLEM", 22, 26]]], ["Hence, all letters on swine flu or mentions of it in TV guides were excluded.", [["swine", "SPECIES", 22, 27], ["swine flu", "SPECIES", 22, 31], ["swine flu", "TREATMENT", 22, 31]]], ["Using these criteria, 3273 articles were classed as ineligible, leaving 2374 eligible articles for detailed coding and analysis.CodingTo develop a coding frame, a random selection of 100 articles were read through to identify the key discourses around A/ H1N1.", [["A/ H1N1", "ORGANISM", 252, 259], ["coding frame", "DNA", 147, 159], ["A/ H1N1", "SPECIES", 252, 259], ["detailed coding and analysis", "TEST", 99, 127], ["a random selection", "TEST", 161, 179], ["H1N1", "PROBLEM", 255, 259]]], ["These discourses became thematic categories in an initial coding frame.", [["thematic categories", "PROBLEM", 24, 43]]], ["The tone of the headline was also rated, because headlines are used to anchor and encapsulate what the journalist/editor defines as the most newsworthy aspect of the story and its main trajectory.", [["tone", "OBSERVATION_MODIFIER", 4, 8]]], ["21 Headlines, and the overall tone of the article, were separately rated as 'alarmist', 'reassuring' or 'neither': 'alarmist' headlines were those that were judged as potentially able to cause the reader anxiety; 'reassuring' headlines were judged to be potentially able to allay the reader's fears.", [["anxiety", "DISEASE", 204, 211], ["the reader anxiety", "PROBLEM", 193, 211]]], ["In order to systematically quantify the manifest content, every article was read line by line and coded to indicate whether or not each of the 44 thematic categories in the coding frame was mentioned and to rate its general tone.", [["coding frame", "DNA", 173, 185]]], ["All data were entered into SPSS V.14.", [["All data", "TEST", 0, 8]]], ["Using descriptive statistics we examine the trends in reporting of A/H1N1 over the 12 month period, formally testing (using c 2 tests) whether the portrayal of Figure 1 plots the number of articles on A/H1N1 and the estimated number of cases of swine flu in the UK by month.", [["swine flu", "DISEASE", 245, 254], ["A/H1N1", "ORGANISM", 67, 73], ["A/H1N1", "ORGANISM", 201, 207], ["swine", "SPECIES", 245, 250], ["A/H1N1", "SPECIES", 67, 73], ["A/H1N1", "SPECIES", 201, 207], ["swine", "SPECIES", 245, 250], ["A/H1N1", "PROBLEM", 67, 73], ["c 2 tests", "TEST", 124, 133], ["H1N1", "PROBLEM", 203, 207]]], ["Most of the articles (45.6%, n\u00bc1082) were published in the 2nd quarter which included the first peak in UK cases.", [["the articles", "TEST", 8, 20]]], ["More than one in four articles (27.0%, n\u00bc633) appeared in the 1st quarter as concerns about a potentially devastating pandemic grew and the number of reported cases began to grow worldwide.", [["a potentially devastating pandemic", "PROBLEM", 92, 126], ["devastating", "OBSERVATION_MODIFIER", 106, 117]]], ["Interest in swine flu declined in the 3rd quarter (21.4%, n\u00bc509), despite a second peak in cases in the UK as the 'normal' flu season came around.", [["swine", "ORGANISM", 12, 17], ["swine", "SPECIES", 12, 17], ["swine flu", "SPECIES", 12, 21]]], ["By the 4th quarter the story had effectively died; only 150 articles (6.3% of total for the year) appeared across the eight newspapers over these 3 months.Trend in reportingAnother sign of declining interest or newsworthiness of swine flu in the latter two quarters was a decline in the mean word count of articles: 398.76, 335.87, 241.68 and 209.89 in the four consecutive quarters.", [["swine flu", "DISEASE", 229, 238], ["swine", "SPECIES", 229, 234], ["swine flu", "PROBLEM", 229, 238], ["a decline", "PROBLEM", 270, 279]]], ["However, the standard deviations for each of these means was high (367.61, 289.65, 193.86 and 335.82, respectively), indicating considerable variation in article length throughout.", [["considerable variation in article length throughout", "PROBLEM", 128, 179], ["high", "OBSERVATION_MODIFIER", 61, 65], ["considerable", "OBSERVATION_MODIFIER", 128, 140], ["variation", "OBSERVATION_MODIFIER", 141, 150], ["article length", "OBSERVATION", 154, 168]]], ["Articles on swine flu had a modest presence on the front pages in the first two quarters (7.9% and 4.6% of articles were front page news in the 1st and 2nd quarters respectively) but were seldom a front page story by the latter two quarters (2.1% and 0.8% of articles in the 3rd and 4th quarters, respectively) (see table 1 ).", [["swine", "SPECIES", 12, 17], ["swine flu", "SPECIES", 12, 21]]], ["However, more articles appeared in the tabloids (1159, 48.8% of sample) than in the 'serious' (n\u00bc646, 27.2%) and middle market (n\u00bc569, 24.0%) newspapers.", [["the tabloids", "TEST", 35, 47], ["middle", "ANATOMY_MODIFIER", 113, 119]]], ["Table 1 presents the percentage of articles covering a selection of the issues coded for by quarter; any issues not included here were only mentioned in a small minority of articles over each quarter.", [["small", "OBSERVATION_MODIFIER", 155, 160]]], ["The headlines of the large majority of articles were rated as neither alarmist nor reassuring (82.9%, 84.4%, 81.1% and 74.0% for each of the four quarters).", [["large", "OBSERVATION_MODIFIER", 21, 26], ["majority", "OBSERVATION_MODIFIER", 27, 35]]], ["Fewer headlines were reassuring in the 2nd quarter, when anxieties about the future potential of the epidemic were at their peak (2.4% of articles), than in the 1st and 3rd quarters (4.4% and 5.3%, respectively), and particularly the last quarter (9.3%) (p\u00bc0.001).", [["anxieties", "PROBLEM", 57, 66], ["the epidemic", "PROBLEM", 97, 109]]], ["A broadly similar pattern was reflected in the ratings of the overall tone of the articles; again the vast majority (88.5%, 88.6%, 86.0% and 76.7%) were neither alarmist nor reassuring in tone overall.", [["broadly", "OBSERVATION_MODIFIER", 2, 9], ["similar", "OBSERVATION", 10, 17], ["overall tone", "OBSERVATION", 62, 74]]], ["There was a modest increase in the proportion of articles adopting a reassuring tone overall as the year wore on (2.8%, 3.2%, 4.7% and 8.0%), but there was also a slight increase in the proportion of articles adopting an alarmist tone overall (8.7%, 8.1%.", [["a slight increase", "PROBLEM", 161, 178], ["an alarmist tone", "TEST", 218, 234], ["modest", "OBSERVATION_MODIFIER", 12, 18], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["slight", "OBSERVATION_MODIFIER", 163, 169], ["increase", "OBSERVATION_MODIFIER", 170, 178]]], ["9.9% and 15.3%) (p\u00bc0.002).Trend in reportingReporting key issues by quarter 1st quarter2nd quarterDuring the 2nd quarter, when swine flu was declared a pandemic (WHO, 11 June 2009), 4 newsprint reporting was at its highest (45.6%, n\u00bc1082), mirroring the first peak in UK cases (see figure 1 ).", [["swine", "SPECIES", 127, 132], ["swine", "SPECIES", 127, 132]]], ["There was a lesser focus on the number of cases of swine flu elsewhere (mentioned in just 8% of articles during this quarter) and a greater focus on UK cases (38.1%) and deaths (26.3%).", [["swine flu", "DISEASE", 51, 60], ["deaths", "DISEASE", 170, 176], ["swine", "SPECIES", 51, 56], ["swine flu", "SPECIES", 51, 60], ["swine flu elsewhere", "PROBLEM", 51, 70], ["UK cases", "TEST", 149, 157], ["deaths", "TEST", 170, 176], ["lesser", "OBSERVATION_MODIFIER", 12, 18], ["focus", "OBSERVATION_MODIFIER", 19, 24], ["swine", "OBSERVATION_MODIFIER", 51, 56], ["flu", "OBSERVATION", 57, 60], ["greater", "OBSERVATION_MODIFIER", 132, 139]]], ["Although articles sometimes mentioned that swine flu symptoms are usually mild (17.3%), the first deaths in the UK during this period may account for the greater reporting of the potentially fatal nature of swine flu (featuring in 24.5% of articles in this quarter).3rd quarterIn the 3rd quarter a predicted surge in the UK was reported in more than one in ten newspaper articles (12.6%), and in October the UK experienced its second peak of swine flu cases.", [["flu symptoms", "DISEASE", 49, 61], ["deaths", "DISEASE", 98, 104], ["swine flu", "DISEASE", 207, 216], ["flu", "DISEASE", 448, 451], ["swine", "SPECIES", 43, 48], ["swine", "SPECIES", 207, 212], ["swine", "SPECIES", 442, 447], ["swine flu", "SPECIES", 43, 52], ["swine flu", "SPECIES", 207, 216], ["swine flu", "SPECIES", 442, 451], ["swine flu symptoms", "PROBLEM", 43, 61], ["swine flu", "PROBLEM", 207, 216], ["mild", "OBSERVATION_MODIFIER", 74, 78], ["fatal", "OBSERVATION_MODIFIER", 191, 196], ["swine", "OBSERVATION_MODIFIER", 207, 212], ["flu", "OBSERVATION", 213, 216]]], ["However, the declining newsworthiness of swine flu meant that there was only a modest increase in the number of swine flu articles which failed to mirror the October peak in UK cases (see figure 1 ).", [["swine", "SPECIES", 41, 46], ["swine flu", "SPECIES", 41, 50], ["swine flu", "SPECIES", 112, 121], ["swine flu articles", "PROBLEM", 112, 130], ["modest", "OBSERVATION_MODIFIER", 79, 85], ["increase", "OBSERVATION_MODIFIER", 86, 94]]], ["The key issues reported during this quarter were UK deaths (reported in 35.4% of articles in this quarter), the number of UK cases (30.5%) and the identification of factors which increased the risk of contracting the disease or suffering from a more severe form of the disease.", [["deaths", "DISEASE", 52, 58], ["the disease", "PROBLEM", 213, 224], ["the disease", "PROBLEM", 265, 276], ["disease", "OBSERVATION", 217, 224], ["more severe", "OBSERVATION_MODIFIER", 245, 256], ["disease", "OBSERVATION", 269, 276]]], ["People with underlying health problems (mentioned in 32% of articles in this quarter), pregnant women (18.3%) and children (13.3%) were identified as being at heightened risk.4th quarterBy the 4th quarter the number of UK swine flu cases had diminished.", [["flu", "DISEASE", 228, 231], ["People", "ORGANISM", 0, 6], ["women", "ORGANISM", 96, 101], ["children", "ORGANISM", 114, 122], ["UK", "ORGANISM", 219, 221], ["swine", "ORGANISM", 222, 227], ["People", "SPECIES", 0, 6], ["women", "SPECIES", 96, 101], ["children", "SPECIES", 114, 122], ["swine", "SPECIES", 222, 227], ["swine flu", "SPECIES", 222, 231], ["underlying health problems", "PROBLEM", 12, 38], ["diminished", "PROBLEM", 242, 252], ["diminished", "OBSERVATION_MODIFIER", 242, 252]]], ["As it was clear that the course of the pandemic had fallen well below the 'best case', let alone 'worst case' predictions made by the chief medical officer (Liam Donaldson) of between 3100 and 65 000 deaths.", [["deaths", "DISEASE", 200, 206]]], ["5 In the last quarter the (relatively low) number of deaths was mentioned in 39.3% of articles, and the fact that swine flu had not been as bad as first predicted was mentioned in almost a fifth of articles (18.7%).", [["deaths", "DISEASE", 53, 59], ["flu", "DISEASE", 120, 123], ["swine", "ORGANISM", 114, 119], ["swine", "SPECIES", 114, 119], ["swine flu", "SPECIES", 114, 123], ["swine flu", "PROBLEM", 114, 123]]], ["However, the issue of blame towards the government or public health academics for exaggerating the risk to the public of the pandemic was seldom mentioned in articles (see table 1 ).Other issuesOther issues that attracted relatively little newsprint coverage throughout the reporting of the pandemic included the development of a vaccine (which retained a relatively steady presence in stories over the first three quarters, being mentioned in just 8.4%, 9.5% 8.8% of articles, but just a single article in the 4th quarter once the second UK peak of cases had shown an early decline).", [["Other issuesOther issues", "PROBLEM", 182, 206], ["little newsprint coverage", "TREATMENT", 233, 258], ["a vaccine", "TREATMENT", 328, 337], ["early", "OBSERVATION_MODIFIER", 569, 574], ["decline", "OBSERVATION", 575, 582]]], ["Very few articles (n\u00bc27 in total) discussed potential side effects of a vaccine, stated that the vaccine was 'safe' (27 articles), or stated that the vaccine had been adequately (10 articles) or inadequately (20 articles) tested; none of these articles appeared in the 1st quarter.", [["a vaccine", "TREATMENT", 70, 79], ["the vaccine", "TREATMENT", 93, 104], ["the vaccine", "TREATMENT", 146, 157]]], ["Similarly, it was only during the last two quarters that a very small number of articles discussed whether the vaccine was safe for pregnant women (n\u00bc11) or for people with particular allergies (n\u00bc4).", [["allergies", "DISEASE", 184, 193], ["women", "ORGANISM", 141, 146], ["people", "ORGANISM", 161, 167], ["women", "SPECIES", 141, 146], ["people", "SPECIES", 161, 167], ["the vaccine", "TREATMENT", 107, 118], ["particular allergies", "PROBLEM", 173, 193], ["very", "OBSERVATION_MODIFIER", 59, 63], ["small", "OBSERVATION_MODIFIER", 64, 69]]], ["There was little discussion about the potential profits that the drug companies might gain from the vaccine (79 articles) or recriminations towards the drug companies (n\u00bc14).", [["the vaccine", "TREATMENT", 96, 107]]], ["There were other notable contrasts with past reporting of other public health issues; for example, surprisingly few articles included alarming personal stories about people who had contracted swine flu (292 articles in total), and only 24 articles included reassuring personal stories.DISCUSSIONSwine flu was the first influenza pandemic of the 21st century 4 and attracted huge media attention.", [["influenza pandemic", "DISEASE", 319, 337], ["people", "ORGANISM", 166, 172], ["people", "SPECIES", 166, 172], ["swine", "SPECIES", 192, 197], ["swine flu", "SPECIES", 192, 201]]], ["This meant that it was not possible for this study to examine media coverage of a range of media sources such as television, internet and radio.", [["this study", "TEST", 40, 50], ["media coverage", "TREATMENT", 62, 76]]], ["However, there is no reason to suppose that the media coverage in these sources would differ substantively since media stories tend to be recycled.", [["the media coverage", "TREATMENT", 44, 62], ["no reason to", "UNCERTAINTY", 18, 30]]], ["Initially in spring 2009 when the novel virus first emerged in Mexico and began to rapidly spread around the world, newspaper reports portrayed a picture of a highly infectious virus.", [["the novel virus", "PROBLEM", 30, 45], ["a highly infectious virus", "PROBLEM", 157, 182], ["infectious", "OBSERVATION", 166, 176]]], ["During this pre-pandemic period there were daily accounts of its transmission, with reports of rising numbers of cases and deaths from countries across the world.", [["deaths", "DISEASE", 123, 129], ["rising numbers of cases", "PROBLEM", 95, 118]]], ["In late April the first cases in the UK were confirmed.", [["UK", "CANCER", 37, 39]]], ["While newspaper reports continued to focus on its transmission, mentioning the rising number of cases and deaths both within the UK and beyond, uncertainties about the threat of this new virus began to feature in this early reporting.", [["deaths", "DISEASE", 106, 112], ["this new virus", "PROBLEM", 178, 192], ["virus", "OBSERVATION", 187, 192]]], ["In trying to make sense of swine flu, print journalists commonly drew on the outcomes of previous pandemics, including the 1918e19 Spanish flu outbreak which was estimated to have killed 40 million people, the 1957 Asian flu outbreak and the 1958 Hong Kong flu outbreak (both estimated to have been responsible for 1 million deaths each 23 ) and the more recent experience of SARS (severe acute respiratory syndrome).", [["flu", "DISEASE", 221, 224], ["deaths", "DISEASE", 325, 331], ["SARS", "DISEASE", 376, 380], ["acute respiratory syndrome", "DISEASE", 389, 415], ["swine", "ORGANISM", 27, 32], ["people", "ORGANISM", 198, 204], ["swine", "SPECIES", 27, 32], ["people", "SPECIES", 198, 204], ["swine flu", "SPECIES", 27, 36], ["Asian flu", "SPECIES", 215, 224], ["Hong Kong flu", "SPECIES", 247, 260], ["SARS (severe acute respiratory syndrome", "PROBLEM", 376, 415], ["severe", "OBSERVATION_MODIFIER", 382, 388], ["acute", "OBSERVATION_MODIFIER", 389, 394], ["respiratory syndrome", "OBSERVATION", 395, 415]]], ["One certainty in newspaper reports was that the virus was readily transmittable, and slowing and preventing its transmission were key features of newspaper reporting during this period.", [["the virus", "PROBLEM", 44, 53], ["slowing", "OBSERVATION_MODIFIER", 85, 92]]], ["In the spring of 2009 newsprint articles mentioned strategic decisions such as closing schools with infected pupils and restricting travel, and reported on the major communication campaign launched by the government in spring 2009 to urge members of the public to play their role in reducing its transmission through the adoption of personal hygiene measures.", [["infected pupils", "PROBLEM", 100, 115], ["personal hygiene measures", "TREATMENT", 333, 358]]], ["Early indications from a cross-sectional telephone survey of the British public to assess whether perceptions of the swine flu outbreak predicted changes in behaviour suggested that over a third of people (37.8%) reported adopting some recommended behaviour change, but those who believed that the outbreak had been exaggerated were less likely to adopt recommended behaviours.", [["flu", "DISEASE", 123, 126], ["swine", "ORGANISM", 117, 122], ["people", "ORGANISM", 198, 204], ["swine", "SPECIES", 117, 122], ["people", "SPECIES", 198, 204], ["swine flu", "SPECIES", 117, 126], ["the swine flu outbreak", "PROBLEM", 113, 135]]], ["24 Newspaper reporting peaked during the summer of 2009, mirroring the UK's first peak in cases.", [["UK", "GENE_OR_GENE_PRODUCT", 71, 73]]], ["During this period there was less focus on the swine flu rates across the world and a shift to reporting UK cases and deaths.", [["deaths", "DISEASE", 118, 124], ["UK", "GENE_OR_GENE_PRODUCT", 105, 107], ["swine flu", "SPECIES", 47, 56], ["the swine flu rates", "PROBLEM", 43, 62], ["less", "OBSERVATION_MODIFIER", 29, 33], ["focus", "OBSERVATION_MODIFIER", 34, 39]]], ["Uncertainties about the threat from the novel virus remained a feature of this reporting, with some reports mentioning that swine flu symptoms were usually mild while others informed the public that swine flu could have serious health consequences.", [["swine flu", "DISEASE", 124, 133], ["swine flu", "DISEASE", 199, 208], ["swine", "ORGANISM", 124, 129], ["swine", "ORGANISM", 199, 204], ["swine", "SPECIES", 124, 129], ["swine", "SPECIES", 199, 204], ["swine flu", "SPECIES", 124, 133], ["swine", "SPECIES", 199, 204], ["the novel virus", "PROBLEM", 36, 51], ["swine flu symptoms", "PROBLEM", 124, 142]]], ["As increasing numbers of people contracted swine flu, newspaper reports announced the first UK deaths, with headlines reporting: 'Swine flu claims its second Scots victim' (Express, 29 June 2009) and 'Woman who had just given birth killed by swine flu' (Guardian, 18 July 2009).", [["deaths", "DISEASE", 95, 101], ["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["swine", "SPECIES", 43, 48], ["Swine", "SPECIES", 130, 135], ["swine", "SPECIES", 242, 247], ["swine", "SPECIES", 43, 48], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["numbers", "OBSERVATION_MODIFIER", 14, 21]]], ["Over the summer there was some newspaper attention to the development of a vaccine, and uncertainty about swine flu's severity still featured in news reports.DISCUSSIONDespite predictions, the second peak in cases in the UK as the 'normal' flu season came around failed to exceed the first peak, and as many cases also proved to be mild, swine flu was no longer front page news.", [["flu", "DISEASE", 344, 347], ["swine", "ORGANISM", 106, 111], ["swine", "SPECIES", 106, 111], ["swine flu", "SPECIES", 106, 115], ["a vaccine", "TREATMENT", 73, 82], ["swine flu's severity", "PROBLEM", 106, 126], ["mild", "OBSERVATION_MODIFIER", 332, 336]]], ["Its perceived threat may have reduced as many people experienced swine flu for themselves with few adverse consequences, and the drop-off in reporting may itself have acted to reassure people.", [["people", "ORGANISM", 46, 52], ["people", "ORGANISM", 185, 191], ["people", "SPECIES", 46, 52], ["swine", "SPECIES", 65, 70], ["people", "SPECIES", 185, 191], ["swine", "SPECIES", 65, 70], ["few adverse consequences", "PROBLEM", 95, 119], ["reduced", "OBSERVATION_MODIFIER", 30, 37]]], ["However, during this period newspaper reports continued to mention UK deaths, and articles gave greater attention to identifying those at most risk.", [["deaths", "DISEASE", 70, 76]]], ["This coincided with the introduction of the swine flu vaccination programme targeting those at highest risk.", [["swine", "ORGANISM", 44, 49], ["swine", "SPECIES", 44, 49], ["swine flu", "SPECIES", 44, 53], ["the swine flu vaccination programme", "TREATMENT", 40, 75]]], ["However, throughout the period there was little attention paid to vaccine development or vaccine safety, suggesting again that the concerns about vaccine safety which were so prominent in the MMR controversy 12 have not been projected forward onto reporting of newer vaccines.DISCUSSIONFrom December onwards the swine flu pandemic diminished substantially as a newspaper story.", [["flu pandemic", "DISEASE", 318, 330], ["swine", "ORGANISM", 312, 317], ["swine", "SPECIES", 312, 317], ["vaccine development", "TREATMENT", 66, 85], ["vaccine safety", "TREATMENT", 89, 103], ["vaccine safety", "TREATMENT", 146, 160], ["newer vaccines", "TREATMENT", 261, 275], ["prominent", "OBSERVATION_MODIFIER", 175, 184]]], ["The early 'worst case' predictions of large numbers in the general population being infected and dying from swine flu had failed to materialise, 5 7 leading to some accusations of 'over-hyping the pandemic'.", [["pandemic", "DISEASE", 197, 205], ["swine", "SPECIES", 108, 113], ["swine flu", "SPECIES", 108, 117], ["large numbers", "PROBLEM", 38, 51], ["large", "OBSERVATION_MODIFIER", 38, 43], ["numbers", "OBSERVATION_MODIFIER", 44, 51], ["infected", "OBSERVATION", 84, 92]]], ["9 10 The fact that swine flu was not as bad as predicted is in part due to the fact that swine flu arrived in the UK towards the summer months and peaked in July when schools were closed, thus interrupting an important route of transmission.", [["swine flu", "DISEASE", 19, 28], ["swine", "ORGANISM", 19, 24], ["swine", "SPECIES", 19, 24], ["swine", "SPECIES", 89, 94], ["swine flu", "SPECIES", 19, 28], ["swine flu", "SPECIES", 89, 98]]], ["Accusations of the 'over-hyping' of stories in the media are not uncommon and result from a growing concern about journalists sensationalising health stories and overstating health risks to the public.", [["media", "ANATOMY", 51, 56]]], ["25 26 Our analysis suggests that this was seldom a feature of newspaper coverage of swine flu.", [["swine", "ORGANISM", 84, 89], ["swine", "SPECIES", 84, 89], ["swine flu", "SPECIES", 84, 93], ["Our analysis", "TEST", 6, 18], ["swine flu", "PROBLEM", 84, 93], ["swine flu", "OBSERVATION", 84, 93]]], ["The overall tone of the vast majority of newspaper articles was neutral (86.2%), a finding consistent with Duncan's media analysis conducted in the first few days of the pandemic, showing that 94% of 3979 media articles collected from 31 European countries were neutral, relaying factual information (70%).", [["Duncan's media analysis", "TEST", 107, 130], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["tone", "OBSERVATION_MODIFIER", 12, 16], ["consistent with", "UNCERTAINTY", 91, 106]]], ["27 In Britain there has been a succession of health scares over the last two decades or so which have raised public anxieties about who to trust to offer unbiased, accurate advice.", [["succession", "OBSERVATION_MODIFIER", 31, 41]]], ["28 Analysis of newspaper coverage of health risks shows that news stories tend to be heavily skewed towards dramatic health stories, such as bovine spongiform encephalitis (BSE), rather than ongoing health issues that statistically have a greater impact on health, such as smoking or obesity.", [["bovine spongiform encephalitis", "DISEASE", 141, 171], ["BSE", "DISEASE", 173, 176], ["obesity", "DISEASE", 284, 291], ["bovine spongiform encephalitis", "ORGANISM", 141, 171], ["bovine", "SPECIES", 141, 147], ["bovine spongiform encephalitis", "SPECIES", 141, 171], ["BSE", "SPECIES", 173, 176], ["bovine spongiform encephalitis", "PROBLEM", 141, 171], ["obesity", "PROBLEM", 284, 291], ["obesity", "OBSERVATION", 284, 291]]], ["16 In conclusion, swine flu attracted immense newspaper coverage in spring 2009 when the novel virus first emerged and spread around the world.", [["swine", "ORGANISM", 18, 23], ["swine", "SPECIES", 18, 23], ["swine flu", "SPECIES", 18, 27], ["the novel virus", "PROBLEM", 85, 100]]], ["Newsprint coverage of public health issues, such as the outbreak of BSE or the controversy over the MMR vaccine, has been an important vehicle in disseminating scientific information and in shaping the public's understanding of public health issues.", [["BSE", "DISEASE", 68, 71], ["BSE", "SPECIES", 68, 71], ["the MMR vaccine", "TREATMENT", 96, 111]]], ["13 Over the past two decades there has been a succession of health scares in which the media has been accused of exaggerating the risks, raising public anxieties and contributing to greater public misunderstandings of the issues.", [["health scares", "TREATMENT", 60, 73], ["public anxieties", "PROBLEM", 145, 161], ["succession", "OBSERVATION_MODIFIER", 46, 56]]], ["29 This in-depth examination of the content and 'framing' of the 2009e10 swine flu pandemic in UK newspapers provides little evidence of the newsprint media distorting the risks of swine flu.", [["flu pandemic", "DISEASE", 79, 91], ["swine flu", "DISEASE", 181, 190], ["2009e10 swine", "ORGANISM", 65, 78], ["swine flu pandemic", "SPECIES", 73, 91], ["swine", "SPECIES", 181, 186], ["swine flu", "SPECIES", 181, 190], ["depth examination", "TEST", 11, 28], ["swine flu", "PROBLEM", 181, 190]]], ["On the whole, coverage reflected genuine scientific uncertainties about the future course of the What is already known on this subject < Newsprint coverage of public health issues, such as the outbreak of bovine spongiform encephalitis or the controversy over the measles, mumps and rubella (MMR) vaccine, has been an important source of public understanding of disease outbreaks and other public health issues. < Often the media has been accused of exaggerating risks, and contributing to public worry and misunderstanding of public health research evidence, and a decrease in the trust in scientific evidence.What this study adds< This is the first in-depth examination of the content and 'framing' of the 2009e10 swine flu pandemic in UK newspapers. < On the whole, news coverage reflected genuine scientific uncertainties about the future course of the pandemic; there is little evidence of the newsprint media distorting the risks of swine flu.What this study addspandemic, and differed from earlier reporting of other public health issues which, in seeking to offer 'balance' in reporting, inappropriately presented two apparently equally well evidenced 'sides' to the issues and drew heavily on personal stories to heighten certain risks.", [["bovine spongiform encephalitis", "DISEASE", 205, 235], ["measles, mumps and rubella", "DISEASE", 264, 290], ["flu pandemic", "DISEASE", 722, 734], ["bovine spongiform encephalitis", "ORGANISM", 205, 235], ["mumps", "ORGANISM", 273, 278], ["rubella", "ORGANISM", 283, 290], ["2009e10 swine", "ORGANISM", 708, 721], ["UK", "ORGANISM", 738, 740], ["bovine", "SPECIES", 205, 211], ["swine", "SPECIES", 716, 721], ["swine", "SPECIES", 939, 944], ["bovine spongiform encephalitis", "SPECIES", 205, 235], ["swine flu", "SPECIES", 939, 948], ["bovine spongiform encephalitis", "PROBLEM", 205, 235], ["the measles", "PROBLEM", 260, 271], ["mumps", "PROBLEM", 273, 278], ["rubella (MMR) vaccine", "TREATMENT", 283, 304], ["disease outbreaks", "PROBLEM", 362, 379], ["this study", "TEST", 616, 626], ["depth examination", "TEST", 654, 671], ["the newsprint media", "PROBLEM", 895, 914], ["swine flu", "PROBLEM", 939, 948], ["this study", "TEST", 954, 964], ["bovine spongiform encephalitis", "OBSERVATION", 205, 235], ["decrease", "OBSERVATION_MODIFIER", 566, 574], ["little evidence of", "UNCERTAINTY", 876, 894], ["swine flu", "OBSERVATION", 939, 948]]], ["12 The disparity between public perception that the UK media over-hyped the risks associated with the swine flu pandemic, 17 and this analysis of UK newspapers suggests that the public may have sensed it was over-hyped due to the level of media coverage rather than due to alarmist, unbalanced news reporting.", [["flu pandemic", "DISEASE", 108, 120], ["swine flu pandemic", "SPECIES", 102, 120], ["swine flu pandemic", "SPECIES", 102, 120], ["the swine flu pandemic", "PROBLEM", 98, 120], ["media coverage", "TREATMENT", 239, 253], ["disparity", "OBSERVATION_MODIFIER", 7, 16]]], ["Thus in the case of the swine flu pandemic the news media's role as disseminators of factual health information on swine flu is to be welcomed, particularly in relation to their handling and responsible reporting on scientific uncertainty.", [["swine", "ORGANISM", 24, 29], ["swine", "SPECIES", 24, 29], ["swine", "SPECIES", 115, 120], ["swine flu", "SPECIES", 115, 124]]]], "03563c00fc01f52d338804ce50d8422dde6266e2": [["Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartDear Editor, Surgical practice is facing numerous challenges posed by the COVID-19 pandemic.", [["Non-Urgent Surgery", "TREATMENT", 12, 30]]], ["The prioritisation of resources towards dealing with COVID-19 patients has led to the postponement of all elective surgical procedures in the United Kingdom and various other nations, in an effort to maximise the number of staff and facilities available to tackle the increase in critically-ill patients (1) .", [["critically-ill", "DISEASE", 280, 294], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 295, 303], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 295, 303], ["all elective surgical procedures", "TREATMENT", 102, 134]]], ["These are clearly necessary steps but how will health services and surgical specialties recover to meet the subsequent operation backlog created by the suspension of elective procedures?Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartA recent article by the CovidSurg Collaborative estimated that the global number of adult elective surgery cancellation could be as high as 28.5 million operations over a period of 12 weeks of suspension and if countries were to increase their normal surgical work volume by 10% postpandemic, the median time to clear the backlog would be 90 weeks.", [["surgical specialties", "TREATMENT", 67, 87], ["the subsequent operation backlog", "TREATMENT", 104, 136], ["elective procedures", "TREATMENT", 166, 185], ["Non-Urgent Surgery", "TREATMENT", 198, 216], ["adult elective surgery cancellation", "TREATMENT", 347, 382], ["suspension", "TREATMENT", 456, 466]]], ["An increase of 20% would take a median of 45 weeks and an increase in volume by 30% would take a median of 30 weeks to clear the backlog.", [["an increase in volume", "TREATMENT", 55, 76], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["increase", "OBSERVATION_MODIFIER", 58, 66]]], ["The article goes further to state, using the UK as an example, that at an average cost of \u00a34,000 per operation the total cost of clearing the backlog would amount to over \u00a32 billion.", [["amount", "OBSERVATION_MODIFIER", 156, 162]]], ["This stresses the great importance of well-designed recovery plans and strategies to mitigate the impact caused by COVID-19 (2).Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartThe Royal College of Surgeons of England has published a guide on the short-term recovery of surgical services post-pandemic.", [["COVID-19", "CHEMICAL", 115, 123], ["strategies", "TREATMENT", 71, 81], ["Non-Urgent Surgery", "TREATMENT", 140, 158], ["surgical services", "TREATMENT", 298, 315]]], ["These are salient points and while these guidelines are providing a framework, they do not provide specific information on how hospitals and their surgical departments should approach the resumption of services, due to the complexity of the situation and the difference in challenges faced by different hospitals (1, 3) .Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartIn a recent letter the Chief Executive and Chief Operation Officer of the National Health Service (NHS) in the UK have asked local systems and organisations to step up and ensure that urgent and time-critical surgery are carried out at pre-pandemic levels; however, the provision of at least some non-urgent elective procedures has been left to the judgement of the local authorities taking into account the resources available to them (4).Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartThe British Orthopaedic Association has recently published guidance on the resumption of nonurgent services post-pandemic.", [["Non-Urgent Surgery", "TREATMENT", 333, 351], ["critical surgery", "TREATMENT", 598, 614], ["some non-urgent elective procedures", "TREATMENT", 690, 725], ["Non-Urgent Surgery", "TREATMENT", 850, 868], ["nonurgent services", "TREATMENT", 1004, 1022]]], ["One of the main points was the separation of patients along COVIDfree (green) and COVID-managed (blue) pathways.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["COVID-managed (blue) pathways", "TREATMENT", 82, 111], ["main", "OBSERVATION_MODIFIER", 11, 15], ["separation", "OBSERVATION_MODIFIER", 31, 41]]], ["It is within these green zones that non-urgent procedures should be planned to go ahead, especially higher risk procedures.", [["non-urgent procedures", "TREATMENT", 36, 57]]], ["The document does not provide a specific timeline but states that these procedures should be resumed in the short to medium term subject to capacity (e.g. theatre throughput, staff, facilities, PPE, drugs) and the establishment and availability of green zones.Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartThe document also provides guidance on precautions taken for patients and staff in the green zones with patients being required to have completed self-isolation or shielding for 14 days prior to surgery as well as 14 days post-op.", [["patients", "ORGANISM", 398, 406], ["patients", "ORGANISM", 441, 449], ["patients", "SPECIES", 398, 406], ["patients", "SPECIES", 441, 449], ["these procedures", "TREATMENT", 66, 82], ["drugs", "TREATMENT", 199, 204], ["Non-Urgent Surgery", "TREATMENT", 272, 290], ["precautions", "TREATMENT", 376, 387], ["self-isolation", "TREATMENT", 483, 497], ["shielding", "TREATMENT", 501, 510], ["surgery", "TREATMENT", 532, 539]]], ["Patients should also be screened for symptoms in this period and be tested for coronavirus 72-48 hours before the operation.", [["coronavirus", "DISEASE", 79, 90], ["Patients", "ORGANISM", 0, 8], ["coronavirus", "ORGANISM", 79, 90], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 37, 45], ["coronavirus", "PROBLEM", 79, 90], ["the operation", "TREATMENT", 110, 123]]], ["Social distancing as well as appropriate transport and directions should be provided for patients travelling to hospital to avoid blue zones as much as possible.Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartThe staff working in green zones should be screened daily for symptoms of COVID-19 and undergo regular testing, whilst ideally not interacting with blue zones for at least a week.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["blue zones", "PROBLEM", 130, 140], ["Non-Urgent Surgery", "TREATMENT", 173, 191], ["symptoms", "PROBLEM", 300, 308], ["COVID", "TEST", 312, 317], ["regular testing", "TEST", 333, 348]]], ["This would mean significant changes to rotas and staff may also be expected to move to new hospitals (5) .Recovery of Non-Urgent Surgery -Operation Backlog and Proposals for a RestartThe challenges ahead are unprecedented and thus it will be a very difficult task to design recovery plans that work for every speciality or hospital.", [["Non-Urgent Surgery", "TREATMENT", 118, 136]]], ["Please note that failure to respond to these questions/statements will mean your submission will be returned.", [["failure", "PROBLEM", 17, 24], ["failure", "OBSERVATION", 17, 24]]], ["If you have nothing to declare in any of these categories, then this should be stated.Please state any conflicts of interestNo conflicts of interest.Please state any sources of funding for your researchNo funding received.Please state whether Ethical Approval was given, by whom and the relevant Judgement's reference numberNo ethical approval required.Research Registration Unique Identifying Number (UIN)Please enter the name of the registry, the hyperlink to the registration and the unique identifying number of the study.", [["your research", "TEST", 189, 202], ["ethical approval", "TREATMENT", 327, 343], ["the study", "TEST", 516, 525], ["conflicts", "OBSERVATION", 127, 136], ["funding", "OBSERVATION", 205, 212], ["ethical", "OBSERVATION", 327, 334]]], ["You can register your research at http://www.researchregistry.com to obtain your UIN if you have not already registered your study.", [["your study", "TEST", 120, 130]]], ["This is mandatory for human studies only.", [["human", "ORGANISM", 22, 27], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["human studies", "TEST", 22, 35]]]], "43d2ccf4916c586e07a70c5b316824ce04433a71": [["IntroductionThe COVID19 pandemic, which has high mortality and infectivity, occurred in Wuhan Province of the People's Republic of China in December 2019 and subsequently become one of the world's major health problems.", [["high", "OBSERVATION_MODIFIER", 44, 48]]], ["As of April 2020, approximately 1 million infected patients and 50,000 deaths have been observed.", [["deaths", "DISEASE", 71, 77], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["Its infectivity is very high, and there is an exponential increase in the number of infections (World Health Organization, 2020) .", [["infections", "DISEASE", 84, 94], ["Its infectivity", "PROBLEM", 0, 15], ["an exponential increase", "PROBLEM", 43, 66], ["infections", "PROBLEM", 84, 94], ["infectivity", "OBSERVATION_MODIFIER", 4, 15], ["very", "OBSERVATION_MODIFIER", 19, 23], ["high", "OBSERVATION_MODIFIER", 24, 28], ["exponential", "OBSERVATION_MODIFIER", 46, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["number", "OBSERVATION_MODIFIER", 74, 80], ["infections", "OBSERVATION", 84, 94]]], ["Numerous treatment studies for COVID19, including medicines, anti-virals and herbal products originally used for different diseases are continuing all over the world.", [["COVID19", "CHEMICAL", 31, 38], ["COVID19", "SIMPLE_CHEMICAL", 31, 38], ["anti-virals", "SIMPLE_CHEMICAL", 61, 72], ["Numerous treatment studies", "TEST", 0, 26], ["COVID19", "TREATMENT", 31, 38], ["medicines", "TREATMENT", 50, 59], ["anti-virals", "TREATMENT", 61, 72], ["herbal products", "TREATMENT", 77, 92], ["different diseases", "PROBLEM", 113, 131]]], ["Many anti-virals, such as the lopinavir/ritonavir combination, favipiravir and arbidol have been experimented with in the treatment of this pandemic (Lim et al., 2020) .IntroductionThe coronavirus leading to COVID19 is the large and enveloped RNA virus with crown-shaped protrusions.IntroductionCoronaviruses (CoVs) can cause respiratory, enteric, hepatic and neurological diseases.", [["respiratory", "ANATOMY", 326, 337], ["hepatic", "ANATOMY", 348, 355], ["neurological", "ANATOMY", 360, 372], ["lopinavir/ritonavir", "CHEMICAL", 30, 49], ["favipiravir", "CHEMICAL", 63, 74], ["arbidol", "CHEMICAL", 79, 86], ["coronavirus", "DISEASE", 185, 196], ["respiratory, enteric, hepatic and neurological diseases", "DISEASE", 326, 381], ["lopinavir", "CHEMICAL", 30, 39], ["ritonavir", "CHEMICAL", 40, 49], ["favipiravir", "CHEMICAL", 63, 74], ["arbidol", "CHEMICAL", 79, 86], ["lopinavir", "SIMPLE_CHEMICAL", 30, 39], ["ritonavir", "SIMPLE_CHEMICAL", 40, 49], ["favipiravir", "SIMPLE_CHEMICAL", 63, 74], ["arbidol", "SIMPLE_CHEMICAL", 79, 86], ["coronavirus", "ORGANISM", 185, 196], ["COVID19", "GENE_OR_GENE_PRODUCT", 208, 215], ["CoVs", "GENE_OR_GENE_PRODUCT", 310, 314], ["hepatic", "MULTI-TISSUE_STRUCTURE", 348, 355], ["COVID19", "DNA", 208, 215], ["Many anti-virals", "TREATMENT", 0, 16], ["the lopinavir", "TREATMENT", 26, 39], ["ritonavir combination", "TREATMENT", 40, 61], ["favipiravir", "TREATMENT", 63, 74], ["arbidol", "TREATMENT", 79, 86], ["The coronavirus", "PROBLEM", 181, 196], ["COVID19", "TREATMENT", 208, 215], ["the large and enveloped RNA virus", "PROBLEM", 219, 252], ["crown-shaped protrusions", "PROBLEM", 258, 282], ["IntroductionCoronaviruses (CoVs)", "TREATMENT", 283, 315], ["respiratory, enteric, hepatic and neurological diseases", "PROBLEM", 326, 381], ["coronavirus", "OBSERVATION", 185, 196], ["large", "OBSERVATION_MODIFIER", 223, 228], ["enveloped", "OBSERVATION_MODIFIER", 233, 242], ["RNA virus", "OBSERVATION", 243, 252], ["crown", "OBSERVATION_MODIFIER", 258, 263], ["shaped", "OBSERVATION_MODIFIER", 264, 270], ["protrusions", "OBSERVATION", 271, 282], ["enteric", "ANATOMY", 339, 346], ["hepatic", "ANATOMY", 348, 355], ["neurological diseases", "OBSERVATION", 360, 381]]], ["CoVs are divided into four subfamilies serologically and genotypically, which are a, b, c and d-CoVs.", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["d-CoVs", "SIMPLE_CHEMICAL", 94, 100], ["CoVs", "PROTEIN", 0, 4], ["CoVs", "PROBLEM", 0, 4], ["d-CoVs", "OBSERVATION", 94, 100]]], ["SARS coronavirus (SARS-CoVs) and MERS coronavirus (MERS-CoVs) are members of the b-CoV family.", [["SARS coronavirus", "DISEASE", 0, 16], ["SARS-CoVs", "DISEASE", 18, 27], ["SARS coronavirus", "ORGANISM", 0, 16], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 18, 27], ["MERS coronavirus", "ORGANISM", 33, 49], ["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 51, 60], ["b-CoV", "GENE_OR_GENE_PRODUCT", 81, 86], ["b-CoV family", "PROTEIN", 81, 93], ["SARS coronavirus", "SPECIES", 0, 16], ["MERS coronavirus", "SPECIES", 33, 49], ["SARS coronavirus", "SPECIES", 0, 16], ["MERS coronavirus", "SPECIES", 33, 49], ["SARS coronavirus (SARS-CoVs)", "PROBLEM", 0, 28], ["MERS coronavirus", "PROBLEM", 33, 49]]], ["In genome analysis, SARS-CoV-2 exhibits 79.5% and 50% similarity with SARS-CoV and MERS-CoV, respectively .IntroductionThe SARS-CoV-2 virus has a 30 kb genome size, similar to other b-CoVs, with a nucleocapsid consisting of a genomic RNA and a phosphorylated nucleocapsid (N) protein.", [["SARS-CoV-2", "ORGANISM", 20, 30], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["SARS-CoV-2 virus", "ORGANISM", 123, 139], ["CoVs", "GENE_OR_GENE_PRODUCT", 184, 188], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 259, 275], ["b-CoVs", "DNA", 182, 188], ["genomic RNA", "RNA", 226, 237], ["phosphorylated nucleocapsid (N) protein", "PROTEIN", 244, 283], ["CoV-2 virus", "SPECIES", 128, 139], ["SARS-CoV", "SPECIES", 20, 28], ["SARS-CoV", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 83, 91], ["SARS-CoV-2 virus", "SPECIES", 123, 139], ["genome analysis", "TEST", 3, 18], ["SARS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["MERS", "TEST", 83, 87], ["The SARS", "TEST", 119, 127], ["CoV", "TEST", 128, 131], ["a 30 kb genome size", "PROBLEM", 144, 163], ["other b-CoVs", "PROBLEM", 176, 188], ["a nucleocapsid", "PROBLEM", 195, 209], ["a genomic RNA", "PROBLEM", 224, 237], ["a phosphorylated nucleocapsid (N) protein", "PROBLEM", 242, 283], ["size", "OBSERVATION_MODIFIER", 159, 163], ["b-CoVs", "OBSERVATION", 182, 188], ["nucleocapsid", "OBSERVATION", 197, 209], ["genomic RNA", "OBSERVATION", 226, 237]]], ["The phospholipid double layers contain nucleocapsids that are surrounded by two different types of spike proteins.", [["phospholipid double layers", "ANATOMY", 4, 30], ["nucleocapsids", "ANATOMY", 39, 52], ["phospholipid", "SIMPLE_CHEMICAL", 4, 16], ["nucleocapsids", "CELLULAR_COMPONENT", 39, 52], ["spike proteins", "PROTEIN", 99, 113], ["The phospholipid double layers", "TREATMENT", 0, 30], ["nucleocapsids", "PROBLEM", 39, 52], ["spike proteins", "PROBLEM", 99, 113], ["phospholipid", "OBSERVATION", 4, 16], ["double layers", "OBSERVATION_MODIFIER", 17, 30], ["nucleocapsids", "OBSERVATION", 39, 52], ["two different", "OBSERVATION_MODIFIER", 76, 89], ["spike proteins", "OBSERVATION", 99, 113]]], ["There are spike glycoprotein trimmers found in all CoVs.", [["CoVs", "CANCER", 51, 55], ["spike glycoprotein trimmers", "PROTEIN", 10, 37], ["CoVs", "PROTEIN", 51, 55], ["spike glycoprotein trimmers", "PROBLEM", 10, 37], ["spike", "OBSERVATION_MODIFIER", 10, 15], ["glycoprotein trimmers", "OBSERVATION", 16, 37], ["all CoVs", "OBSERVATION", 47, 55]]], ["Also, some CoVs contain hemagglutinin-esterase.", [["CoVs", "GENE_OR_GENE_PRODUCT", 11, 15], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 24, 46], ["CoVs", "PROTEIN", 11, 15], ["hemagglutinin", "PROTEIN", 24, 37], ["esterase", "PROTEIN", 38, 46], ["some CoVs contain hemagglutinin-esterase", "PROBLEM", 6, 46], ["hemagglutinin", "OBSERVATION", 24, 37], ["esterase", "OBSERVATION_MODIFIER", 38, 46]]], ["The membrane protein and the envelope protein are among the S proteins in the viral envelope (Elfiky, 2020) .", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["membrane protein", "PROTEIN", 4, 20], ["envelope protein", "PROTEIN", 29, 45], ["S proteins", "PROTEIN", 60, 70], ["The membrane protein", "TEST", 0, 20], ["the envelope protein", "TEST", 25, 45], ["membrane protein", "OBSERVATION", 4, 20], ["envelope protein", "OBSERVATION", 29, 45], ["viral envelope", "OBSERVATION", 78, 92]]], ["The SARS-CoV-2 cell representation is shown in Figure 1 .IntroductionLike other RNA viruses, SARS-CoV-2 contains the RNA Polymerase 2 enzyme.", [["cell", "ANATOMY", 15, 19], ["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 93, 97], ["SARS-CoV-2 cell", "CELL", 4, 19], ["SARS-CoV-2", "ORGANISM", 93, 103], ["RNA Polymerase 2", "GENE_OR_GENE_PRODUCT", 117, 133], ["RNA Polymerase 2 enzyme", "PROTEIN", 117, 140], ["SARS-CoV", "SPECIES", 93, 101], ["The SARS", "TEST", 0, 8], ["other RNA viruses", "PROBLEM", 74, 91], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["the RNA Polymerase", "TEST", 113, 131], ["RNA viruses", "OBSERVATION", 80, 91]]], ["It performs RNA replication, as well as virus replication (Furuta et al., 2017) .", [["RNA replication", "TREATMENT", 12, 27], ["virus replication", "TREATMENT", 40, 57]]], ["Favipiravir is an antiviral agent that selectively and strongly inhibits the RNAdependent RNA polymerase (RdRp) of RNA viruses.", [["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["RNAdependent RNA polymerase", "PROTEIN", 77, 104], ["RdRp", "PROTEIN", 106, 110], ["Favipiravir", "TREATMENT", 0, 11], ["an antiviral agent", "TREATMENT", 15, 33], ["RNA viruses", "PROBLEM", 115, 126], ["RNA viruses", "OBSERVATION", 115, 126]]], ["Favipiravir is effective against a wide range of influenza viruses and subtypes, including strains resistant to existing anti-influenza drugs.", [["Favipiravir", "CHEMICAL", 0, 11], ["influenza viruses", "DISEASE", 49, 66], ["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["influenza viruses", "ORGANISM", 49, 66], ["Favipiravir", "TREATMENT", 0, 11], ["influenza viruses", "PROBLEM", 49, 66], ["strains", "PROBLEM", 91, 98], ["existing anti-influenza drugs", "TREATMENT", 112, 141], ["influenza viruses", "OBSERVATION", 49, 66], ["anti-influenza drugs", "OBSERVATION", 121, 141]]], ["Favipiravir also affects other RNA viruses, such as arenaviruses, bunyaviruses, filoviruses, and coronaviruses.", [["Favipiravir", "CHEMICAL", 0, 11], ["filoviruses", "DISEASE", 80, 91], ["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["bunyaviruses", "GENE_OR_GENE_PRODUCT", 66, 78], ["filoviruses", "GENE_OR_GENE_PRODUCT", 80, 91], ["Favipiravir", "TREATMENT", 0, 11], ["other RNA viruses", "PROBLEM", 25, 42], ["arenaviruses", "PROBLEM", 52, 64], ["bunyaviruses", "PROBLEM", 66, 78], ["filoviruses", "PROBLEM", 80, 91], ["coronaviruses", "PROBLEM", 97, 110], ["RNA viruses", "OBSERVATION", 31, 42], ["filoviruses", "OBSERVATION", 80, 91]]], ["Due to these effects, it is thought that favipiravir can be used in the treatment of diseases occurring not only with influenza infection, but also with other RNA viruses (Cai et al., 2020) .", [["favipiravir", "CHEMICAL", 41, 52], ["influenza infection", "DISEASE", 118, 137], ["favipiravir", "CHEMICAL", 41, 52], ["favipiravir", "SIMPLE_CHEMICAL", 41, 52], ["favipiravir", "TREATMENT", 41, 52], ["diseases", "PROBLEM", 85, 93], ["influenza infection", "PROBLEM", 118, 137], ["diseases", "OBSERVATION", 85, 93]]], ["The results of a study conducted with a total of 80 patients (the experimental group consisted of 35 patients given favipiravir, and the control group consisted of 45 patients given lopinavir/ritonavir) showed that favipiravir had a better anti-viral effect than lopinavir/ritonavir.", [["favipiravir", "CHEMICAL", 116, 127], ["lopinavir/ritonavir", "CHEMICAL", 182, 201], ["favipiravir", "CHEMICAL", 215, 226], ["lopinavir/ritonavir", "CHEMICAL", 263, 282], ["favipiravir", "CHEMICAL", 116, 127], ["lopinavir", "CHEMICAL", 182, 191], ["ritonavir", "CHEMICAL", 192, 201], ["favipiravir", "CHEMICAL", 215, 226], ["lopinavir", "CHEMICAL", 263, 272], ["ritonavir", "CHEMICAL", 273, 282], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 101, 109], ["favipiravir", "SIMPLE_CHEMICAL", 116, 127], ["patients", "ORGANISM", 167, 175], ["lopinavir", "SIMPLE_CHEMICAL", 182, 191], ["ritonavir", "SIMPLE_CHEMICAL", 192, 201], ["favipiravir", "SIMPLE_CHEMICAL", 215, 226], ["lopinavir", "SIMPLE_CHEMICAL", 263, 272], ["ritonavir", "SIMPLE_CHEMICAL", 273, 282], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 167, 175], ["a study", "TEST", 15, 22], ["favipiravir", "TREATMENT", 116, 127], ["lopinavir", "TREATMENT", 182, 191], ["ritonavir", "TREATMENT", 192, 201], ["favipiravir", "TREATMENT", 215, 226], ["lopinavir", "TREATMENT", 263, 272], ["ritonavir", "TREATMENT", 273, 282]]], ["The study showed that patients treated with favipiravir recover faster than the other treatments.", [["favipiravir", "CHEMICAL", 44, 55], ["favipiravir", "CHEMICAL", 44, 55], ["patients", "ORGANISM", 22, 30], ["favipiravir", "SIMPLE_CHEMICAL", 44, 55], ["patients", "SPECIES", 22, 30], ["The study", "TEST", 0, 9], ["favipiravir", "TREATMENT", 44, 55], ["the other treatments", "TREATMENT", 76, 96]]], ["The favipiravir group showed that the patient lungs healed better than in the control group.", [["lungs", "ANATOMY", 46, 51], ["favipiravir", "CHEMICAL", 4, 15], ["favipiravir", "CHEMICAL", 4, 15], ["favipiravir", "SIMPLE_CHEMICAL", 4, 15], ["patient", "ORGANISM", 38, 45], ["lungs", "ORGAN", 46, 51], ["patient", "SPECIES", 38, 45], ["The favipiravir group", "TEST", 0, 21], ["lungs", "ANATOMY", 46, 51], ["healed", "OBSERVATION", 52, 58]]], ["It was observed that patients receiving favipiravir gave positive results in terms of the virus within four days after treatment, while patients in the control group showed positive results only after 11 days.", [["favipiravir", "CHEMICAL", 40, 51], ["favipiravir", "CHEMICAL", 40, 51], ["patients", "ORGANISM", 21, 29], ["favipiravir", "SIMPLE_CHEMICAL", 40, 51], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 136, 144], ["favipiravir", "TREATMENT", 40, 51], ["the virus", "PROBLEM", 86, 95], ["treatment", "TREATMENT", 119, 128]]], ["Finally, it was observed that 91.4% of those given favipiravir showed better results from imaging tests of the lungs, whereas only 62.2% of the control group showed an improvement.", [["lungs", "ANATOMY", 111, 116], ["favipiravir", "CHEMICAL", 51, 62], ["favipiravir", "CHEMICAL", 51, 62], ["favipiravir", "SIMPLE_CHEMICAL", 51, 62], ["lungs", "ORGAN", 111, 116], ["favipiravir", "TREATMENT", 51, 62], ["imaging tests", "TEST", 90, 103], ["lungs", "ANATOMY", 111, 116], ["improvement", "OBSERVATION_MODIFIER", 168, 179]]], ["While no favourable side effects were observed in the treatment group, favipiravir was shown to have significantly fewer side effects than the lopinavir/ritonavir group (Nguyen & Haenni, 2003) .IntroductionWhile viruses are replicating, an RNA with positive polarity is similar to mRNA and can be read directly by host cell ribosomes.", [["cell ribosomes", "ANATOMY", 319, 333], ["favipiravir", "CHEMICAL", 71, 82], ["lopinavir/ritonavir", "CHEMICAL", 143, 162], ["favipiravir", "CHEMICAL", 71, 82], ["lopinavir", "CHEMICAL", 143, 152], ["ritonavir", "CHEMICAL", 153, 162], ["favipiravir", "SIMPLE_CHEMICAL", 71, 82], ["lopinavir", "SIMPLE_CHEMICAL", 143, 152], ["ritonavir", "SIMPLE_CHEMICAL", 153, 162], ["host cell", "CELL", 314, 323], ["ribosomes", "CELLULAR_COMPONENT", 324, 333], ["mRNA", "RNA", 281, 285], ["favourable side effects", "PROBLEM", 9, 32], ["favipiravir", "TREATMENT", 71, 82], ["significantly fewer side effects", "PROBLEM", 101, 133], ["the lopinavir/ritonavir group", "TREATMENT", 139, 168], ["no", "UNCERTAINTY", 6, 8], ["favourable", "OBSERVATION_MODIFIER", 9, 19], ["host cell ribosomes", "OBSERVATION", 314, 333]]], ["RNA with negative polarity is the complement of mRNA; it must be converted to a positive-strand by the enzyme RNA polymerase for the host cell ribosomes to be able to read it (Fodor, 2013) .", [["cell ribosomes", "ANATOMY", 138, 152], ["cell", "CELL", 138, 142], ["RNA", "RNA", 0, 3], ["mRNA", "RNA", 48, 52], ["enzyme RNA polymerase", "PROTEIN", 103, 124], ["the enzyme RNA polymerase", "TEST", 99, 124], ["the host cell ribosomes", "PROBLEM", 129, 152], ["negative polarity", "OBSERVATION_MODIFIER", 9, 26]]], ["In influenza viruses with negative polarity, during RNA polymerase transcription, viral RNA polymerase synthesizes mRNA using 5q-capped RNA primers.", [["influenza viruses", "DISEASE", 3, 20], ["influenza viruses", "ORGANISM", 3, 20], ["RNA polymerase", "PROTEIN", 52, 66], ["viral RNA polymerase", "RNA", 82, 102], ["mRNA", "RNA", 115, 119], ["5q-capped RNA primers", "DNA", 126, 147], ["influenza viruses", "PROBLEM", 3, 20], ["RNA polymerase transcription", "TREATMENT", 52, 80], ["viral RNA polymerase synthesizes mRNA", "PROBLEM", 82, 119], ["5q-capped RNA primers", "TREATMENT", 126, 147], ["influenza viruses", "OBSERVATION", 3, 20], ["negative polarity", "OBSERVATION_MODIFIER", 26, 43]]], ["During replication, the viral RNA polymerase forms a complementary RNA (cRNA) replication intermediate, which is the complement of the RNA that acts as a pattern for the synthesis of new vRNA copies (Turkish Min. of Health, 2020) .", [["viral RNA polymerase", "RNA", 24, 44], ["complementary RNA", "RNA", 53, 70], ["vRNA copies", "DNA", 187, 198], ["the viral RNA polymerase", "TEST", 20, 44], ["viral RNA", "OBSERVATION", 24, 33]]], ["During replication, coronaviruses do not contain RNA-dependent RNA polymerase (RdRp) enzymes because they have a positive polarity, but they encode this enzyme into their genome.", [["coronaviruses", "ORGANISM", 20, 33], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 49, 77], ["RNA-dependent RNA polymerase (RdRp) enzymes", "PROTEIN", 49, 92], ["enzyme", "PROTEIN", 153, 159], ["coronaviruses", "PROBLEM", 20, 33], ["RNA", "TEST", 49, 52], ["dependent RNA polymerase", "PROBLEM", 53, 77], ["RdRp) enzymes", "TEST", 79, 92], ["positive", "OBSERVATION", 113, 121]]], ["Coronaviruses have a large RNA genome encoded by viral replicase/polymerase (Bost et al., 2000) .", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["RNA genome", "DNA", 27, 37], ["viral replicase/polymerase", "PROTEIN", 49, 75], ["Coronaviruses", "PROBLEM", 0, 13], ["a large RNA genome", "PROBLEM", 19, 37], ["viral replicase/polymerase", "PROBLEM", 49, 75], ["large", "OBSERVATION_MODIFIER", 21, 26], ["RNA genome", "OBSERVATION", 27, 37]]], ["Similar to other positivechain RNA viruses, the SARS-CoV RdRp is estimated to be the central enzyme that forms a replication complex responsible for replication of the viral RNA genome with other viral and cellular proteins (Brockway et al., 2003; Fudo et al., 2016) .IntroductionIn this article, the analogues of favipiravir, with a PubChem ID of 492405, are scanned from the PubChem website (https://pubchem.ncbi.nlm.nih.gov/).", [["cellular", "ANATOMY", 206, 214], ["SARS", "DISEASE", 48, 52], ["favipiravir", "CHEMICAL", 314, 325], ["favipiravir", "CHEMICAL", 314, 325], ["positivechain", "GENE_OR_GENE_PRODUCT", 17, 30], ["SARS-CoV", "ORGANISM", 48, 56], ["RdRp", "ORGANISM", 57, 61], ["cellular", "CELL", 206, 214], ["favipiravir", "SIMPLE_CHEMICAL", 314, 325], ["SARS-CoV RdRp", "PROTEIN", 48, 61], ["replication complex", "PROTEIN", 113, 132], ["viral RNA genome", "DNA", 168, 184], ["viral and cellular proteins", "PROTEIN", 196, 223], ["SARS-CoV", "SPECIES", 48, 56], ["other positivechain RNA viruses", "PROBLEM", 11, 42], ["the SARS-CoV RdRp", "PROBLEM", 44, 61], ["the central enzyme", "TEST", 81, 99], ["a replication complex", "PROBLEM", 111, 132], ["the viral RNA genome", "PROBLEM", 164, 184], ["favipiravir", "TREATMENT", 314, 325], ["a PubChem ID", "TEST", 332, 344], ["RNA viruses", "OBSERVATION", 31, 42], ["CoV RdRp", "OBSERVATION", 53, 61], ["viral RNA genome", "OBSERVATION", 168, 184], ["cellular proteins", "OBSERVATION", 206, 223], ["PubChem", "ANATOMY", 377, 384]]], ["The selected whole molecules are minimized by the OPLS3e method using Maestro 12.2.", [["Maestro", "TEST", 70, 77]]], ["At this stage, the acidity (pH) is determined in the range of 1 \u00c0 9.", [["the acidity (pH", "TEST", 15, 30], ["acidity", "OBSERVATION_MODIFIER", 19, 26]]], ["The possible state structures belonging to each compound is calculated at pH\u00bc 1-9.", [["pH\u00bc 1-9", "CHEMICAL", 74, 81], ["pH\u00bc", "TEST", 74, 77], ["possible", "UNCERTAINTY", 4, 12]]], ["As for the target protein, RNA polymerase is investigated in the Protein Data Bank (PDB) web tool.", [["target protein", "PROTEIN", 11, 25], ["RNA polymerase", "PROTEIN", 27, 41], ["the target protein", "TEST", 7, 25], ["RNA polymerase", "TEST", 27, 41]]], ["PDB IDs of selected target proteins, which belong to different virus types, are 5FDD, 5I13, 5W44, 6CFP, 6E6V, 6FS8, 6QWL, 6QX3 and 6QX8 (Beylkin et al., 2017; Credille et al., 2019; Fan et al., 2019; Kirchdoerfer & Ward, 2019; Omoto et al., 2018) .", [["5W44", "GENE_OR_GENE_PRODUCT", 92, 96], ["6CFP", "GENE_OR_GENE_PRODUCT", 98, 102], ["6E6V", "GENE_OR_GENE_PRODUCT", 104, 108], ["6FS8", "GENE_OR_GENE_PRODUCT", 110, 114], ["6QWL", "GENE_OR_GENE_PRODUCT", 116, 120], ["6QX3", "GENE_OR_GENE_PRODUCT", 122, 126], ["target proteins", "PROTEIN", 20, 35], ["selected target proteins", "PROBLEM", 11, 35], ["6CFP", "TEST", 98, 102]]], ["Some of these proteins are multi-chain while others are single chain.", [["proteins", "OBSERVATION", 14, 22], ["multi-chain", "OBSERVATION_MODIFIER", 27, 38], ["chain", "OBSERVATION_MODIFIER", 63, 68]]], ["Molecular docking calculations are performed between the studied compounds and target proteins.", [["target proteins", "PROTEIN", 79, 94], ["Molecular docking calculations", "TEST", 0, 30], ["docking calculations", "OBSERVATION", 10, 30]]], ["Then, all results are compared with favipiravir due to favipiravir being selected as the reference material in this study.IntroductionAs for the second stage of the study, the inhibition activities of the selected drug candidates are re-investigated against SARS-CoV RNA polymerase proteins which are 6NUR and 6NUS (Harder et al., 2016; Mesecar, 2020) .", [["favipiravir", "CHEMICAL", 36, 47], ["favipiravir", "CHEMICAL", 55, 66], ["favipiravir", "CHEMICAL", 36, 47], ["favipiravir", "CHEMICAL", 55, 66], ["favipiravir", "SIMPLE_CHEMICAL", 36, 47], ["favipiravir", "SIMPLE_CHEMICAL", 55, 66], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 258, 266], ["SARS-CoV RNA polymerase proteins", "PROTEIN", 258, 290], ["SARS-CoV", "SPECIES", 258, 266], ["favipiravir", "TREATMENT", 36, 47], ["favipiravir", "TREATMENT", 55, 66], ["this study", "TEST", 111, 121], ["the study", "TEST", 161, 170], ["SARS", "PROBLEM", 258, 262], ["CoV RNA polymerase proteins", "TEST", 263, 290]]], ["All of these proteins were reported in 2020 and belong to the COVID virus.IntroductionThe molecular mechanics Poisson-Boltzmann surface binding free energy values of area (MM-PBSA) calculations are completed to investigate the interaction stability between inhibitors and proteins, each at 100ps.", [["COVID virus", "ORGANISM", 62, 73], ["COVID virus", "SPECIES", 62, 73], ["these proteins", "TEST", 7, 21], ["The molecular mechanics Poisson", "TREATMENT", 86, 117], ["Boltzmann surface binding", "TREATMENT", 118, 143], ["area (MM-PBSA) calculations", "TREATMENT", 166, 193], ["inhibitors and proteins", "TREATMENT", 257, 280]]], ["Finally, absorption, distribution, metabolism and excretion/toxicity (ADME) analyses are performed for the related compounds and favipiravir.Molecular docking and ADME analysesThe studied compounds were downloaded from the PubChem web tool.", [["toxicity", "DISEASE", 60, 68], ["favipiravir", "CHEMICAL", 129, 140], ["favipiravir", "CHEMICAL", 129, 140], ["favipiravir", "SIMPLE_CHEMICAL", 129, 140], ["metabolism and excretion/toxicity", "PROBLEM", 35, 68], ["ADME) analyses", "TEST", 70, 84], ["the related compounds", "PROBLEM", 103, 124], ["favipiravir", "TREATMENT", 129, 140], ["ADME analyses", "TEST", 163, 176]]], ["At this stage, the favipiravir was taken into account, and eleven compounds were determined as favipiravir analogues.", [["favipiravir", "CHEMICAL", 19, 30], ["favipiravir", "CHEMICAL", 95, 106], ["favipiravir", "CHEMICAL", 19, 30], ["favipiravir", "CHEMICAL", 95, 106], ["favipiravir", "SIMPLE_CHEMICAL", 19, 30], ["favipiravir", "SIMPLE_CHEMICAL", 95, 106], ["the favipiravir", "TREATMENT", 15, 30], ["favipiravir analogues", "TREATMENT", 95, 116]]], ["The whole compounds are prepared as ligands under a pH condition of 5 \u00b1 4.Molecular docking and ADME analysesAs for the target proteins, all proteins were downloaded from the PDB web tool.", [["target proteins", "PROTEIN", 120, 135], ["The whole compounds", "TREATMENT", 0, 19], ["a pH condition", "TEST", 50, 64], ["ADME analyses", "TEST", 96, 109], ["the target proteins", "TEST", 116, 135], ["all proteins", "TEST", 137, 149]]], ["Firstly, attention was paid to ensure that RNA depended RNA polymerase (RdRp) proteins are obtained from homosapiens.", [["RNA depended RNA polymerase (RdRp) proteins", "PROTEIN", 43, 86], ["RNA depended RNA polymerase (RdRp) proteins", "PROBLEM", 43, 86]]], ["Then, 14 target proteins with the IDs of 5FDD, 5I13, 5W44, 6CFP, 6E6V, 6FS8, 6QWL, 6QX3, 6QX8, 6NUR, 6NUS, 6W63 and 6LU7 were selected.", [["5W44", "GENE_OR_GENE_PRODUCT", 53, 57], ["6CFP", "GENE_OR_GENE_PRODUCT", 59, 63], ["6E6V", "GENE_OR_GENE_PRODUCT", 65, 69], ["6QWL", "GENE_OR_GENE_PRODUCT", 77, 81], ["6QX3", "GENE_OR_GENE_PRODUCT", 83, 87], ["NUR", "GENE_OR_GENE_PRODUCT", 96, 99], ["6W63", "GENE_OR_GENE_PRODUCT", 107, 111], ["6LU7", "GENE_OR_GENE_PRODUCT", 116, 120], ["5FDD, 5I13, 5W44, 6CFP, 6E6V, 6FS8, 6QWL, 6QX3, 6QX8, 6NUR, 6NUS, 6W63 and 6LU7", "DNA", 41, 120], ["the IDs", "TEST", 30, 37], ["6CFP", "TEST", 59, 63], ["NUR", "TEST", 96, 99], ["6NUS", "TEST", 101, 105]]], ["These proteins were minimized using the OPLS3e method to prepare them for docking calculations at pH \u00bc 5 \u00b1 4.", [["the OPLS3e method", "TREATMENT", 36, 53], ["docking calculations at pH", "TEST", 74, 100]]], ["Active sites of these proteins were prepared using the Maestro 12.Molecular docking and ADME analysesand its analogues were then examined against different virus types and the better ones were selected for further analyses.", [["the Maestro", "TREATMENT", 51, 62], ["Molecular docking and ADME analysesand its analogues", "PROBLEM", 66, 118], ["different virus types", "PROBLEM", 146, 167], ["further analyses", "TEST", 206, 222]]], ["Then, the inhibition activity of favipiravir and the selected samples were investigated against RdRp proteins of SARS-CoV.", [["samples", "ANATOMY", 62, 69], ["favipiravir", "CHEMICAL", 33, 44], ["SARS", "DISEASE", 113, 117], ["favipiravir", "CHEMICAL", 33, 44], ["favipiravir", "SIMPLE_CHEMICAL", 33, 44], ["SARS-CoV", "ORGANISM", 113, 121], ["RdRp proteins", "PROTEIN", 96, 109], ["SARS-CoV", "SPECIES", 113, 121], ["favipiravir", "TREATMENT", 33, 44], ["the selected samples", "TEST", 49, 69]]], ["Finally, ADME analyses were performed for favipiravir and the selected samples.", [["samples", "ANATOMY", 71, 78], ["favipiravir", "CHEMICAL", 42, 53], ["favipiravir", "CHEMICAL", 42, 53], ["favipiravir", "SIMPLE_CHEMICAL", 42, 53], ["ADME analyses", "TEST", 9, 22], ["favipiravir", "TREATMENT", 42, 53], ["the selected samples", "TEST", 58, 78]]], ["All these calculations were performed using the OPLS3e method with the Maestro 12.2 Schr\u20ac odinger software program (Friesner et al., 2004 (Friesner et al., , 2006 Schr\u20ac odinger, 2019a Schr\u20ac odinger, , 2019b Schr\u20ac odinger, , 2020 .", [["All these calculations", "TEST", 0, 22]]], ["Molecular docking calculations were completed at extra precision (XP).", [["Molecular docking calculations", "TEST", 0, 30]]], ["As for the ADME analyses, the Qik-prop module of the Maestro software is used to perform this analysis (Mermer et al., 2019) .Mm-PBSA binding free energy calculationsMolecular mechanics Poisson-Boltzmann surface area (MM-PBSA) calculations were performed for favipiravir, CID 294642 and CID 76973015.", [["favipiravir", "CHEMICAL", 259, 270], ["CID 294642", "CHEMICAL", 272, 282], ["CID 76973015", "CHEMICAL", 287, 299], ["favipiravir", "CHEMICAL", 259, 270], ["CID 294642", "CHEMICAL", 272, 282], ["CID 76973015", "CHEMICAL", 287, 299], ["favipiravir", "SIMPLE_CHEMICAL", 259, 270], ["Qik-prop module", "DNA", 30, 45], ["the ADME analyses", "TEST", 7, 24], ["this analysis", "TEST", 89, 102], ["energy calculations", "TEST", 147, 166], ["Molecular mechanics Poisson", "PROBLEM", 166, 193], ["Boltzmann surface area", "TREATMENT", 194, 216], ["calculations", "TEST", 227, 239], ["favipiravir", "TREATMENT", 259, 270], ["CID", "TEST", 287, 290], ["mechanics Poisson", "OBSERVATION", 176, 193]]], ["Binding free energy, van der Waals energy, electrostatic energy, kinetic energy and potential energy changes were determined for these ligand-protein structures in 6NUR and 6NUS from 0 ns to 100 ns (Kollman et al., 2000) .", [["potential energy changes", "PROBLEM", 84, 108], ["these ligand-protein structures", "TEST", 129, 160]]], ["For these calculations, Nanoscale Molecular Dynamics (NAMD) (Nelson et al., 1996) and Visual Molecular Dynamics (VMD) software programs were used.where; is the binding free energy, and demonstrates the total free energy of the protein-ligand complex and total free energies of the isolated protein and ligand, respectively.", [["protein-ligand complex", "PROTEIN", 227, 249], ["these calculations", "TEST", 4, 22], ["Visual Molecular Dynamics (VMD) software programs", "TREATMENT", 86, 135], ["free energies", "OBSERVATION", 260, 273]]], ["Each of the above terms is also used in the calculation of various energy components, including van der Waals energy, electrostatic energy, polar contribution to internal energy and solvent energy collected from molecular mechanics.Favipiravir and its analoguesThe PubChem ID, name and structures of favipiravir and selected analogues are given in Table 1 .", [["Favipiravir", "CHEMICAL", 232, 243], ["favipiravir", "CHEMICAL", 300, 311], ["Favipiravir", "CHEMICAL", 232, 243], ["favipiravir", "CHEMICAL", 300, 311], ["Favipiravir", "SIMPLE_CHEMICAL", 232, 243], ["favipiravir", "SIMPLE_CHEMICAL", 300, 311], ["internal energy and solvent energy", "TREATMENT", 162, 196], ["Favipiravir", "TREATMENT", 232, 243], ["its analogues", "TREATMENT", 248, 261], ["favipiravir", "TREATMENT", 300, 311], ["selected analogues", "TREATMENT", 316, 334]]], ["PubChem ID Name Structure CID 76973034 5,6-dideuterio-2-oxo-(5,6-13 C 2 )1H-pyrazine-3-carboxamideFavipiravir and its analoguesAll compounds were minimized with the OPLS3e method, and a pH of 5 \u00b1 4 was used in the calculations.", [["CID 76973034 5,6-dideuterio-2-oxo-(5,6-13 C 2 )1H-pyrazine-3-carboxamideFavipiravir", "CHEMICAL", 26, 109], ["76973034 5,6-dideuterio-2-oxo-(5,6-13 C 2 )1H-pyrazine-3-carboxamideFavipiravir", "CHEMICAL", 30, 109], ["5,6-dideuterio-2-oxo-(5,6-13 C 2 )1H-pyrazine-3-carboxamideFavipiravir", "SIMPLE_CHEMICAL", 39, 109], ["CID", "TEST", 26, 29], ["pyrazine", "TREATMENT", 76, 84], ["-carboxamideFavipiravir", "TREATMENT", 86, 109], ["its analogues", "TREATMENT", 114, 127], ["a pH", "TEST", 184, 188]]], ["The possible state structure at pH \u00bc 5 \u00b1 4 was determined for all studied compounds.", [["possible", "UNCERTAINTY", 4, 12]]], ["The number of total investigated structures with their possible states were determined as nearly 120 compounds.Determination of active compoundsMolecular docking calculations were performed between the selected ligands and target proteins.", [["target proteins", "PROTEIN", 223, 238], ["active compoundsMolecular docking calculations", "PROBLEM", 128, 174], ["active", "OBSERVATION_MODIFIER", 128, 134], ["compounds", "OBSERVATION_MODIFIER", 135, 144]]], ["It was found that CID 22674959 and CID 89869520 have no activity against RdRp proteins.", [["CID 22674959", "CHEMICAL", 18, 30], ["CID 89869520", "CHEMICAL", 35, 47], ["CID 89869520", "CHEMICAL", 35, 47], ["RdRp proteins", "PROTEIN", 73, 86], ["CID", "TEST", 35, 38], ["RdRp proteins", "PROBLEM", 73, 86]]], ["As for the other samples, compounds and their possible states were docked with some of the selected proteins.", [["the other samples", "PROBLEM", 7, 24]]], ["Only the original structure of some of the studied compounds, such as favipiravir, were found to be active while both original and possible state structures, like CID 294642 were found to be active.", [["favipiravir", "CHEMICAL", 70, 81], ["CID 294642", "CHEMICAL", 163, 173], ["favipiravir", "CHEMICAL", 70, 81], ["CID 294642", "CHEMICAL", 163, 173], ["favipiravir", "SIMPLE_CHEMICAL", 70, 81], ["favipiravir", "TREATMENT", 70, 81], ["original", "OBSERVATION_MODIFIER", 9, 17], ["structure", "OBSERVATION_MODIFIER", 18, 27], ["some", "OBSERVATION_MODIFIER", 31, 35], ["active", "OBSERVATION_MODIFIER", 100, 106], ["active", "OBSERVATION_MODIFIER", 191, 197]]], ["The table lists each protein, its interaction with each drug candidate, and the interacting ligand structure types.Determination of active compoundsAccording to Table 2 , the 6CFP protein is not inhibited by any ligands.", [["6CFP", "GENE_OR_GENE_PRODUCT", 175, 179], ["6CFP protein", "PROTEIN", 175, 187], ["active compounds", "PROBLEM", 132, 148], ["the 6CFP protein", "TEST", 171, 187], ["ligand structure", "OBSERVATION", 92, 108], ["active", "OBSERVATION_MODIFIER", 132, 138], ["compounds", "OBSERVATION", 139, 148]]], ["Additionally, the CID 22674959 and CID 89869520 compounds are found to be inactive as they failed to interact with the proteins.", [["CID 22674959", "CHEMICAL", 18, 30], ["CID 89869520", "CHEMICAL", 35, 47], ["CID 89869520", "CHEMICAL", 35, 47], ["inactive", "OBSERVATION", 74, 82]]], ["As for favipiravir, it interacted with 5W44, 6FS8 and 6QX8.", [["favipiravir", "CHEMICAL", 7, 18], ["favipiravir", "CHEMICAL", 7, 18], ["5W44", "CHEMICAL", 39, 43], ["6FS8", "CHEMICAL", 45, 49], ["6QX8", "CHEMICAL", 54, 58], ["favipiravir", "SIMPLE_CHEMICAL", 7, 18], ["5W44", "SIMPLE_CHEMICAL", 39, 43], ["6FS8", "SIMPLE_CHEMICAL", 45, 49], ["6QX8", "GENE_OR_GENE_PRODUCT", 54, 58], ["favipiravir", "TREATMENT", 7, 18]]], ["CID 294642 and favipiravir inhibit the same proteins.", [["CID 294642", "CHEMICAL", 0, 10], ["favipiravir", "CHEMICAL", 15, 26], ["CID 294642", "CHEMICAL", 0, 10], ["favipiravir", "CHEMICAL", 15, 26], ["favipiravir", "SIMPLE_CHEMICAL", 15, 26], ["CID", "TEST", 0, 3], ["favipiravir", "TREATMENT", 15, 26]]], ["However, the original structure and possible state structures of CID 294642 interacted with 5W44, while only the original structure of favipiravir inhibits the protein.", [["CID 294642", "CHEMICAL", 65, 75], ["5W44", "CHEMICAL", 92, 96], ["favipiravir", "CHEMICAL", 135, 146], ["CID 294642", "CHEMICAL", 65, 75], ["5W44", "CHEMICAL", 92, 96], ["favipiravir", "CHEMICAL", 135, 146], ["CID 294642", "SIMPLE_CHEMICAL", 65, 75], ["5W44", "SIMPLE_CHEMICAL", 92, 96], ["favipiravir", "SIMPLE_CHEMICAL", 135, 146], ["5W44", "PROTEIN", 92, 96]]], ["Considering the total number of interacting structures, CID 294642 has an advantage in respect to favipiravir.", [["CID 294642", "CHEMICAL", 56, 66], ["favipiravir", "CHEMICAL", 98, 109], ["CID 294642", "CHEMICAL", 56, 66], ["favipiravir", "CHEMICAL", 98, 109], ["favipiravir", "SIMPLE_CHEMICAL", 98, 109], ["favipiravir", "TREATMENT", 98, 109], ["total", "OBSERVATION_MODIFIER", 16, 21], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["In terms of the total number of interacting molecules, CID 294642 exhibits better properties than the others.", [["CID 294642", "CHEMICAL", 55, 65], ["CID 294642", "CHEMICAL", 55, 65], ["interacting molecules", "PROTEIN", 32, 53], ["total", "OBSERVATION_MODIFIER", 16, 21], ["number", "OBSERVATION_MODIFIER", 22, 28], ["interacting molecules", "OBSERVATION", 32, 53]]], ["The results of CID 76973015 and CID 1350011386 are better than that of favipiravir because the possible state structures of them both inhibit the target proteins too.", [["CID 76973015", "CHEMICAL", 15, 27], ["CID 1350011386", "CHEMICAL", 32, 46], ["favipiravir", "CHEMICAL", 71, 82], ["CID 1350011386", "CHEMICAL", 32, 46], ["favipiravir", "CHEMICAL", 71, 82], ["favipiravir", "SIMPLE_CHEMICAL", 71, 82], ["target proteins", "PROTEIN", 146, 161], ["CID", "TEST", 15, 18], ["CID", "TEST", 32, 35], ["favipiravir", "TREATMENT", 71, 82]]], ["The docking score (DS), van der Waals energy (E vdw ), coulomb energy (E Coul ) and total interaction energy (E Total ) of CID 294642, CID 76973015, CID 1350011386 and favipiravir are given in Table 3 .Determination of active compoundsTo determine the better drug candidate, the first criteria is the docking score, and the total energy is the second criteria.", [["CID 294642", "CHEMICAL", 123, 133], ["CID 76973015", "CHEMICAL", 135, 147], ["CID 1350011386", "CHEMICAL", 149, 163], ["favipiravir", "CHEMICAL", 168, 179], ["CID 294642", "CHEMICAL", 123, 133], ["CID 76973015", "CHEMICAL", 135, 147], ["CID 1350011386", "CHEMICAL", 149, 163], ["favipiravir", "CHEMICAL", 168, 179], ["favipiravir", "SIMPLE_CHEMICAL", 168, 179], ["The docking score", "TEST", 0, 17], ["favipiravir", "TREATMENT", 168, 179], ["active compounds", "PROBLEM", 219, 235], ["active", "OBSERVATION_MODIFIER", 219, 225], ["compounds", "OBSERVATION", 226, 235]]], ["According to Table 3 , the docking score of CID 1350011386 is worse than that of favipiravir, and therefore, is excluded from further analyses.", [["CID 1350011386", "CHEMICAL", 44, 58], ["favipiravir", "CHEMICAL", 81, 92], ["favipiravir", "CHEMICAL", 81, 92], ["favipiravir", "SIMPLE_CHEMICAL", 81, 92], ["favipiravir", "TREATMENT", 81, 92], ["further analyses", "TEST", 126, 142]]], ["Because the docking score implies the key-lock compatibility in the ligand-receptor complex, it is desired that the docking score of any ligand should be better than that of the reference substance.", [["ligand-receptor complex", "PROTEIN", 68, 91], ["the docking score", "PROBLEM", 8, 25]]], ["As for the other compounds, the docking and van der Waals energy scores are better than that of favipiravir.", [["favipiravir", "CHEMICAL", 96, 107], ["favipiravir", "CHEMICAL", 96, 107], ["favipiravir", "SIMPLE_CHEMICAL", 96, 107], ["the other compounds", "PROBLEM", 7, 26], ["the docking and van der Waals energy scores", "TREATMENT", 28, 71], ["favipiravir", "TREATMENT", 96, 107]]], ["Although total interaction energy in CID 76973015 is smaller than favipiravir, they are closely similar to each other.", [["CID 76973015", "CHEMICAL", 37, 49], ["favipiravir", "CHEMICAL", 66, 77], ["CID 76973015", "CHEMICAL", 37, 49], ["favipiravir", "CHEMICAL", 66, 77], ["favipiravir", "SIMPLE_CHEMICAL", 66, 77], ["favipiravir", "TREATMENT", 66, 77], ["smaller", "OBSERVATION_MODIFIER", 53, 60]]], ["As a result, CID 294642 and 76973015 are selected for further analyses.", [["CID 294642", "CHEMICAL", 13, 23], ["76973015", "CHEMICAL", 28, 36], ["further analyses", "TEST", 54, 70]]], ["The docking structures for favipiravir and CID 294642 with the 6QX8 protein are represented in Figure 2.", [["favipiravir", "CHEMICAL", 27, 38], ["CID 294642", "CHEMICAL", 43, 53], ["favipiravir", "CHEMICAL", 27, 38], ["CID 294642", "CHEMICAL", 43, 53], ["favipiravir", "SIMPLE_CHEMICAL", 27, 38], ["6QX8 protein", "PROTEIN", 63, 75], ["favipiravir", "TREATMENT", 27, 38]]], ["The interaction with COVID19 RNA depends on the RNA polymerase protein RNA polymerase proteins with PDB IDs of 6NUR and 6NUS were reported in late 2019 and early 2020 as belonging to SARS-CoV Kirchdoerfer & Ward, 2019; Mesecar, 2020) .", [["SARS", "DISEASE", 183, 187], ["COVID19", "GENE_OR_GENE_PRODUCT", 21, 28], ["COVID19 RNA", "RNA", 21, 32], ["RNA polymerase protein RNA polymerase proteins", "PROTEIN", 48, 94], ["NUR", "PROTEIN", 112, 115], ["NUS", "PROTEIN", 121, 124], ["SARS-CoV Kirchdoerfer & Ward, 2019", "SPECIES", 183, 217], ["COVID19 RNA", "TREATMENT", 21, 32], ["the RNA polymerase", "TEST", 44, 62], ["polymerase proteins", "TEST", 75, 94], ["PDB IDs", "TEST", 100, 107]]], ["The active region of related proteins was calculated by using the Maestro 12.2 software program, and this region of 6NUR is represented in Figure 3 .", [["NUR", "PROTEIN", 117, 120], ["related proteins", "PROBLEM", 21, 37], ["active", "OBSERVATION_MODIFIER", 4, 10], ["region", "OBSERVATION_MODIFIER", 11, 17], ["proteins", "OBSERVATION", 29, 37]]], ["According to Figure 3 , the active sites of 6NUR are represented with a dummy ball and different colored (blue, red and yellow) surfaces.", [["NUR", "PROTEIN", 45, 48], ["a dummy ball", "PROBLEM", 70, 82], ["different colored (blue, red and yellow) surfaces", "PROBLEM", 87, 136], ["active", "OBSERVATION_MODIFIER", 28, 34]]], ["These regions are the active sites of the RdRp proteins for inhibitors.", [["RdRp proteins", "PROTEIN", 42, 55], ["inhibitors", "TREATMENT", 60, 70], ["active", "OBSERVATION_MODIFIER", 22, 28], ["RdRp proteins", "OBSERVATION", 42, 55]]], ["The three colors red, blue and yellow imply the hydrogen bond acceptor, hydrogen bond donor and hydrophobic interaction regions, respectively.", [["hydrogen", "CHEMICAL", 48, 56], ["hydrogen", "CHEMICAL", 72, 80], ["hydrophobic interaction regions", "PROTEIN", 96, 127], ["the hydrogen bond acceptor", "TREATMENT", 44, 70], ["hydrogen bond donor and hydrophobic interaction regions", "TREATMENT", 72, 127], ["colors red", "OBSERVATION", 10, 20], ["blue", "OBSERVATION_MODIFIER", 22, 26], ["hydrogen bond", "OBSERVATION", 48, 61], ["hydrogen bond", "OBSERVATION", 72, 85], ["hydrophobic", "OBSERVATION_MODIFIER", 96, 107]]], ["The inhibition properties of the selected compounds and favipiravir are determined from the docking calculations, and the active and passive structures against 6NUR and 6NUS are expressed in Table 4 .Determination of active compoundsAccording to Table 4 , favipiravir inhibited only the 6NUS protein while CID 294642 and CID 76973015 inhibited both proteins.", [["favipiravir", "CHEMICAL", 56, 67], ["favipiravir", "CHEMICAL", 256, 267], ["CID 294642", "CHEMICAL", 306, 316], ["CID 76973015", "CHEMICAL", 321, 333], ["favipiravir", "CHEMICAL", 56, 67], ["favipiravir", "CHEMICAL", 256, 267], ["CID 294642", "CHEMICAL", 306, 316], ["CID 76973015", "CHEMICAL", 321, 333], ["favipiravir", "SIMPLE_CHEMICAL", 56, 67], ["favipiravir", "SIMPLE_CHEMICAL", 256, 267], ["NUR", "PROTEIN", 161, 164], ["NUS", "PROTEIN", 170, 173], ["6NUS protein", "PROTEIN", 287, 299], ["favipiravir", "TREATMENT", 56, 67], ["the docking calculations", "TEST", 88, 112], ["active compounds", "PROBLEM", 217, 233], ["CID", "TEST", 321, 324], ["active", "OBSERVATION_MODIFIER", 122, 128], ["active", "OBSERVATION_MODIFIER", 217, 223], ["compounds", "OBSERVATION", 224, 233]]], ["The complex (ligand-receptor) structures and the ligand binding domain electrostatic potential map of 6NUS are represented in Figure 4 .", [["ligand-receptor", "PROTEIN", 13, 28], ["ligand binding domain", "PROTEIN", 49, 70], ["NUS", "PROTEIN", 103, 106], ["The complex (ligand-receptor) structures", "TREATMENT", 0, 40], ["complex", "OBSERVATION_MODIFIER", 4, 11]]], ["Additionally, DS, E vdw , E Coul and E Total are reported in Table 5 for each target protein.Determination of active compoundsAccording to Table 5 , docking results of CID 294642 and CID 76973015 are better than that of favipiravir.", [["CID 294642", "CHEMICAL", 168, 178], ["CID 76973015", "CHEMICAL", 183, 195], ["favipiravir", "CHEMICAL", 220, 231], ["CID 76973015", "CHEMICAL", 183, 195], ["favipiravir", "CHEMICAL", 220, 231], ["favipiravir", "SIMPLE_CHEMICAL", 220, 231], ["DS", "TEST", 14, 16], ["favipiravir", "TREATMENT", 220, 231], ["active", "OBSERVATION_MODIFIER", 110, 116]]], ["If the results are examined in detail, especially the docking score and total interaction energy, it can be easily said that CID 294642 shows better results than the other molecules.", [["CID 294642", "CHEMICAL", 125, 135], ["CID 294642", "CHEMICAL", 125, 135]]], ["For 6NUR, CID 294642 and CID 76973015 have similar properties.", [["CID 294642", "CHEMICAL", 10, 20], ["CID 76973015", "CHEMICAL", 25, 37], ["CID 76973015", "CHEMICAL", 25, 37]]], ["However, the calculated results of CID 294642 are superior compared to the calculated results of the others.", [["CID 294642", "CHEMICAL", 35, 45]]], ["As a result, CID 294642 and CID 76973015 have the potential to be good alternatives of favipiravir in the treatment of patients with COVID19.", [["CID 294642", "CHEMICAL", 13, 23], ["CID 76973015", "CHEMICAL", 28, 40], ["favipiravir", "CHEMICAL", 87, 98], ["COVID19", "CHEMICAL", 133, 140], ["CID 294642", "CHEMICAL", 13, 23], ["CID 76973015", "CHEMICAL", 28, 40], ["favipiravir", "CHEMICAL", 87, 98], ["favipiravir", "SIMPLE_CHEMICAL", 87, 98], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["favipiravir", "TREATMENT", 87, 98], ["COVID19", "TREATMENT", 133, 140]]], ["Compound ID 5FDD 5I13 5W44 6CFP 6E6V 6FS8 6QWL 6QX3 6QX8294642- The interaction scheme of related ligands against 6NUS is represented in Figure 5 .294642According to Figure 5 , the hydrogen bond is especially significant in the interaction between the receptors of the ligands.", [["6QWL 6QX3 6QX8294642", "CHEMICAL", 42, 62], ["6QX3 6QX8294642", "CHEMICAL", 47, 62], ["hydrogen", "CHEMICAL", 181, 189], ["NUS", "PROTEIN", 115, 118], ["significant", "OBSERVATION_MODIFIER", 209, 220], ["ligands", "ANATOMY", 269, 276]]], ["Furthermore, hydrophobic, polar, charged (negative and positive), glycine and solvent exposure plays a significant role in the interaction.Mm-PSBA calculationsMolecular docking has some disadvantages in the analysis of binding stability at the nano-second level of the ligand-protein complex.", [["glycine", "CHEMICAL", 66, 73], ["glycine", "CHEMICAL", 66, 73], ["glycine", "SIMPLE_CHEMICAL", 66, 73], ["ligand-protein complex", "PROTEIN", 269, 291], ["glycine and solvent exposure", "TREATMENT", 66, 94], ["PSBA calculations", "TEST", 142, 159], ["some disadvantages", "PROBLEM", 181, 199], ["the analysis", "TEST", 203, 215], ["binding stability", "PROBLEM", 219, 236], ["hydrophobic", "OBSERVATION_MODIFIER", 13, 24], ["polar", "ANATOMY_MODIFIER", 26, 31], ["some", "OBSERVATION_MODIFIER", 181, 185], ["disadvantages", "OBSERVATION_MODIFIER", 186, 199], ["ligand", "ANATOMY", 269, 275]]], ["The protein accepts a rigid structure in the docking calculations while the ligand is flexible.", [["a rigid structure", "PROBLEM", 20, 37], ["rigid structure", "OBSERVATION", 22, 37]]], ["Molecular mechanics-Poisson-Boltzmann surface area (MM-PSBA) calculations should be made for a more detailed examination of the stability between the ligand and protein.", [["Molecular mechanics", "PROBLEM", 0, 19], ["Poisson-Boltzmann surface area (MM-PSBA) calculations", "TREATMENT", 20, 73], ["a more detailed examination", "TEST", 93, 120]]], ["In this calculation, the ligand and protein are flexible and solvent molecules surround the entire structure.", [["this calculation", "TEST", 3, 19], ["flexible", "OBSERVATION", 48, 56], ["solvent molecules", "OBSERVATION", 61, 78], ["entire", "OBSERVATION_MODIFIER", 92, 98], ["structure", "OBSERVATION_MODIFIER", 99, 108]]], ["In this study, the binding stabilities of protein-ligand structures are investigated in each 100ps.", [["this study", "TEST", 3, 13]]], ["Gibbs free energy of protein and ligand-protein structures are represented in Figures 6 and 7 for 6NUR and 6NUS proteins, respectively.Mm-PSBA calculationsThe binding free energy changes and their deviations in each five ns intervals are given in Table 6 .", [["NUR", "PROTEIN", 99, 102], ["NUS proteins", "PROTEIN", 108, 120], ["Gibbs free energy of protein and ligand-protein structures", "TEST", 0, 58], ["Figures", "TEST", 78, 85], ["PSBA calculations", "TEST", 138, 155], ["The binding free energy changes", "PROBLEM", 155, 186], ["free energy", "OBSERVATION", 167, 178]]], ["The van der Waals energy, electrostatic energy, kinetic energy and potential energy changes are given in supp.", [["potential energy changes", "TREATMENT", 67, 91]]], ["Table S1 -S4, respectively.Mm-PSBA calculationsInhibitor activities of favipiravir and its analogues against RNA dependent RNA polymerase (RdRp) proteins were compared.", [["favipiravir", "CHEMICAL", 71, 82], ["favipiravir", "CHEMICAL", 71, 82], ["favipiravir", "SIMPLE_CHEMICAL", 71, 82], ["RNA dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 109, 137], ["RNA dependent RNA polymerase (RdRp) proteins", "PROTEIN", 109, 153], ["PSBA calculations", "TEST", 30, 47], ["Inhibitor activities", "TREATMENT", 47, 67], ["favipiravir", "TREATMENT", 71, 82], ["its analogues", "TREATMENT", 87, 100], ["RNA dependent RNA polymerase (RdRp) proteins", "PROBLEM", 109, 153], ["S4", "ANATOMY", 10, 12]]], ["With this comparison, calculations were made to support the estimation of the free energies of binding using the molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) method.", [["the molecular mechanics", "TREATMENT", 109, 132], ["Poisson-Boltzmann surface area (MM-PBSA) method", "TREATMENT", 133, 180]]], ["The negative value of the related parameters indicates better binding (Gupta et al., 2020) .", [["negative", "OBSERVATION", 4, 12]]], ["As a result of the calculations, the average values of Gibbs free energies were \u00c036.6 kcal/mol for 6NUR-CID294642; and 43.7 kcal/mol for 6NUR-CID76973015.", [["6NUR-CID76973015", "CHEMICAL", 137, 153], ["6NUR-CID76973015", "SIMPLE_CHEMICAL", 137, 153], ["the calculations", "TEST", 15, 31]]], ["According to these results, CID294642 exhibits better inhibiting properties for the 6NUR protein.", [["CID294642", "CHEMICAL", 28, 37], ["CID294642", "CHEMICAL", 28, 37], ["CID294642", "SIMPLE_CHEMICAL", 28, 37], ["6NUR", "GENE_OR_GENE_PRODUCT", 84, 88], ["6NUR protein", "PROTEIN", 84, 96]]], ["Moreover, CID294642 becomes more stable with 6NUR more quickly.", [["CID294642", "CHEMICAL", 10, 19], ["CID294642", "CHEMICAL", 10, 19], ["CID294642", "SIMPLE_CHEMICAL", 10, 19], ["stable", "OBSERVATION_MODIFIER", 33, 39]]], ["As for 6NUS, CID294642 and favipiravir exhibit better properties than CID76973015 due to the Gibbs free energy changes.", [["CID294642", "CHEMICAL", 13, 22], ["favipiravir", "CHEMICAL", 27, 38], ["CID76973015", "CHEMICAL", 70, 81], ["CID294642", "CHEMICAL", 13, 22], ["favipiravir", "CHEMICAL", 27, 38], ["CID76973015", "CHEMICAL", 70, 81], ["CID294642", "SIMPLE_CHEMICAL", 13, 22], ["favipiravir", "SIMPLE_CHEMICAL", 27, 38], ["CID76973015", "SIMPLE_CHEMICAL", 70, 81], ["favipiravir", "TREATMENT", 27, 38], ["the Gibbs free energy changes", "PROBLEM", 89, 118]]], ["When these results are examined in more detail, the negative Gibbs free energy in the CID294642-6NUS complex is more than that of the favipiravir-6NUS complex.", [["favipiravir-6", "CHEMICAL", 134, 147], ["CID294642-6NUS", "GENE_OR_GENE_PRODUCT", 86, 100], ["favipiravir-6NUS", "GENE_OR_GENE_PRODUCT", 134, 150], ["CID294642-6NUS complex", "PROTEIN", 86, 108], ["favipiravir-6NUS complex", "PROTEIN", 134, 158], ["the favipiravir", "TEST", 130, 145]]], ["As a result, CID294642 is selected as the best drug candidate for the SARS-CoV-2 virus via MM-PSBA calculations.Adme analysisAbsorption, distribution, metabolism, and excretion (ADME) is related to the pharmacokinetics and pharmacology properties of drug candidates.", [["CID294642", "CHEMICAL", 13, 22], ["ADME", "CHEMICAL", 178, 182], ["CID294642", "CHEMICAL", 13, 22], ["CID294642", "SIMPLE_CHEMICAL", 13, 22], ["SARS-CoV-2 virus", "ORGANISM", 70, 86], ["SARS-CoV-2 virus", "SPECIES", 70, 86], ["the SARS", "TEST", 66, 74], ["CoV", "TEST", 75, 78], ["PSBA calculations", "TEST", 94, 111], ["drug candidates", "TREATMENT", 250, 265]]], ["Absorption is related to the uptake into the bloodstream of the compound to reach the target tissue.", [["bloodstream", "ANATOMY", 45, 56], ["tissue", "ANATOMY", 93, 99], ["tissue", "TISSUE", 93, 99], ["the uptake into the bloodstream", "PROBLEM", 25, 56], ["bloodstream", "ANATOMY", 45, 56], ["target tissue", "OBSERVATION", 86, 99]]], ["Distribution is related to the carrying of the compounds in the circulatory system.", [["circulatory system", "ANATOMY", 64, 82], ["circulatory system", "ANATOMICAL_SYSTEM", 64, 82], ["compounds", "OBSERVATION", 47, 56], ["circulatory system", "ANATOMY", 64, 82]]], ["Metabolism is related to the breaking down of compounds as soon as entering the body and excretion is related to the removing of the compound from the body.", [["body", "ANATOMY", 80, 84], ["body", "ANATOMY", 151, 155], ["body", "ORGANISM_SUBDIVISION", 80, 84], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["body", "ANATOMY", 151, 155]]], ["These properties are vitally important for drug candidates because ADME analyses give us significant clues about the likely success of the drug.", [["drug candidates", "TREATMENT", 43, 58], ["ADME analyses", "TEST", 67, 80]]], ["There are some parameters to investigate the ADME properties of drug candidates such as the solute total SASA, QPlogHERG, RuleOfFive, etc. ADME analyses of CID 294642, CID 76973015 and favipiravir were completed and all results were compared with reference ranges.", [["CID 294642", "CHEMICAL", 156, 166], ["CID 76973015", "CHEMICAL", 168, 180], ["favipiravir", "CHEMICAL", 185, 196], ["CID 294642", "CHEMICAL", 156, 166], ["CID 76973015", "CHEMICAL", 168, 180], ["favipiravir", "CHEMICAL", 185, 196], ["SASA", "SIMPLE_CHEMICAL", 105, 109], ["favipiravir", "SIMPLE_CHEMICAL", 185, 196], ["drug candidates", "TREATMENT", 64, 79], ["the solute total SASA", "TREATMENT", 88, 109], ["CID", "TEST", 156, 159], ["CID", "TEST", 168, 171], ["favipiravir", "TEST", 185, 196]]], ["In this study, thirty-one parameters, which are the most commonly used, are calculated by the Maestro program.", [["this study", "TEST", 3, 13]]], ["The ADME results of selected compounds are given in Table 7 .Adme analysisAccording to Table 7 , the calculated parameters of CID 264642, CID 76973015 and favipiravir are mainly in the desired range.", [["CID 264642", "CHEMICAL", 126, 136], ["CID 76973015", "CHEMICAL", 138, 150], ["favipiravir", "CHEMICAL", 155, 166], ["CID 76973015", "CHEMICAL", 138, 150], ["favipiravir", "CHEMICAL", 155, 166], ["favipiravir", "SIMPLE_CHEMICAL", 155, 166], ["CID", "TEST", 126, 129], ["CID", "TEST", 138, 141], ["favipiravir", "TREATMENT", 155, 166]]], ["There are three deviations, which are, solute molar volume, QP polarizability and QPlogHERG.", [["three deviations", "PROBLEM", 10, 26], ["solute molar volume", "TREATMENT", 39, 58], ["QP polarizability", "TREATMENT", 60, 77], ["QPlogHERG", "TEST", 82, 91], ["three", "OBSERVATION_MODIFIER", 10, 15], ["deviations", "OBSERVATION", 16, 26], ["solute molar", "OBSERVATION_MODIFIER", 39, 51], ["volume", "OBSERVATION_MODIFIER", 52, 58], ["QP polarizability", "OBSERVATION", 60, 77]]], ["In these parameters, the results of selected compounds are out of the desired range.", [["selected compounds", "TEST", 36, 54]]], ["The meanings of the investigated parameters are given below.Adme analysisMany parameters obtained from the calculations have been examined for the future probability of ligand molecules to be drugs.", [["ligand molecules", "PROTEIN", 169, 185], ["Adme analysis", "TEST", 60, 73], ["the calculations", "TEST", 103, 119], ["ligand molecules", "PROBLEM", 169, 185]]], ["Molecules are required to be between the Solute Dipole Moment of 1.0-12.5 Debye.", [["the Solute Dipole Moment", "TEST", 37, 61], ["Solute Dipole", "OBSERVATION_MODIFIER", 41, 54]]], ["Many other parameters are indicated as follows -Solute Total SASA: total solvent-accessible surface area; Solute Carbom Pi SASA: Van der Waals surface area of polar nitrogen and oxygen atoms and carbonyl carbon atoms; QPlogPo/w: Predicted octanol/water partition coefficient; QPlogS: Predicted aqueous solubility; log S: S in mol dm-3 is the concentration of the solute in a saturated solution that is in equilibrium with the crystalline solid; QPlogBB: brain/blood partition coefficient; QPlogKhsa: binding to human serum albumin; Apparent Caco-2 Permeability: Predicted apparent Caco-2 cell permeability (nm/s) where Caco-2 cells are a model for the gut-blood barrier; QP log BB for brain/blood: Predicted brain/blood partition coefficient for orally delivered drugs; Apparent MDCK Permeability: Predicted apparent MDCK cell permeability (nm/s) where MDCK cells are considered to be a good mimic for the blood-brain barrier; % Human Oral Absorption in Gl: Human oral absorption on a 0-100% scale (>80% is high, <25% is poor); Solute as Donor-Hydrogen Bonds: Predicted number of donor hydrogen bonds; Solute as Acceptor-Hydrogen: Predicted number of acceptor hydrogen bond; QP log p for X/Y: Predicted X/Y partition coefficient; IC50 value for the blockage of HERG K \u00fe channels (acceptable range: above 25.0); Solute CdW Polar SA (PSA): total polar surface area (Acar et al., 2019; Bicak et al., 2019; Budama-Kilinc et al., 2018; Ertas et al., 2019; Kecel-Gunduz et al., 2020; Mente\u015fe et al., 2019; Mermer et al., 2019; Sari et al., 2019; Singh & Bast, 2014 ); Lipinski Rule of 5 Violations: Number of violations of Lipinski's rule of five where the rules are: mol_MW (molecular weight of the molecule) < 500; QPlogPo/w (predicted octanol/water partition coefficient) < 5; donorHB (hydrogenbond donor atoms) 5; accptHB (hydrogen-bond acceptor atoms) 10 where compounds that provide these rules are considered as drug-like molecules (Sagl\u0131k et al., 2019a; Sagl\u0131k Lipinski et al., 1997; Jorgensen & Duffy, 2002) ; and Jorgensen Rule of 3 Violations: Number of violations of Jorgensen's rule of three where the three rules are: QPlogS (predicted aqueous solubility) > \u00c05.7, QPPCaco (predicted apparent Caco-2 cell permeability in nm/s) > 22 nm/s, # Primary Metabolites < 7 where compounds with fewer (and preferably no) violations of these rules are more likely to be orally available agents.", [["surface", "ANATOMY", 92, 99], ["brain", "ANATOMY", 454, 459], ["blood", "ANATOMY", 460, 465], ["serum", "ANATOMY", 517, 522], ["Caco-2 cell", "ANATOMY", 581, 592], ["Caco-2 cells", "ANATOMY", 619, 631], ["gut", "ANATOMY", 652, 655], ["blood", "ANATOMY", 656, 661], ["brain", "ANATOMY", 685, 690], ["blood", "ANATOMY", 691, 696], ["brain", "ANATOMY", 708, 713], ["blood", "ANATOMY", 714, 719], ["orally", "ANATOMY", 746, 752], ["MDCK cell", "ANATOMY", 817, 826], ["MDCK cells", "ANATOMY", 853, 863], ["blood", "ANATOMY", 906, 911], ["brain", "ANATOMY", 912, 917], ["oral", "ANATOMY", 964, 968], ["cell", "ANATOMY", 2207, 2211], ["Pi", "CHEMICAL", 120, 122], ["polar nitrogen", "CHEMICAL", 159, 173], ["oxygen", "CHEMICAL", 178, 184], ["carbonyl carbon", "CHEMICAL", 195, 210], ["octanol", "CHEMICAL", 239, 246], ["Hydrogen", "CHEMICAL", 1044, 1052], ["Hydrogen", "CHEMICAL", 1121, 1129], ["K", "CHEMICAL", 1266, 1267], ["octanol", "CHEMICAL", 1732, 1739], ["nitrogen", "CHEMICAL", 165, 173], ["oxygen", "CHEMICAL", 178, 184], ["carbonyl", "CHEMICAL", 195, 203], ["carbon", "CHEMICAL", 204, 210], ["octanol", "CHEMICAL", 239, 246], ["Hydrogen", "CHEMICAL", 1044, 1052], ["hydrogen", "CHEMICAL", 1086, 1094], ["Hydrogen", "CHEMICAL", 1121, 1129], ["hydrogen", "CHEMICAL", 1160, 1168], ["octanol", "CHEMICAL", 1732, 1739], ["donorHB", "CHEMICAL", 1774, 1781], ["accptHB", "CHEMICAL", 1812, 1819], ["hydrogen", "CHEMICAL", 1821, 1829], ["nitrogen", "SIMPLE_CHEMICAL", 165, 173], ["oxygen atoms", "SIMPLE_CHEMICAL", 178, 190], ["carbonyl carbon atoms", "SIMPLE_CHEMICAL", 195, 216], ["octanol", "SIMPLE_CHEMICAL", 239, 246], ["QPlogS", "SIMPLE_CHEMICAL", 276, 282], ["mol dm-3", "SIMPLE_CHEMICAL", 326, 334], ["QPlogBB", "SIMPLE_CHEMICAL", 445, 452], ["brain", "ORGAN", 454, 459], ["blood", "ORGANISM_SUBSTANCE", 460, 465], ["QPlogKhsa", "SIMPLE_CHEMICAL", 489, 498], ["human", "ORGANISM", 511, 516], ["serum", "ORGANISM_SUBSTANCE", 517, 522], ["albumin", "GENE_OR_GENE_PRODUCT", 523, 530], ["Caco-2 cell", "CELL", 581, 592], ["Caco-2 cells", "CELL", 619, 631], ["gut", "ORGANISM_SUBDIVISION", 652, 655], ["blood", "ORGANISM_SUBSTANCE", 656, 661], ["brain", "ORGAN", 685, 690], ["blood", "ORGANISM_SUBSTANCE", 691, 696], ["brain", "ORGAN", 708, 713], ["blood", "ORGANISM_SUBSTANCE", 714, 719], ["MDCK cell", "CELL", 817, 826], ["MDCK cells", "CELL", 853, 863], ["blood", "ORGANISM_SUBSTANCE", 906, 911], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 912, 925], ["Human", "ORGANISM", 929, 934], ["Oral", "ORGANISM_SUBDIVISION", 935, 939], ["Human", "ORGANISM", 958, 963], ["oral", "ORGANISM_SUBDIVISION", 964, 968], ["Solute", "SIMPLE_CHEMICAL", 1102, 1108], ["Acceptor-Hydrogen", "SIMPLE_CHEMICAL", 1112, 1129], ["octanol", "SIMPLE_CHEMICAL", 1732, 1739], ["donorHB", "SIMPLE_CHEMICAL", 1774, 1781], ["hydrogenbond donor atoms", "SIMPLE_CHEMICAL", 1783, 1807], ["accptHB", "SIMPLE_CHEMICAL", 1812, 1819], ["hydrogen-bond acceptor atoms", "SIMPLE_CHEMICAL", 1821, 1849], ["cell", "CELL", 2207, 2211], ["Caco-2 cells", "CELL_LINE", 619, 631], ["MDCK cells", "CELL_LINE", 853, 863], ["HERG K", "PROTEIN", 1261, 1267], ["PSA", "PROTEIN", 1332, 1335], ["human", "SPECIES", 511, 516], ["Human", "SPECIES", 929, 934], ["Human", "SPECIES", 958, 963], ["human", "SPECIES", 511, 516], ["total solvent", "TREATMENT", 67, 80], ["accessible surface area", "TREATMENT", 81, 104], ["Solute Carbom Pi", "TREATMENT", 106, 122], ["Van der Waals surface area", "TREATMENT", 129, 155], ["polar nitrogen", "TREATMENT", 159, 173], ["oxygen atoms", "TREATMENT", 178, 190], ["carbonyl carbon atoms", "TREATMENT", 195, 216], ["the solute in a saturated solution", "TREATMENT", 359, 393], ["brain/blood partition coefficient", "TEST", 454, 487], ["human serum", "TEST", 511, 522], ["albumin", "TEST", 523, 530], ["Caco", "TEST", 541, 545], ["Caco", "TEST", 581, 585], ["cell permeability", "TEST", 588, 605], ["nm/s", "TEST", 607, 611], ["Caco", "TEST", 619, 623], ["blood barrier", "TEST", 656, 669], ["QP log BB", "TEST", 671, 680], ["brain/blood", "TEST", 685, 696], ["orally delivered drugs", "TREATMENT", 746, 768], ["MDCK cell permeability", "TEST", 817, 839], ["nm/s", "TEST", 841, 845], ["MDCK cells", "TEST", 853, 863], ["the blood-brain barrier", "TREATMENT", 902, 925], ["donor hydrogen bonds", "TREATMENT", 1080, 1100], ["acceptor hydrogen bond", "TREATMENT", 1151, 1173], ["IC50 value", "TEST", 1230, 1240], ["HERG K", "TEST", 1261, 1267], ["channels", "TEST", 1270, 1278], ["Solute CdW Polar SA (PSA", "TREATMENT", 1311, 1335], ["total polar surface area", "TREATMENT", 1338, 1362], ["Budama", "TEST", 1403, 1409], ["Kecel", "TEST", 1451, 1456], ["Bast", "TEST", 1548, 1552], ["Lipinski", "TEST", 1562, 1570], ["Lipinski", "TEST", 1617, 1625], ["mol_MW", "TEST", 1662, 1668], ["QPlogPo", "TEST", 1711, 1718], ["octanol", "TEST", 1732, 1739], ["donorHB (hydrogenbond donor atoms)", "TREATMENT", 1774, 1808], ["accptHB (hydrogen-bond acceptor atoms)", "TREATMENT", 1812, 1850], ["aqueous solubility", "TEST", 2144, 2162], ["QPPCaco", "TEST", 2172, 2179], ["Caco", "TEST", 2200, 2204], ["cell permeability", "TEST", 2207, 2224], ["nm/s", "TEST", 2228, 2232], ["nm/s", "TEST", 2239, 2243], ["Primary Metabolites", "TEST", 2247, 2266], ["brain", "ANATOMY", 454, 459], ["gut", "ANATOMY", 652, 655], ["brain", "ANATOMY", 685, 690], ["brain", "ANATOMY", 708, 713], ["MDCK cell", "OBSERVATION", 817, 826], ["brain", "ANATOMY", 912, 917]]], ["When the numerical values of these parameters are very close to each other, as can be seen from Table 7 , it can be concluded that the results obtained show the potential future use of these three molecules as drugs, and will not cause a problem according to ADME analyses.ConclusionCurrently countries worldwide are taking precautions against the COVID19 epidemic, and active molecule research and vaccination studies against the SARS-CoV-2 virus are of great importance.", [["SARS", "DISEASE", 431, 435], ["SARS-CoV-2 virus", "ORGANISM", 431, 447], ["CoV-2 virus", "SPECIES", 436, 447], ["SARS-CoV-2 virus", "SPECIES", 431, 447], ["the numerical values", "TEST", 5, 25], ["drugs", "TREATMENT", 210, 215], ["ADME analyses", "TEST", 259, 272], ["vaccination studies", "TEST", 399, 418], ["the SARS", "PROBLEM", 427, 435], ["CoV", "TEST", 436, 439]]], ["Most research has focused on COVID19.", [["COVID19", "GENE_OR_GENE_PRODUCT", 29, 36], ["COVID19", "DNA", 29, 36], ["COVID19", "TREATMENT", 29, 36]]], ["Favipiravir is one of the drugs used in the treatment of the virus.", [["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "CHEMICAL", 0, 11], ["Favipiravir", "SIMPLE_CHEMICAL", 0, 11], ["Favipiravir", "TREATMENT", 0, 11], ["the drugs", "TREATMENT", 22, 31], ["the virus", "PROBLEM", 57, 66], ["virus", "OBSERVATION", 61, 66]]], ["In this study, a target molecule investigation is completed against RNA polymerase of different virus types and RNA polymerase proteins of the SARS-CoV-2 virus.", [["SARS-CoV-2 virus", "ORGANISM", 143, 159], ["RNA polymerase", "PROTEIN", 68, 82], ["RNA polymerase proteins", "PROTEIN", 112, 135], ["CoV-2 virus", "SPECIES", 148, 159], ["SARS-CoV-2 virus", "SPECIES", 143, 159], ["this study", "TEST", 3, 13], ["a target molecule investigation", "TEST", 15, 46], ["RNA polymerase", "PROBLEM", 68, 82], ["different virus types", "PROBLEM", 86, 107], ["RNA polymerase proteins", "TEST", 112, 135], ["the SARS", "TEST", 139, 147], ["CoV", "TEST", 148, 151]]], ["The drug candidates are identified as analogues of favipiravir from PubChem.", [["favipiravir", "CHEMICAL", 51, 62], ["favipiravir", "CHEMICAL", 51, 62], ["favipiravir", "SIMPLE_CHEMICAL", 51, 62], ["favipiravir", "TREATMENT", 51, 62]]], ["All analyzes are performed in silico, and the target proteins selected from the protein data bank are 5FDD, 5I13, 5W44, 6CFP, 6E6V, 6FS8, 6QWL, 6QX3, 6QX8, 6NUR and 6NUS.", [["NUR", "PROTEIN", 157, 160], ["6NUS", "PROTEIN", 165, 169], ["the target proteins", "TEST", 42, 61]]], ["The last four of the selected proteins belong to the SARS-CoV virus.", [["SARS", "DISEASE", 53, 57], ["SARS-CoV virus", "ORGANISM", 53, 67], ["SARS-CoV virus", "SPECIES", 53, 67], ["the SARS-CoV virus", "PROBLEM", 49, 67]]], ["As a result of docking analysis, drug candidates which may be more effective than favipiravir are identified.", [["favipiravir", "CHEMICAL", 82, 93], ["favipiravir", "CHEMICAL", 82, 93], ["favipiravir", "SIMPLE_CHEMICAL", 82, 93], ["docking analysis", "TEST", 15, 31], ["drug candidates", "TREATMENT", 33, 48], ["favipiravir", "TREATMENT", 82, 93]]], ["The PubChem IDs of these drug candidates are CID 294642 and CID 76973015.", [["CID 294642", "CHEMICAL", 45, 55], ["CID 76973015", "CHEMICAL", 60, 72], ["CID 76973015", "CHEMICAL", 60, 72]]], ["The ADME of related compounds of the two drug candidates and favipiravir are performed.", [["favipiravir", "CHEMICAL", 61, 72], ["favipiravir", "CHEMICAL", 61, 72], ["favipiravir", "SIMPLE_CHEMICAL", 61, 72], ["favipiravir", "TREATMENT", 61, 72]]], ["Additionally, MM-PSBA calculations are performed and it is found that CID 294642 exhibits superior activity.", [["CID 294642", "CHEMICAL", 70, 80], ["CID 294642", "CHEMICAL", 70, 80], ["MM-PSBA calculations", "TEST", 14, 34], ["superior", "OBSERVATION_MODIFIER", 90, 98], ["activity", "OBSERVATION_MODIFIER", 99, 107]]], ["As a result, CID 294642 can be a good candidate as an antiviral drug against SARS-CoV-2.", [["CID 294642", "CHEMICAL", 13, 23], ["SARS", "DISEASE", 77, 81], ["CID 294642", "CHEMICAL", 13, 23], ["CID 294642", "SIMPLE_CHEMICAL", 13, 23], ["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV", "SPECIES", 77, 85], ["an antiviral drug", "TREATMENT", 51, 68], ["CoV", "TEST", 82, 85]]], ["2.0 \u00c0 20.0 Solute Globularity (Sphere \u00bc1) 0.9 0.9 0.9 0.75 \u00c0 0.95 QP Polarizability (A 3 ) 12.7 12.8 12.7 13.0 \u00c0 70.0 QP log p for hexadecane/gas 5.0 4.5 5.1 4.0 \u00c0 18.0 QP log p for octanol/gas 9.6 9.0 9.1 8.0 \u00c0 35.0 QP log p for water/gas 7.7 7.5 7.8 4.0 \u00c0 45.0 QP log p for octanol/water \u00c00.6 \u00c00.4 \u00c00.6 \u00c02 \u00c0 6.5 QP log S aqueous solubility \u00c00.6 \u00c01.2 \u00c00.6 \u00c06.5 \u00c0 0.5 QP log S-conformation independent \u00c01.0 \u00c01.3 \u00c01.0 \u00c06.5 \u00c0 0.5 QPlogHERG -3.1 -2.9 -3.0 (concern below \u00c05) QPPCaco (nm/sec) 107.1 115.2 109.9 25 < X < 500 QPlogBB \u00c01.1 \u00c00.9 \u00c01.1 \u00c03 \u00c0 1.2 QPPMDCK (nm/sec) 44.2 88.7 45.5 25 < X < 500 QPlogKp \u00c04.9 \u00c05.0 \u00c04.9 (-8.0) -(-1.0) IP (ev) 9.4 9.6 9.6 7.9 \u00c0 10.5 EA (eV)", [["hexadecane", "CHEMICAL", 131, 141], ["octanol", "CHEMICAL", 182, 189], ["octanol", "CHEMICAL", 276, 283], ["hexadecane", "CHEMICAL", 131, 141], ["octanol", "CHEMICAL", 182, 189], ["octanol", "CHEMICAL", 276, 283], ["hexadecane", "SIMPLE_CHEMICAL", 131, 141], ["octanol", "SIMPLE_CHEMICAL", 182, 189], ["octanol", "SIMPLE_CHEMICAL", 276, 283], ["Solute Globularity", "TEST", 11, 29], ["Sphere", "TEST", 31, 37], ["QP Polarizability", "TEST", 66, 83], ["A", "TEST", 85, 86], ["\u00c0", "TEST", 111, 112], ["QP log p", "TEST", 118, 126], ["hexadecane", "TEST", 131, 141], ["gas", "TEST", 142, 145], ["QP log p", "TEST", 169, 177], ["octanol/gas", "TEST", 182, 193], ["QP log p", "TEST", 217, 225], ["water/gas", "TEST", 230, 239], ["octanol", "TEST", 276, 283], ["water", "TEST", 284, 289], ["\u00c0", "TEST", 308, 309], ["aqueous", "TEST", 323, 330], ["solubility", "TEST", 331, 341], ["\u00c0", "TEST", 362, 363], ["S-conformation", "TEST", 375, 389], ["independent", "TEST", 390, 401], ["\u00c0", "TEST", 422, 423], ["QPlogHERG", "TEST", 428, 437], ["QPPCaco (nm/sec", "TEST", 472, 487], ["QPlogBB", "TEST", 520, 527], ["\u00c0", "TEST", 546, 547], ["QPPMDCK", "TEST", 552, 559], ["nm/sec", "TEST", 561, 567], ["QPlogKp", "TEST", 597, 604], ["IP (ev", "TEST", 635, 641], ["EA", "TEST", 666, 668]]]], "PMC7266123": [["IntroductionThe 2020 widespread of the Coronavirus or COVID-19 virus could be compared to the spread of the Red Weevil (Rhynchophorus Ferrugineus) in the Mediterranean or fires in California.", [["Coronavirus", "GENE_OR_GENE_PRODUCT", 39, 50], ["COVID-19 virus", "ORGANISM", 54, 68], ["Rhynchophorus Ferrugineus", "ORGANISM", 120, 145], ["Rhynchophorus Ferrugineus", "SPECIES", 120, 145], ["COVID-19 virus", "SPECIES", 54, 68], ["Red Weevil", "SPECIES", 108, 118], ["the Coronavirus", "PROBLEM", 35, 50], ["COVID-19 virus", "PROBLEM", 54, 68], ["the Red Weevil (Rhynchophorus Ferrugineus", "TREATMENT", 104, 145], ["Coronavirus", "OBSERVATION", 39, 50], ["Mediterranean", "ANATOMY", 154, 167], ["fires", "OBSERVATION_MODIFIER", 171, 176], ["California", "ANATOMY_MODIFIER", 180, 190]]], ["They start in one or more localized places and quickly spread over larger and larger regions until it becomes difficult to stop them.", [["larger", "OBSERVATION_MODIFIER", 78, 84]]], ["This mechanism is similar to physical systems, for instance turbulent flow or chaotic maps [1\u20137], where a small perturbation grows exponentially and then saturates to a finite value.", [["instance turbulent flow", "PROBLEM", 51, 74], ["chaotic maps", "TEST", 78, 90], ["a small perturbation grows", "PROBLEM", 104, 130], ["small", "OBSERVATION_MODIFIER", 106, 111], ["perturbation", "OBSERVATION", 112, 124], ["grows", "OBSERVATION_MODIFIER", 125, 130], ["exponentially", "OBSERVATION_MODIFIER", 131, 144]]], ["These at first sht different systems have some common features: a small perturbation, which we will indicate as d0, grows exponentially with a coefficient \u03b3, the Lyapunov exponent, and finally saturates [1\u20133] to a value", [["a small perturbation", "PROBLEM", 64, 84], ["small", "OBSERVATION_MODIFIER", 66, 71], ["perturbation", "OBSERVATION", 72, 84]]]], "0e355f12b2f1bd0558719e3ebe58e27cef29d730": [["The SARS-CoV-2 (COVID-19) pandemic is disrupting modern societies.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["COVID-19", "ORGANISM", 16, 24], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["COVID", "TEST", 16, 21], ["pandemic", "PROBLEM", 26, 34]]], ["By April 12, 2020, more than 1.5 million people had been infected and 114 197 had died worldwide as a result of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 112, 132], ["people", "ORGANISM", 41, 47], ["SARS-CoV-2", "ORGANISM", 112, 122], ["people", "SPECIES", 41, 47], ["SARS-CoV-2", "SPECIES", 112, 122], ["SARS", "PROBLEM", 112, 116], ["CoV", "PROBLEM", 117, 120], ["2 infection", "PROBLEM", 121, 132], ["infection", "OBSERVATION", 123, 132]]], ["By April 12, a total of 16 585 cases had been confirmed in Portugal; 504 individuals (3.0% of those confirmed as infected) had succumbed to COVID-19 and 228 (1.4%) were in the intensive care unit (ICU).", [["individuals", "ORGANISM", 73, 84], ["COVID", "TEST", 140, 145]]]], "bce8b90608da793e08885320435d661704812456": [["Although it is unrealistic to think that expenditures on overseas travel could precede day-to-day necessities, the assumption in the literature directly follows a syllogism based on two fundamental premises.", [["syllogism", "DISEASE", 163, 172]]], ["Second, since it is a luxury good, demand should be dependent on the discretionary income of consumers (Crouch, 1992) , which is the proportion of real earnings after normal expenses (i.e. food, living, medical) are deducted.IntroductionAccordingly, the concept that international tourism has a higher sensitivity to income than a normal good (income elasticity higher than unity) has been thoroughly tested by academics (Lanza, Temple, & Urga, 2003; Smeral, 2003) .", [["a higher sensitivity", "PROBLEM", 293, 313]]], ["These studies commonly found that the income elasticity of international tourism is greater than unity.", [["These studies", "TEST", 0, 13], ["greater", "OBSERVATION_MODIFIER", 84, 91]]], ["Certainly, the absolute availability of cash flows is likely to place a strict upper limit on tourism demand.", [["upper limit", "OBSERVATION_MODIFIER", 79, 90]]], ["When consumer spending is not guided by extremes of myopia and liquidity constraints (Shea, 1995a) , the distribution of wealth consumption across various stages of a consumer's life depends not only on current earnings but also on their beliefs regarding their future earnings and permanent income.", [["myopia", "DISEASE", 52, 58], ["myopia", "PROBLEM", 52, 58], ["myopia", "OBSERVATION", 52, 58]]], ["The way in which changes in the value of these two prominent asset classes impact consumption is popularly known as the 'wealth effect.'", [["prominent", "OBSERVATION_MODIFIER", 51, 60]]], ["Case et al. (2005) concluded that there was a significant increase in consumption explained by gains in housing and financial wealth in the US.", [["significant", "OBSERVATION_MODIFIER", 46, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66]]], ["Lettau and Ludvigson (2004) contended that most changes in asset values are \"transitory and unrelated\" to aggregate consumption.", [["\"transitory", "PROBLEM", 76, 87]]], ["Case et al. (2005) found a significant housing wealth effect for a panel of 14 developed countries, but an insignificant financial wealth effect.", [["a panel", "TEST", 65, 72]]], ["Likewise, Campbell and Cocco (2007) observed a relatively large housing wealth effect using micro data in the UK.IntroductionThe persistent debates and discussion stem from a few inevitable challenges in verifying this relationship at the aggregate level, as the wealth of consumers may respond differently to a directional movement of asset prices.", [["micro data", "TEST", 92, 102], ["discussion stem", "TREATMENT", 152, 167], ["a few inevitable challenges", "TREATMENT", 173, 200], ["persistent", "OBSERVATION_MODIFIER", 129, 139]]], ["For example, an increase in housing prices may lead to enhanced expectations of future wealth (or in some cases an actual gain should the house be sold) for home owners.", [["increase", "OBSERVATION_MODIFIER", 16, 24], ["housing prices", "OBSERVATION", 28, 42]]], ["Consequently, an increase in housing prices would imply a net negative wealth effect for those who do not own their homes.", [["increase", "OBSERVATION_MODIFIER", 17, 25]]], ["Based on a 1997 Michigan survey, Starr-McCluer (1998) reported that only those who own a considerable amount of equity investments were significantly affected by movements in capital asset prices.", [["equity investments", "OBSERVATION", 112, 130]]], ["With the exception of households in significant need, there is certainly no need to consume more inferior or normal goods under the expectation that future income will increase.IntroductionIn effect, testing the wealth effect on aggregate consumption is complicated and difficult due to the sizable number of criteria to be met.", [["sizable", "OBSERVATION_MODIFIER", 291, 298]]], ["A significant absolute amount of wealth should also be invested in these assets, even by low income households.", [["significant", "OBSERVATION_MODIFIER", 2, 13], ["absolute", "OBSERVATION_MODIFIER", 14, 22], ["amount", "OBSERVATION_MODIFIER", 23, 29]]], ["Further, the asset's value should remain relatively stable over time and be traded constantly while price information needs to be consistently disseminated.", [["the asset's value", "TEST", 9, 26], ["stable", "OBSERVATION_MODIFIER", 52, 58]]], ["In order to ensure that owners actively respond to the wealth effect by changing consumption patterns, the effect on luxury goods should be tested rather than normal or inferior goods.", [["luxury goods", "TREATMENT", 117, 129]]], ["Although participation in international tourism is likely to be regarded as a luxury good for the most part, it is difficult to presume that on average those individuals and households who engage in international tourism have considerable investments in similar assets that are consistently traded in the market.IntroductionTo this end, the current study proposes that Korean outbound travelers constitute a unique sample for testing the wealth effect on international tourism demand.", [["the current study", "TEST", 337, 354]]], ["Consistent price increases have led Korean apartments to become an actively traded asset in the wealth portfolios of middle-class households.", [["middle", "ANATOMY_MODIFIER", 117, 123]]], ["In essence, the wealth of the Korean people is concentrated in just two asset types, which are broadly held and actively traded with accurate and immediate dissemination of price information.IntroductionTherefore, the current study purports to investigate the wealth effect of housing and financial assets on Korean outbound travel demand.", [["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43], ["the current study purports", "TEST", 214, 240], ["concentrated", "OBSERVATION_MODIFIER", 47, 59]]], ["In turn, misunderstanding consumption behaviors implies ineffective and misguided pricing and marketing strategies for tourism products and targeting of demand segments.", [["misguided pricing", "TREATMENT", 72, 89], ["tourism products", "TREATMENT", 119, 135]]], ["Moreover, by identifying another driver of tourism efficiency in demand forecasting and modeling may be improved.", [["tourism efficiency", "OBSERVATION", 43, 61], ["may be", "UNCERTAINTY", 97, 103], ["improved", "OBSERVATION_MODIFIER", 104, 112]]], ["Implications and suggestions are presented along with the findings of the study.Related literature and hypothesesThe housing market in Korea is dominated by multi-family residential buildings referred to as 'apartments,' (Kim, Yang, Yeo, & Kim, 2005) .", [["the study", "TEST", 70, 79]]], ["Nearly 81 percent of all new housing in the country between 1995 and 2000 were apartments, while as of 2005 they accounted for more than half of the housing stock in Korea (Ham & Lee, 2010) .", [["new", "OBSERVATION_MODIFIER", 25, 28]]], ["The housing market shares similar expectations when information on an apartment's location, size, and year built are provided.", [["size", "OBSERVATION_MODIFIER", 92, 96]]], ["Homogeneous expectations combined with low transaction costs have led to easy trading and rental of apartments among individuals.", [["low transaction costs", "PROBLEM", 39, 60]]], ["As a result, the Korean apartment market is deeper and more active than most other housing markets (Hwang et al., 2006) .", [["active", "OBSERVATION_MODIFIER", 60, 66]]], ["This high volume of active trading and ease of comparability facilitate the construction and dissemination of reliable reference prices.", [["the construction", "TREATMENT", 72, 88], ["high", "OBSERVATION_MODIFIER", 5, 9], ["volume", "OBSERVATION_MODIFIER", 10, 16], ["active", "OBSERVATION_MODIFIER", 20, 26]]], ["Thus, individuals have a very accurate estimate of housing prices.Related literature and hypothesesAn active market, consistent and stable price inflation, a lack of permanent rental accommodations in Korea, and a high desire to own real estate (Park, 2008) have all contributed to making apartments an important consumption asset.", [["active", "OBSERVATION_MODIFIER", 102, 108], ["market", "OBSERVATION", 109, 115], ["stable", "OBSERVATION_MODIFIER", 132, 138], ["price inflation", "OBSERVATION", 139, 154]]], ["Apartments are also considered a crucial investment in the wealth portfolios of the Korean people.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97]]], ["According to the Korea Statistical Office, in 2007 the highest income group (top 20 percent) reported that 77.9% of their wealth was in real estate whereas the bottom 20% reported 79.4% in real estate assets.Related literature and hypothesesGiven the unique characteristic of Korean apartments being actively traded investment assets, the efficiency of the Korean housing market, and the broad ownership of apartments throughout various income classes, the appreciation of apartments is likely to be perceived as permanent wealth gains by the Korean people.", [["people", "ORGANISM", 550, 556], ["people", "SPECIES", 550, 556]]], ["Consequently, outbound tourism, a luxury good, may be consumed to a greater extent by aggregate demand when expectations of permanent increases in wealth are pervasive.", [["outbound tourism", "OBSERVATION", 14, 30]]], ["Although much smaller than the equity markets of developed countries, the Korean Stock Exchange is fairly sizable in terms of market capitalization and is the 14th largest stock exchange in the world (Kim, Baek, Noh, & Kim, 2007) .", [["smaller", "OBSERVATION_MODIFIER", 14, 21], ["fairly", "OBSERVATION_MODIFIER", 99, 105], ["sizable", "OBSERVATION_MODIFIER", 106, 113]]], ["The Korea Statistical Office reported in 2007 that financial assets are consistently held by different income groups; the proportion of household wealth invested in the financial market is practically the same across society, with 19.0% for the highest income group and 19.1% for the lowest income group.Related literature and hypothesesThe high volatility of the Korean stock market has been noted (Fratzscher & Oh, 2002) and investments in the equity market by Korean households are considerably lower than in the housing market.", [["high", "OBSERVATION_MODIFIER", 341, 345], ["volatility", "OBSERVATION_MODIFIER", 346, 356], ["considerably", "OBSERVATION_MODIFIER", 485, 497], ["lower", "OBSERVATION_MODIFIER", 498, 503]]], ["Appreciation of stocks will increase demand for outbound travel in Korea.Sample and dataIn order to examine the wealth effect from apartments and the stock market on Korean outbound tourism demand, quarterly timeseries data from the first quarter of 1989 through the fourth quarter of 2009 (N \u00bc 83) was obtained from the following sources: number of outbound tourists from the Korea Tourism Organization (KTO), average household incomes and apartment sales price index from the Bank of Korea, real effective exchange rates from the Bank for International Settlements, composite Korean stock price index from Korea Stock Exchange, and Singapore Kerosene-Type Jet Fuel spot price from the U.S. Energy Information Administration.", [["Sample", "TEST", 73, 79]]], ["The Singapore Kerosene-Type Jet Fuel spot price is the Mean of Platts Singapore (MOPS), used as the jet fuel price index by most airlines in Asia.", [["The Singapore Kerosene", "TREATMENT", 0, 22], ["Platts Singapore (MOPS)", "TREATMENT", 63, 86]]], ["Fig. 1 illustrates the trends of data series.", [["data series", "TEST", 33, 44]]], ["Summary statistics and Pearson correlations of the data are provided in Tables 1 and 2, respectively.", [["the data", "TEST", 47, 55]]], ["There are two noteworthy observations to be made based on the data in the figure and tables.", [["the data", "TEST", 58, 66]]], ["When the wealth effect is significant, omitting asset variables and including only income as an explanatory variable is likely to cause a misspecification bias, which would result in overestimation of the income elasticity of demand.Model specificationA log-linear specification, or elasticity model, tests for the wealth effects from apartment and stock market appreciation on outbound travel demand in South Korea: ln\u00f0TOURIST t \u00de\u00bca\u00feb 1 ln\u00f0INCOME t \u00de\u00feb 2 ln\u00f0EX t \u00de\u00feb 3 ln\u00f0KOSPI t \u00de \u00feb 4 ln\u00f0APT t \u00de\u00feb 5 ln\u00f0FUEL t \u00de\u00feb 6w8 X Q 1w3Model specificationwhere TOURIST is the number of outbound travelers departing from South Korea, INCOME is the average household income index, EX is the real effective exchange rate that accounts for changes in relative purchasing power parity in both prices and currency valuation, KOSPI is the index value of the Korean stock market, APT is the aggregate sales price index of apartments in Korea, FUEL is jet fuel price proxying for airfare, SQ 1w3 are the quarter dummies, the AFC DUMMY (1 if 1997:Q3e1998:Q2, 0 elsewhere) for the Asian Financial Crisis, 9/11 DUMMY for the September 11th Attack (1 if 2001:Q4, 0 elsewhere), and the SARS DUMMY (1 if 2003: Q2, 0 elsewhere) are dummy variables taking on the value of unity upon the occurrence of a macro event and zero if not, and t is the time subscript denoting the pertaining quarter.", [["SARS", "DISEASE", 1164, 1168], ["a misspecification bias", "PROBLEM", 136, 159], ["elasticity model", "TEST", 283, 299], ["\u00de\u00bca\u00feb", "TEST", 430, 435], ["t", "TEST", 448, 449], ["\u00de\u00feb", "TEST", 450, 453], ["t", "TEST", 462, 463], ["\u00de\u00feb", "TEST", 464, 467], ["ln\u00f0KOSPI", "TEST", 470, 478], ["t", "TEST", 479, 480], ["\u00de", "TEST", 481, 482], ["\u00feb", "TEST", 483, 485], ["ln\u00f0", "TEST", 488, 491], ["APT", "TEST", 491, 494], ["t", "TEST", 495, 496], ["\u00de\u00feb", "TEST", 497, 500], ["ln", "TEST", 503, 505], ["FUEL", "TEST", 506, 510], ["t", "TEST", 511, 512], ["\u00de\u00feb", "TEST", 513, 516], ["dummy variables", "PROBLEM", 1208, 1223], ["a macro event", "PROBLEM", 1276, 1289], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["Following a popular approach, the number of outbound tourist departures was used to measure tourism demand.", [["a popular approach", "TREATMENT", 10, 28]]], ["Income and purchasing power parities were expected to be significant in the model (Song & Li, 2008) .", [["significant", "OBSERVATION_MODIFIER", 57, 68]]], ["The hypotheses regarding the wealth effect from financial and housing assets were tested by coefficients on KOSPI and APT,b 3 andb 4 , respectively.", [["KOSPI", "TEST", 108, 113], ["APT", "TEST", 118, 121]]], ["Following Wang's (2009) approach, jet fuel price was used as a proxy for airfare while binary variables controlled for the effects of macro socioeconomic events on tourism demand, namely the Asian Financial Crisis, the September 11th Attack, and spread of the Severe Acute Respiratory Syndrome (SARS).", [["Acute Respiratory Syndrome", "DISEASE", 267, 293], ["SARS", "DISEASE", 295, 299], ["jet fuel price", "TREATMENT", 34, 48], ["macro socioeconomic events", "PROBLEM", 134, 160], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 256, 293], ["Severe", "OBSERVATION_MODIFIER", 260, 266], ["Acute", "OBSERVATION_MODIFIER", 267, 272], ["Respiratory Syndrome", "OBSERVATION", 273, 293]]], ["The use of a log-linear model allows easy interpretation of the results as the elasticity of demand where the units of data for the current study are difficult to interpret (Wang, 2009 ), while the log-linear form is also widely advocated for its robustness against heteroscedasticity (Wang, 1995) .Model specificationBefore estimation, heteroscedasticity and multicollinearity were examined using the BreuschePagan test and the variation inflation factor (VIF).", [["variation inflation factor", "PROTEIN", 429, 455], ["VIF", "PROTEIN", 457, 460], ["the current study", "TEST", 128, 145], ["the BreuschePagan test", "TEST", 398, 420], ["the variation inflation factor", "TREATMENT", 425, 455]]], ["The BreuschePagan test did not reject the null at pvalue of 0.486, supporting the homoscedasticity assumption.", [["The BreuschePagan test", "TEST", 0, 22]]], ["In addition, no variable had a VIF exceeding the potential problematic level of 10.", [["a VIF", "PROBLEM", 29, 34], ["no", "UNCERTAINTY", 13, 15], ["variable", "OBSERVATION_MODIFIER", 16, 24]]], ["We inferred that much of the collinearity expected from Table 2 is alleviated after the logarithmic transformation (Buongiorno, 1977; Grime & Smith, 1982) .", [["the logarithmic transformation", "PROBLEM", 84, 114], ["logarithmic transformation", "OBSERVATION", 88, 114]]], ["Also, in order to address the concerns of endogeneity from omitted-variable bias we identified the factors that influence housing prices in Asia as: construction costs, household income, household formation, housing supply, stock prices, and monetary supply (Chen & Patel, 1998) .", [["omitted-variable bias", "PROBLEM", 59, 80]]], ["Among these factors, those that may have an effect on tourism demand (income and stock prices) entered the regression equation as explanatory variables as ln(INCOME t ) and ln(KOSPI t ), relieving concerns of endogeneity.Model specificationAs autocorrelation of the dependent variables is expected, even using quarterly data, many studies employ a lagged dependent variable as an explanatory variable (Witt & Witt, 1995) .", [["the dependent variables", "PROBLEM", 262, 285], ["many studies", "TEST", 326, 338], ["ln", "ANATOMY", 173, 175], ["dependent", "OBSERVATION_MODIFIER", 266, 275]]], ["Although including the lagged dependent variable does not create a bias in the coefficients, it is expected to underestimate the variance of the estimator in the presence of positive autocorrelation, thereby overstating the significance of the coefficients (Wooldridge, 2002) .", [["positive", "OBSERVATION", 174, 182]]], ["In order to conduct an efficient estimation and obtain reliable results, the current study implemented two different estimation techniques: PraiseWinsten and ordinary least squares (OLS) with NeweyeWest standard errors.", [["the current study", "TEST", 73, 90]]], ["Estimators and statistics from the PraiseWinsten procedure are asymptotically efficient and valid for autoregressive models of the first-order, while the NeweyeWest procedure provides a robust inference of serial correlations of a higher-order (Traub & Jayne, 2004) .", [["the PraiseWinsten procedure", "TREATMENT", 31, 58], ["autoregressive models", "TEST", 102, 123], ["the NeweyeWest procedure", "TREATMENT", 150, 174]]], ["More specifically, if the model to be estimated includes a first-order autoregressive disturbance term, the PraiseWinsten method transforms the error vector that yields serially uncorrelated classical disturbances (Baltagi, Song, Jung, & Koh, 2007) .", [["autoregressive disturbance term", "PROBLEM", 71, 102], ["serially uncorrelated classical disturbances", "PROBLEM", 169, 213]]], ["In the presence of higher-order lags, the New-eyeWest method allows for the robust inference of standard errors on the coefficients (Ferson, Sarkissian, & Simin, 2003) and is standard in the economics literature (Greene, 2008) .Model specificationFor the PraiseWinsten estimation, a CochraneeOrcutt transformation was done on (1) after estimation of the autocorrelation parameter, r.", [["r.", "SPECIES", 381, 383], ["a CochraneeOrcutt transformation", "PROBLEM", 281, 313], ["the autocorrelation parameter", "TEST", 350, 379], ["higher", "OBSERVATION_MODIFIER", 19, 25]]], ["For data quarters t and t-1 this can be written as:Model specificationwhere x 1w11 are all independent variables on the right-hand side of (1).", [["right-hand", "ANATOMY", 120, 130], ["right", "ANATOMY_MODIFIER", 120, 125]]], ["By expressing the first-order autocorrelation in the error term as r, the error term can be expressed as a Markov scheme of an autoregressive and random component:Model specificationwhere y t is serially independent random disturbances.", [["serially independent random disturbances", "PROBLEM", 195, 235]]], ["SubstitutingModel specification(3) into (2), the equation can be rewritten as an equivalent system:Model specificationAn estimation of (4) using the Generalized Least Squares (GLS) method yields coefficients and a variance structure unaffected by autocorrelation parameter r.Results and discussionResults of estimation by both PraiseWinsten and NeweyeWest procedures are displayed in Table 3 .", [["a variance structure", "PROBLEM", 212, 232]]], ["The results are similar in general, representing the reliability of the model, although there are some differences in significance and magnitude of the coefficients for variables EX, APT and dummy variables, as noted.", [["variables EX", "TEST", 169, 181], ["APT", "TEST", 183, 186], ["dummy variables", "TEST", 191, 206], ["similar", "OBSERVATION_MODIFIER", 16, 23], ["some", "OBSERVATION_MODIFIER", 98, 102], ["differences", "OBSERVATION_MODIFIER", 103, 114]]], ["The Since the NeweyeWest procedure is only expected to outperform the PraiseWinsten method in the presence of higher-order autocorrelation, inferences were subsequently made based on the results from the PraiseWinsten estimation method.", [["the NeweyeWest procedure", "TREATMENT", 10, 34]]], ["The coefficients of income and real effective exchange rates were the greatest in size and highly significant, consistent with the results of preceding studies (Lim, 1997) .", [["real effective exchange rates", "TREATMENT", 31, 60], ["preceding studies", "TEST", 142, 159], ["greatest", "OBSERVATION_MODIFIER", 70, 78], ["size", "OBSERVATION_MODIFIER", 82, 86], ["significant", "OBSERVATION_MODIFIER", 98, 109]]], ["A one percent increase in average household income caused 1.5 percent increase approximately, in the number of quarterly outbound travelers.", [["one", "OBSERVATION_MODIFIER", 2, 5], ["percent", "OBSERVATION_MODIFIER", 6, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["average", "OBSERVATION_MODIFIER", 26, 33], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["approximately", "OBSERVATION_MODIFIER", 79, 92]]], ["The effect from purchasing parity changes was relatively smaller at 0.65 percent.", [["smaller", "OBSERVATION_MODIFIER", 57, 64]]], ["As hypothesized, the income elasticity greater than unity confirmed that outbound travel is considered as a luxury good by the Korean people.", [["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140]]], ["Accordingly, the consumption of international travel increased at a rate greater than that of income.Results and discussionThe coefficient of APT was significant and stable across both models.", [["stable", "OBSERVATION_MODIFIER", 166, 172]]], ["A one percent increase in apartment prices in Korea caused an approximately 0.39 percent increase in the number of outbound travelers per quarter.", [["one", "OBSERVATION_MODIFIER", 2, 5], ["percent", "OBSERVATION_MODIFIER", 6, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["approximately", "OBSERVATION_MODIFIER", 62, 75], ["0.39 percent", "OBSERVATION_MODIFIER", 76, 88], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["number", "OBSERVATION_MODIFIER", 105, 111]]], ["Although the magnitude of the effect on aggregate demand was less than one third of that from income, the results nevertheless serve as evidence of the effect of adjusted expectations of wealth on consumption patterns.", [["aggregate demand", "PROBLEM", 40, 56], ["magnitude", "OBSERVATION_MODIFIER", 13, 22]]], ["As a result, Hypothesis 1 was supported and the current study found that housing assets had a significant wealth effect on Korean demand for outbound tourism.Results and discussionOn the other hand, Hypothesis 2 was rejected in both models with a low probability.", [["the current study", "TEST", 44, 61], ["a low probability", "PROBLEM", 245, 262]]], ["One possibility is that the high volatility of stock prices might prevent owners from viewing the appreciation as a permanent gain.", [["stock prices", "TREATMENT", 47, 59], ["high", "OBSERVATION_MODIFIER", 28, 32], ["volatility", "OBSERVATION_MODIFIER", 33, 43]]], ["The insignificant results could also be attributed to inefficient estimation; quarterly data may have insufficient sensitivity as stock prices are highly volatile in nature, as seen in Fig. 1 .", [["insufficient sensitivity", "PROBLEM", 102, 126], ["could also be attributed to", "UNCERTAINTY", 26, 53], ["volatile", "OBSERVATION_MODIFIER", 154, 162]]], ["This may be due to a comparably low allocation of relative wealth in the stock market, which accounts for less than 20% of total household wealth, whereas housing assets account for more than 75%.", [["may be due to", "UNCERTAINTY", 5, 18], ["low", "OBSERVATION_MODIFIER", 32, 35], ["stock market", "OBSERVATION", 73, 85]]], ["The smaller amount of total investments in equity stocks, which resulted in a trivial absolute increase in expected wealth, may also account for the result (Cho, 2006) .Results and discussionAmong the quarter dummies, the third quarter, which includes the Korean summer vacation season, was the most sizable and significant.", [["total investments in equity stocks", "TREATMENT", 22, 56], ["a trivial absolute increase", "PROBLEM", 76, 103], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["amount", "OBSERVATION_MODIFIER", 12, 18], ["total", "OBSERVATION_MODIFIER", 22, 27], ["investments", "OBSERVATION_MODIFIER", 28, 39], ["equity stocks", "OBSERVATION", 43, 56], ["trivial", "OBSERVATION_MODIFIER", 78, 85], ["absolute", "OBSERVATION_MODIFIER", 86, 94], ["increase", "OBSERVATION_MODIFIER", 95, 103], ["may also account for", "UNCERTAINTY", 124, 144], ["most sizable", "OBSERVATION_MODIFIER", 295, 307], ["significant", "OBSERVATION_MODIFIER", 312, 323]]], ["The dummy variables for macro events, except for the September 11 dummy, were significant.", [["macro events", "PROBLEM", 24, 36], ["significant", "OBSERVATION_MODIFIER", 78, 89]]], ["The Asian Financial Crisis, the net effect of depressed income and purchasing parity, decreased outbound travel demand by roughly 1 percent.", [["depressed", "DISEASE", 46, 55]]], ["Severe Acute Respiratory Syndrome (SARS) decreased outbound travel demand by approximately 4 percent.", [["Acute Respiratory Syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["Severe Acute Respiratory Syndrome", "PROBLEM", 0, 33], ["SARS)", "PROBLEM", 35, 40], ["decreased outbound travel demand", "PROBLEM", 41, 73], ["Acute", "OBSERVATION_MODIFIER", 7, 12], ["Respiratory Syndrome", "OBSERVATION", 13, 33], ["decreased", "OBSERVATION_MODIFIER", 41, 50]]], ["A possible explanation for the insignificant coefficient of the 9/11 DUMMY variable is the effect of substitution to other destinations.", [["substitution", "TREATMENT", 101, 113], ["possible explanation for", "UNCERTAINTY", 2, 26]]], ["Although trips to the US from Korea significantly declined immediately after the 9/11 attack, total outbound demand may have been sustained by substituting other nearby destinations, such as Southeast Asia or Oceania, that had a relatively lower perceived risk of terrorism (Lim, 2004) .Results and discussionAs observed, the effect of unrealized wealth, the net of income and purchasing power parity changes, seems to influence the outbound travel of the Korean people.", [["people", "ORGANISM", 463, 469], ["people", "SPECIES", 463, 469], ["the US", "TEST", 18, 24], ["total outbound demand", "PROBLEM", 94, 115], ["terrorism", "OBSERVATION", 264, 273]]], ["Although the effect is rather small compared to the two most important variables that govern international travel, we nevertheless found a significant causal relationship between expectations of wealth and the decision to travel internationally.Results and discussionConsequently, distinguishing wealth and income in travel demand may be an important task based on analytic results.", [["small", "OBSERVATION_MODIFIER", 30, 35]]], ["However, in order to produce more efficient estimates of income and/or price effects on tourism goods, changes in net assets and the relative location of a person in the society's wealth distribution curve can be taken into account.", [["person", "SPECIES", 156, 162]]], ["This suggests that efficiency of conventional tourism demand models can be enhanced and their accuracy improved by utilizing important wealth variables.ConclusionAndo and Modigliani's (1963) Life Cycle Hypotheses (LCH) predicts that a shift in demand can be induced without an actual change in income, but instead based solely on a change in expectations for future income.", [["LCH", "DISEASE", 214, 217], ["ConclusionAndo", "TEST", 152, 166], ["Modigliani's", "TREATMENT", 171, 183], ["efficiency", "OBSERVATION_MODIFIER", 19, 29]]], ["Based on LCH, the current study hypothesized that consumption of international tourism is also subject to changes in unrealized, expected wealth tied to the prices of housing and financial assets.", [["LCH", "DISEASE", 9, 12], ["the current study", "TEST", 14, 31], ["LCH", "OBSERVATION", 9, 12]]], ["Since examining the relationship at the aggregate level requires liquidity, active trading, an efficient market, and broad ownership of assets throughout demand segments, the Korean housing and financial markets, which fulfill these conditions, were used to investigate the recursive relationship with outbound travel demand.ConclusionEstimating the constant elasticity model using time-series data with PraiseWinsten and NeweyeWest procedures, it was found that the appreciation of apartments, the dominant type of housing in Korea, significantly increased outbound travel demand from 1989 to 2009.", [["PraiseWinsten", "TREATMENT", 404, 417], ["NeweyeWest procedures", "TREATMENT", 422, 443], ["active", "OBSERVATION_MODIFIER", 76, 82], ["dominant", "OBSERVATION_MODIFIER", 499, 507], ["significantly", "OBSERVATION_MODIFIER", 534, 547], ["increased", "OBSERVATION_MODIFIER", 548, 557]]], ["Rather than naively interpreting these results as proof that the financial wealth effect is invalid, it should be noted that low data sensitivity, the relatively lower importance of financial assets in household wealth portfolios, and high price volatility may have led to the insignificant empirical results for financial assets.ConclusionBy identifying unrealized wealth or adaptive expectations based on future income, as a potential determinant of tourism demand the current study makes a significant contribution to the contemporary tourism literature.", [["low data sensitivity", "PROBLEM", 125, 145], ["the current study", "TEST", 467, 484]]], ["Wealth effects may appear insignificant and vary depending on the characteristics of the demand, product, and asset, and caution should be employed when drawing on the effect of unrealized wealth.", [["insignificant", "OBSERVATION_MODIFIER", 26, 39]]], ["When the wealth effect is significant, forecasting systems can make use of new asset variables to improve efficiency and predictability.", [["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["Developing better tourism forecasting models requires identifying new variables and integrating quantitative and qualitative forecasting approaches (Song & Li, 2008) .", [["better tourism", "OBSERVATION", 11, 25]]], ["In this regard, micro and qualitative data on demand characteristics, including demand elasticities, destination preferences, and the propensity to travel, may enter the econometric equations to improve model fit and forecasting accuracy.", [["forecasting accuracy", "TEST", 217, 237]]], ["Such efforts are not new and have been gaining attention in relatively new demand models (Stepchenkova & Eales, 2011) .", [["new", "OBSERVATION_MODIFIER", 21, 24]]], ["Although the current study operationalizes two assets suitable for the Korean economy e housing and stocks e demand models for other groups, countries, or economies will benefit from testing and utilizing other potentially relevant asset variables, such as cultural beliefs (Guiso, Sapienza, & Zingales, 2006) or hopes regarding future economic conditions (Canina & Carvell, 2005) .ConclusionConsequently, organizations promoting tourism, such as destination marketing organizations and conventions and visitors bureaus, can better allocate limited resources and coordinate marketing and sales efforts in order to respond to expected demand fluctuations from changes in the consumption behaviors of potential visitors that do not result from realized income.ConclusionFor example, instead of relying on crude forecasts based solely on gross domestic product, consumer price index, and travel costs, analysts may use market-specific data on destination preferences of sending countries regarding respective receiving countries and income elasticity to those destinations.", [["the current study", "TEST", 9, 26], ["the Korean economy e housing", "TREATMENT", 67, 95], ["stocks e demand models", "TREATMENT", 100, 122], ["testing", "TEST", 183, 190]]], ["This approach may be further augmented by connecting spending behaviors with cultural beliefs and expectations regarding future economic conditions.ConclusionDespite its relevance, this study has several limitations in terms of generalizing and extending the results to other settings.", [["cultural beliefs", "TEST", 77, 93], ["future economic conditions", "PROBLEM", 121, 147], ["this study", "TEST", 181, 191]]], ["The Korean economy and travel demand are a unique case among the numerous countries constituting the global economy and the demand for international tourism.", [["travel demand", "TREATMENT", 23, 36], ["economy", "OBSERVATION_MODIFIER", 11, 18]]], ["As such, there is no guarantee that the wealth effect is universal or common across a number of economies, as it is jointly dependent on the nature of the economy, the asset type in question, and characteristics of the demand.", [["no", "UNCERTAINTY", 18, 20], ["dependent", "OBSERVATION_MODIFIER", 124, 133]]], ["It should also be noted that incorporating the effect of wealth in demand modeling or marketing strategies when it is insignificant could also sacrifice efficiency and reliability.", [["demand modeling", "TREATMENT", 67, 82]]], ["Furthermore, inflation and volatility of housing and stock prices differ greatly case by case, while adaptive expectations based on future income resulting from price changes are also likely to be inconsistent or distinctive on the part of the consumers.", [["inflation", "TREATMENT", 13, 22], ["volatility", "OBSERVATION_MODIFIER", 27, 37]]], ["For example, in an extreme situation the wealth-elasticity of high income demand for low cost tourism destinations may be negative, as wealthier travelers will shift toward more prestigious and costly alternatives.ConclusionAlthough the current study utilized Korean data to overcome the limitations originating from the 'aggregation economy,' the theory of wealth effect on consumption has been supported and empirically validated to a significant extent, especially by studies using micro data (Poterba, 1988) .", [["aggregation", "DISEASE", 322, 333], ["high income demand", "PROBLEM", 62, 80], ["the current study", "TEST", 233, 250], ["Korean data", "TEST", 260, 271], ["micro data", "TEST", 485, 495], ["high", "OBSERVATION_MODIFIER", 62, 66]]], ["Accordingly, the effect might be universal, despite the limited testability with macroeconomic data.ConclusionIndeed, it would not be easy to find a similar developed economy where a considerable mass of wealth is concentrated in one or two asset classes.", [["macroeconomic data", "TEST", 81, 99], ["a considerable mass", "PROBLEM", 181, 200], ["considerable", "OBSERVATION_MODIFIER", 183, 195], ["mass", "OBSERVATION", 196, 200], ["concentrated", "OBSERVATION_MODIFIER", 214, 226]]], ["As shown, the current study could not find a significant wealth effect from financial assets, even though almost 20% of total household wealth in Korea is concentrated in them.", [["the current study", "TEST", 10, 27], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["concentrated", "OBSERVATION", 155, 167]]], ["A potential explanation for the results could be that financial assets in the Korean economy may not generate a sufficient wealth effect for the people, presumably due to the volatility of stock prices.ConclusionMyopia, liquidity and credit constraints (Rosenzweig & Wolpin, 1993; Shea, 1995b; Zeldes, 1989) , the main factors that also govern spending, vary greatly even for people of comparable net wealth.", [["people", "ORGANISM", 145, 151], ["people", "ORGANISM", 376, 382], ["people", "SPECIES", 145, 151], ["people", "SPECIES", 376, 382], ["ConclusionMyopia", "TEST", 202, 218], ["potential explanation for", "UNCERTAINTY", 2, 27], ["stock prices", "OBSERVATION", 189, 201]]], ["Others may face reductions in future discretionary spending.", [["reductions", "OBSERVATION_MODIFIER", 16, 26]]], ["In this regard, collecting refined income and tourism spending data, segmented by income and wealth level, would be invaluable in examining the marginal sensitivity of the wealth effect and provide a base of comparison across cultures and societies.ConclusionAs such, further research efforts on this topic should focus on the behavior and response of travel demand to economic cycles.", [["a base of comparison across cultures", "TEST", 198, 234], ["economic cycles", "TREATMENT", 369, 384]]], ["In this regard, refining estimation techniques and examining psychological and cultural differences are viable options to pursue.", [["refining estimation techniques", "TEST", 16, 46]]], ["Considering other potentially influential factors on demand such as liquidity, savings, credit constraints, and myopic behavior are also warranted.", [["myopic behavior", "PROBLEM", 112, 127]]], ["Although the controversy around the effect of wealth on consumption is unlikely to be resolved conclusively (Poterba, 1988) in the near future, untangling the complex dynamics among income, wealth, and consumption will be central in the future enhancement of forecasting techniques and models for travel demand.", [["forecasting techniques", "TEST", 259, 281], ["unlikely to be", "UNCERTAINTY", 71, 85], ["complex", "OBSERVATION_MODIFIER", 159, 166]]]], "PMC7472384": [], "fae83f4b878d7a70f81ea245014256271d3b687d": [["IntroductionMost new developments in the area of microprocessors use RISC instruction sets.", [["new", "OBSERVATION_MODIFIER", 17, 20]]], ["The RISC nature of instruction sets eases decoding and creation of pipelines.", [["creation of pipelines", "TREATMENT", 55, 76]]], ["On the down side, analyzing such instruction sequences can be very difficult.", [["analyzing such instruction sequences", "TEST", 18, 54]]], ["Thus, it will be easier to reverse engineer the intention of the programmer.IntroductionThis is an essential property if we consider dynamic software/hardware migration.", [["dynamic software/hardware migration", "TREATMENT", 133, 168], ["hardware migration", "OBSERVATION", 150, 168]]], ["In AMIDAR processors, such online synthesis is one major factor for an efficient application execution.", [["AMIDAR processors", "TREATMENT", 3, 20]]], ["Existing AMIDAR processors use Java Bytecode as their instruction set.", [["Existing AMIDAR processors", "TREATMENT", 0, 26]]], ["Alternatively, a true Java Bytecode processor like an AMIDAR processor could be used in such platforms.", [["a true Java Bytecode processor", "TREATMENT", 15, 45], ["an AMIDAR processor", "TREATMENT", 51, 70]]], ["2) Java as programming language has gained a lot of attention for embedded systems due to its inherent safety features.", [["embedded systems", "PROBLEM", 66, 82]]], ["Consequently, real HW implementations of Java Bytecode processors exist and are in commercial use.IntroductionIn this contribution, we present a novel instruction set architecture (ISA) that preserves the high abstraction level of Java Bytecode, while at the same time reducing the amount of data transports to a minimum.", [["Java Bytecode processors", "TREATMENT", 41, 65]]], ["On average, the resulting instruction set can be executed with less than one third of the original AMIDAR clock cycles.IntroductionThe paper is structured as follows.", [["the original AMIDAR clock cycles", "TREATMENT", 86, 118]]], ["Section 4 presents challenges together with our solutions for many detail problems with the new ISA.", [["our solutions", "TREATMENT", 44, 57], ["many detail problems", "PROBLEM", 62, 82]]], ["An evaluation of the new ISA is shown in Sect.", [["An evaluation", "TEST", 0, 13], ["new", "OBSERVATION_MODIFIER", 21, 24]]], ["Finally, a conclusion and an outlook are given.The AMIDAR PrincipleAMIDAR [3] processors are composed of multiple functional units (FUs) which work independently of each other.", [["AMIDAR PrincipleAMIDAR [3] processors", "DNA", 51, 88], ["The AMIDAR PrincipleAMIDAR [3] processors", "TREATMENT", 47, 88], ["multiple functional units (FUs)", "TREATMENT", 105, 136]]], ["Independence of FUs is a major strength of AMIDAR.", [["FUs", "GENE_OR_GENE_PRODUCT", 16, 19], ["AMIDAR", "GENE_OR_GENE_PRODUCT", 43, 49], ["FUs", "PROTEIN", 16, 19], ["AMIDAR", "PROTEIN", 43, 49]]], ["It facilitates hardware design and provides opportunities for runtime reconfiguration.", [["hardware design", "TREATMENT", 15, 30], ["hardware", "OBSERVATION", 15, 23]]], ["Figure 1 illustrates the structure of a Java processor.", [["a Java processor", "TREATMENT", 38, 54]]], ["The Token Machine is a special FU which decodes program instructions into tokens and sends them to FUs using the token distribution network.", [["FUs", "PROTEIN", 99, 102]]], ["In previous versions of AMIDAR processors, tags are used for synchronizing data with FU operations.", [["FU", "SIMPLE_CHEMICAL", 85, 87], ["AMIDAR processors", "DNA", 24, 41], ["AMIDAR processors", "TREATMENT", 24, 41], ["FU operations", "TREATMENT", 85, 98]]], ["Using this technique, every token and data packet contains a tag number.", [["this technique", "TREATMENT", 6, 20]]], ["Consequently, no assumptions about the timing of FUs are required and communication between FUs is self-timed.The AMIDAR PrincipleApart from its role as instruction decoder, the Token Machine executes all operations which change control flow like branches and method invocations.", [["FUs", "GENE_OR_GENE_PRODUCT", 49, 52], ["FUs", "GENE_OR_GENE_PRODUCT", 92, 95], ["the Token Machine", "TREATMENT", 174, 191], ["all operations", "TREATMENT", 201, 215], ["method invocations", "TREATMENT", 260, 278], ["branches", "OBSERVATION_MODIFIER", 247, 255]]], ["The Frame Stack FU stores for each thread a stack of method frames.", [["Frame Stack FU", "DNA", 4, 18]]], ["Every frame comprises a section for local variables and an operand stack.", [["a section", "TREATMENT", 22, 31], ["an operand stack", "TREATMENT", 56, 72]]], ["The Object Heap FU stores objects, arrays and static variables.", [["static variables", "TEST", 46, 62], ["stores objects", "OBSERVATION", 19, 33]]], ["The Thread Scheduler FU decides which thread to execute and provides thread synchronization using monitors.", [["thread synchronization", "TREATMENT", 69, 91]]], ["Several ALUs exist for integer and floating point arithmetic.", [["ALUs", "CANCER", 8, 12]]], ["A coarse grained reconfigurable array (CGRA) is used as flexible hardware accelerator [10] .MotivationThe Frame Stack FU has been identified as bottleneck in previous versions of AMIDAR processors, which use Java Bytecode as their instruction set.", [["FU", "CHEMICAL", 118, 120], ["A coarse grained reconfigurable array (CGRA)", "TREATMENT", 0, 44], ["flexible hardware accelerator", "TREATMENT", 56, 85], ["AMIDAR processors", "TREATMENT", 179, 196]]], ["This results in many transfers from and to the Frame Stack FU.", [["FU", "CHEMICAL", 59, 61]]], ["Consequently, reducing these data transfers is the main motivation for developing a new ISA.RequirementsThe processor should run Java programs on a high level of abstraction, like the previous AMIDAR implementation.", [["the previous AMIDAR implementation", "TREATMENT", 180, 214]]], ["Reconfiguration features like dynamic software/hardware migration should still be supported.", [["Reconfiguration features", "PROBLEM", 0, 24], ["dynamic software", "PROBLEM", 30, 46], ["hardware migration", "TREATMENT", 47, 65], ["dynamic software", "OBSERVATION", 30, 46], ["hardware migration", "OBSERVATION", 47, 65]]], ["This leads to the following requirements.Requirements-Data should be transmitted directly between FUs whenever possible without using intermediate storage.Basic ConceptThe basic idea of the new ISA is to specify data flow between instructions explicitly instead of using an operand stack.", [["FUs", "SIMPLE_CHEMICAL", 98, 101], ["an operand stack", "TREATMENT", 271, 287]]], ["The four components of an instruction are shown in Fig. 2 .", [["four", "OBSERVATION_MODIFIER", 4, 8], ["components", "OBSERVATION_MODIFIER", 9, 19]]], ["Every instruction specifies the operation to execute.", [["the operation", "TREATMENT", 28, 41]]], ["Some operations require an additional constant.", [["Some operations", "TREATMENT", 0, 15], ["operations", "OBSERVATION", 5, 15]]], ["It consists of an instruction offset and a port.", [["a port", "TREATMENT", 41, 47]]], ["The offset is relative to the current instruction in order of execution.", [["offset", "OBSERVATION_MODIFIER", 4, 10]]], ["Many operations require more than one operand.", [["Many operations", "TREATMENT", 0, 15], ["operations", "OBSERVATION", 5, 15]]], ["Therefore, a port number is used in the result reference to specify which of these operands is sent.Fig.", [["a port", "TREATMENT", 11, 17], ["these operands", "TEST", 77, 91]]], ["Assembler representation of one instructionAn example of the resulting code is given in Fig. 3 together with an illustration of control and data flow.", [["data flow", "TEST", 140, 149]]], ["The next instruction in line 3 sends a value from scratch pad memory to port 1 of either the add or the sub instruction.", [["scratch pad memory to port", "TREATMENT", 50, 76]]], ["The branch instruction in line 4 determines which of both is executed by comparing the received value with zero.", [["branch", "OBSERVATION_MODIFIER", 4, 10]]], ["Both the add and the sub instructions send their result to port 0 of the mul instruction in line 11.", [["the mul instruction in line", "TREATMENT", 69, 96]]], ["This value is multiplied with the value read from scratch pad memory address 4.", [["This value", "TEST", 0, 10], ["the value", "TEST", 30, 39]]], ["Port 0 of the mul instruction is an example for this.", [["Port", "TREATMENT", 0, 4], ["the mul instruction", "TREATMENT", 10, 29]]], ["Either the result of the addition or of the subtraction is received depending on the previously executed program path.Code GenerationCode for the new ISA can be generated from two types of sources.", [["the subtraction", "TREATMENT", 40, 55]]], ["The first type is assembler code.", [["assembler code", "OBSERVATION", 18, 32]]], ["This binary contains all information which is required to execute a program on a hardware implementation of the processor.", [["a hardware implementation of the processor", "TREATMENT", 79, 121]]], ["The corresponding tool flow is depicted in Fig. 4 .", [["tool flow", "OBSERVATION", 18, 27], ["Fig", "OBSERVATION_MODIFIER", 43, 46]]], ["A newly developed transpiler converts a set of class files to a NAX file.", [["NAX", "PROTEIN", 64, 67]]], ["Figure 4 also shows a simplified version of this transpilation process.", [["this transpilation process", "TREATMENT", 44, 70]]], ["The Java analysis and optimization framework Soot is used to convert Bytecode from class files to an SSA form called Shimple [6] .", [["Bytecode", "PROTEIN", 69, 77], ["The Java analysis", "TEST", 0, 17], ["optimization framework Soot", "TREATMENT", 22, 49]]], ["Instruction selection creates a control flow graph for each method of the Shimple representation.", [["Instruction selection", "TREATMENT", 0, 21], ["a control flow graph", "TREATMENT", 30, 50]]], ["Each node of such a control flow graph in turn points to a directed acyclic graph (DAG) defining data dependencies between instructions in the corresponding block.", [["node", "ANATOMY", 5, 9], ["DAG", "SIMPLE_CHEMICAL", 83, 86], ["a control flow graph", "TEST", 18, 38], ["a directed acyclic graph (DAG)", "TREATMENT", 57, 87], ["node", "OBSERVATION", 5, 9]]], ["Instruction scheduling orders the instructions in each block to respect dependencies implied by the DAG on the one hand and hardware restrictions on the other hand.Binary FormatA binary format for the instructions has already been defined as shown in Fig. 5 .", [["DAG", "CHEMICAL", 100, 103], ["DAG", "CHEMICAL", 100, 103], ["DAG", "SIMPLE_CHEMICAL", 100, 103], ["hand", "ORGANISM_SUBDIVISION", 159, 163], ["hardware restrictions", "TREATMENT", 124, 145], ["hardware", "OBSERVATION", 124, 132]]], ["This is the smallest multiple of one byte which can store all relevant information and leaves small room for extensions.", [["smallest", "OBSERVATION_MODIFIER", 12, 20], ["multiple", "OBSERVATION_MODIFIER", 21, 29]]], ["Code is stored in an external DRAM which is accessed using a 32 bit AXI interface.", [["DRAM", "PROTEIN", 30, 34], ["an external DRAM", "TREATMENT", 18, 34], ["a 32 bit AXI interface", "TREATMENT", 59, 81]]], ["This is typically the case for memory store operations.", [["memory store operations", "TREATMENT", 31, 54]]], ["The Funct7 field holds the operation.", [["the operation", "TREATMENT", 23, 36], ["operation", "OBSERVATION", 27, 36]]], ["Bit 12 distinguishes between 32 bit and 64 bit operations. -R-type is used for normal instructions which produce results.", [["64 bit operations", "TREATMENT", 40, 57]]], ["This type contains the same fields as S-type plus instruction offset and port for specifying the result reference.", [["port", "TREATMENT", 73, 77]]], ["Larger constants must either be computed or stored in the constant pool.", [["Larger constants", "PROBLEM", 0, 16]]], ["Special operations exist for loading these constants from the pool. -J-type is used for unconditional jumps.", [["Special operations", "TREATMENT", 0, 18], ["unconditional jumps", "PROBLEM", 88, 107], ["J-type", "OBSERVATION_MODIFIER", 69, 75]]], ["The Imm21 field holds the address of the jump target relative to current position in the code. -B-type is used for conditional branches.", [["Imm21", "PROTEIN", 4, 9], ["conditional branches", "PROBLEM", 115, 135], ["branches", "OBSERVATION_MODIFIER", 127, 135]]], ["The comparison which decides whether the branch is taken or not is encoded in field Funct3.", [["Funct3", "PROTEIN", 84, 90], ["branch", "ANATOMY_MODIFIER", 41, 47]]], ["Afterwards, the transpilation process has been developed to be able to write programs in Java.", [["the transpilation process", "TREATMENT", 12, 37]]], ["All design choices have been taken with possible hardware implementations in mind.", [["hardware implementations", "TREATMENT", 49, 73]]], ["This section depicts some of the challenges which have been encountered on this way and their solutions.Duplicating DataAs already mentioned in Sect.", [["DataAs", "PROTEIN", 116, 122], ["This section", "TREATMENT", 0, 12]]], ["However, one value might be required as operand for multiple operations.", [["multiple operations", "TREATMENT", 52, 71]]], ["The first one is a small scratch pad memory, which is implemented as additional functional unit.", [["a small scratch pad memory", "PROBLEM", 17, 43], ["small", "OBSERVATION_MODIFIER", 19, 24], ["scratch", "OBSERVATION_MODIFIER", 25, 32], ["pad memory", "OBSERVATION", 33, 43]]], ["Nevertheless, this contradicts the original idea of transferring data directly between FUs without intermediate storage.Duplicating DataUsing the second mechanism, instructions can specify that their result should not be removed from the output queue of the sending FU.", [["FU", "CHEMICAL", 266, 268], ["FUs", "SIMPLE_CHEMICAL", 87, 90], ["FU", "SIMPLE_CHEMICAL", 266, 268]]], ["Otherwise, scratch pad memory is used.", [["scratch", "OBSERVATION_MODIFIER", 11, 18], ["pad memory", "OBSERVATION", 19, 29]]], ["The generic structure of an FU is shown in Fig. 6 and is explained in Sect.", [["FU", "CHEMICAL", 28, 30], ["FU", "SIMPLE_CHEMICAL", 28, 30]]], ["For example, if control flow branches and a value is only required in one branch, the processor must be instructed to discard this value.", [["a value", "TEST", 42, 49], ["branches", "OBSERVATION_MODIFIER", 29, 37]]], ["When a result is targeted to such an instruction during execution, the sending FU is informed to remove the value from its output queue without sending it.Data SynchronizationThe tag mechanism used for data synchronization in the previous AMIDAR implementation has several disadvantages.", [["FU", "SIMPLE_CHEMICAL", 79, 81], ["The tag mechanism", "TREATMENT", 175, 192], ["data synchronization", "TREATMENT", 202, 222], ["the previous AMIDAR implementation", "TREATMENT", 226, 260]]], ["Thirdly, depending on size and topology of the interconnect, tag comparators can be part of a long combinatorial path starting from the sending FU via the comparator of the receiving FU back to the acknowledgment signal of the sending FU.", [["FU", "CHEMICAL", 144, 146], ["FU", "CHEMICAL", 235, 237], ["FU", "SIMPLE_CHEMICAL", 144, 146], ["FU", "SIMPLE_CHEMICAL", 235, 237], ["a long combinatorial path", "PROBLEM", 92, 117], ["size", "OBSERVATION_MODIFIER", 22, 26]]], ["It uses explicit operation addresses to match data and operations.", [["explicit operation", "TREATMENT", 8, 26]]], ["The important hardware components for this mechanism are depicted in Fig. 6 .", [["The important hardware components", "TREATMENT", 0, 33], ["hardware", "OBSERVATION", 14, 22]]], ["The first thing to note is that tokens are transferred to an FU in two parts.", [["FU", "SIMPLE_CHEMICAL", 61, 63]]], ["The target information is sent afterwards when the receiving instruction has been decoded.Data SynchronizationIt is assumed, that an instruction IN 1 has already been decoded which results in operation OP 1 to be executed on F U 1 .", [["F U 1", "GENE_OR_GENE_PRODUCT", 225, 230]]], ["The result of OP 1 has already been computed and stored in the result queue of F U 1 .", [["OP", "CHEMICAL", 14, 16], ["F U 1", "GENE_OR_GENE_PRODUCT", 79, 84], ["OP", "TEST", 14, 16]]], ["Now, the Token Machine decodes IN 2 and sends the corresponding operation OP 2 to the operation memory of F U 2 .", [["F U 2", "GENE_OR_GENE_PRODUCT", 106, 111]]], ["A line of this memory consists of an operation and one data word for each port of F U 2 .", [["an operation", "TREATMENT", 34, 46], ["line", "OBSERVATION_MODIFIER", 2, 6], ["operation", "OBSERVATION", 37, 46]]], ["An operation is stored together with its operands in one line.", [["An operation", "TREATMENT", 0, 12], ["operation", "OBSERVATION", 3, 12]]], ["The address of a line is named operation address.", [["a line", "TREATMENT", 15, 21], ["line", "OBSERVATION", 17, 21]]], ["Before the next operation can be written to a line, this line must be read and sent to execution.", [["the next operation", "TREATMENT", 7, 25], ["a line", "TREATMENT", 44, 50], ["this line", "TREATMENT", 52, 61]]], ["Hence, operation storage has FIFO semantics.", [["FIFO", "PROTEIN", 29, 33]]], ["Instructions which are mapped to the same FU are executed in the order they are decoded.", [["FU", "SIMPLE_CHEMICAL", 42, 44], ["FU", "DNA", 42, 44]]], ["In contrast, operands can be stored to the memory in any order using operation address and port.", [["operation", "TREATMENT", 69, 78], ["port", "TREATMENT", 91, 95]]], ["An operation can only be sent to execution when all its operands have been stored to the memory.Data SynchronizationThe Token Machine has an operation counter for F U 2 which is in sync with the operation write address of the operation memory.", [["An operation", "TREATMENT", 0, 12], ["an operation counter", "TREATMENT", 138, 158], ["the operation", "TREATMENT", 191, 204], ["operation", "OBSERVATION", 3, 12]]], ["Therefore, the token machine knows the operation address of OP 2 .", [["the operation", "TREATMENT", 35, 48]]], ["It sends FU address and operation address of OP 2 together with the result port specified in IN 1 to the target queue of F U 1 .", [["FU", "SIMPLE_CHEMICAL", 9, 11], ["F U 1", "GENE_OR_GENE_PRODUCT", 121, 126], ["the result port", "TREATMENT", 64, 79]]], ["They are removed simultaneously and sent via data interconnect to F U 2 where the data word is written to the memory location given by operation address and port.Data SynchronizationDecoding is blocked when the target queue is full or no free operation address is available.", [["F U 2", "DNA", 66, 71], ["port", "TREATMENT", 157, 161], ["free operation", "TREATMENT", 238, 252]]], ["As an operation is always sent before the target information pointing to this operation, it can be guaranteed that free space is always available in the operation memory when sending a data word.", [["this operation", "TREATMENT", 73, 87]]], ["Consequently, no acknowledgment signal is required from the receiver to the sender.Data SynchronizationSizes of result queues and numbers of lines in the operation memories are free parameters which still have to be optimized.", [["acknowledgment signal", "PROBLEM", 17, 38], ["lines in the operation memories", "TREATMENT", 141, 172], ["no", "UNCERTAINTY", 14, 16]]], ["The values assumed during code generation may be lower than those provided by hardware.Target ResolutionAfter the Token Machine has decoded an instruction and has assigned it to an FU, it must resolve the result reference and send this target information to the FU.", [["FU", "SIMPLE_CHEMICAL", 262, 264], ["hardware", "OBSERVATION", 78, 86]]], ["The required hardware components are illustrated in Fig. 7 .", [["hardware components", "TREATMENT", 13, 32], ["hardware", "OBSERVATION", 13, 21], ["Fig", "OBSERVATION_MODIFIER", 52, 55]]], ["The main component is the resolution memory.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["component", "OBSERVATION_MODIFIER", 9, 18], ["resolution memory", "OBSERVATION", 26, 43]]], ["It stores FU and operation addresses of the instructions which have been decoded last.", [["FU", "CHEMICAL", 10, 12], ["FU", "SIMPLE_CHEMICAL", 10, 12]]], ["Now assume instruction IN 1 has just been decoded and assigned to F U 1 with resolution address RES 1 .", [["RES", "CHEMICAL", 96, 99], ["F U 1", "DNA", 66, 71]]], ["Its instruction offset points to instruction IN 2 , which will be executed by F U 2 with resolution address RES 2 .", [["RES", "CHEMICAL", 108, 111]]], ["Port and offset are directly extracted from the instruction.", [["Port", "TREATMENT", 0, 4]]], ["Adding RES 1 to the offset yields RES 2 , which is stored in the unresolved target queue of F U 1 together with the port.Target ResolutionWhen IN 2 is decoded, its FU and operation addresses are stored to the resolution memory at address RES 2 .", [["RES", "CHEMICAL", 7, 10], ["RES", "CHEMICAL", 34, 37], ["RES", "CHEMICAL", 238, 241], ["F U 1", "GENE_OR_GENE_PRODUCT", 92, 97], ["the port", "TREATMENT", 112, 120], ["operation", "TREATMENT", 171, 180]]], ["At the same time, RES 2 is located at the front of the unresolved target queue.", [["RES", "CHEMICAL", 18, 21], ["RES 2", "GENE_OR_GENE_PRODUCT", 18, 23], ["target queue", "OBSERVATION", 66, 78]]], ["The circuit detects when FU and operation addresses of IN 2 are available and sends this information together with the port to the target queue of F U 2 .", [["IN 2", "GENE_OR_GENE_PRODUCT", 55, 59], ["F U 2", "GENE_OR_GENE_PRODUCT", 147, 152]]], ["This can be seen in Fig. 3 .", [["Fig", "OBSERVATION", 20, 23]]], ["If a nop would be inserted before the sub instruction, the operands of the subtraction would not be received. -The code must be free of deadlocks.", [["the subtraction", "TREATMENT", 71, 86]]], ["Both addition and comparison are executed on the same FU.", [["FU", "SIMPLE_CHEMICAL", 54, 56]]], ["Consequently, the result of the addition is placed at the front of the output queue, the result of the comparison behind it.", [["output queue", "OBSERVATION", 71, 83]]], ["However, the receiver of the addition result cannot be resolved because the branch has not been evaluated yet.", [["branch", "ANATOMY_MODIFIER", 76, 82]]], ["The branch in turn is waiting for the result of the comparison, which is blocked by the result of the addition.", [["branch", "OBSERVATION_MODIFIER", 4, 10]]], ["A simple solution for this deadlock is to change the order of addition and comparison.Instruction SchedulingThere are many more constellations causing deadlocks.", [["deadlocks", "DISEASE", 151, 160], ["deadlocks", "PATHOLOGICAL_FORMATION", 151, 160], ["A simple solution", "TREATMENT", 0, 17]]], ["They can be statically detected by building dependency graphs and searching for cycles in these graphs.", [["these graphs", "TEST", 90, 102]]], ["Theoretically, a dependency graph must be constructed for each possible execution path in a program.", [["a dependency graph", "PROBLEM", 15, 33]]], ["However, result references are limited to the current or the next loop iteration.", [["the next loop iteration", "TREATMENT", 57, 80]]], ["In practice, this problem is solved using a sliding window algorithm.", [["a sliding window algorithm", "TREATMENT", 42, 68]]], ["The window slides along the control flow of the method.", [["The window slides", "TREATMENT", 0, 17], ["the method", "TREATMENT", 44, 54]]], ["Afterwards, instructions which can be proven not to cause new deadlocks are removed from the window.", [["deadlocks", "CANCER", 62, 71], ["new deadlocks", "PROBLEM", 58, 71]]], ["When the algorithm detects that a window position has already been encountered, analysis of this path can be finished.", [["the algorithm", "TEST", 5, 18], ["a window position", "TREATMENT", 32, 49]]], ["While the problem still has exponential complexity, this algorithm finds all deadlocks in reasonable time even in methods with very complex control flow.Instruction SchedulingDifferent actions for removing deadlocks have been implemented.", [["removing deadlocks", "TREATMENT", 197, 215], ["exponential", "OBSERVATION_MODIFIER", 28, 39], ["complexity", "OBSERVATION_MODIFIER", 40, 50]]], ["In contrast to finding deadlocks, the problem of removing deadlocks has not been fully solved yet.", [["deadlocks", "CANCER", 58, 67], ["removing deadlocks", "TREATMENT", 49, 67]]], ["In hardware, forwarding is done by a separate FU, which helps to fulfill the mentioned constraints.Instruction SchedulingNo new dependencies are introduced if two instructions are executed on distinct FUs instead of on a single FU.", [["FU", "SIMPLE_CHEMICAL", 46, 48], ["hardware", "TREATMENT", 3, 11], ["hardware", "OBSERVATION", 3, 11]]], ["Consequently, exact assignment of operations to FUs is not required for deadlock analysis.", [["deadlock analysis", "TEST", 72, 89]]], ["It must only be guaranteed that certain categories of instructions will not be executed on the same FU.EvaluationThe benchmark set used for evaluation comprises 9 encryption algorithms, 7 hash algorithms, and 4 image filters.", [["FU", "SIMPLE_CHEMICAL", 100, 102], ["Evaluation", "TEST", 103, 113], ["evaluation", "TEST", 140, 150], ["4 image filters", "TREATMENT", 209, 224]]], ["Additionally, ADPCM encoding/decoding, JPEG encoding, and regular expression matching have been evaluated.", [["ADPCM", "PROTEIN", 14, 19], ["JPEG encoding", "TREATMENT", 39, 52], ["regular expression matching", "TREATMENT", 58, 85]]], ["FU timings of the existing hardware implementation are applied.", [["the existing hardware implementation", "TREATMENT", 14, 50], ["hardware", "OBSERVATION", 27, 35]]], ["Each benchmark has been executed once in the simulator for the Bytecode based AMIDAR processor and twice in the simulator for the new ISA.", [["the Bytecode based AMIDAR processor", "TREATMENT", 59, 94]]], ["For the new ISA, the following parameters have been chosen, which seem to be minimal values for reasonable execution.", [["minimal", "OBSERVATION_MODIFIER", 77, 84]]], ["The first exception is Contrast Filter, which uses floating point operations.", [["Contrast Filter", "TREATMENT", 23, 38], ["floating point operations", "TREATMENT", 51, 76], ["Contrast Filter", "OBSERVATION", 23, 38]]], ["As these operations are time consuming, speedup achieved by an improved ISA is lower.", [["lower", "OBSERVATION_MODIFIER", 79, 84]]], ["JPEG encode is a complex, data dominated algorithm, which is split across multiple methods.", [["JPEG", "DNA", 0, 4], ["split", "OBSERVATION_MODIFIER", 61, 66], ["multiple", "OBSERVATION_MODIFIER", 74, 82]]], ["RegExp is an example for control flow dominated algorithms with many method invocations.", [["many method invocations", "TREATMENT", 64, 87]]], ["It shows a speedup of 2.14.EvaluationThe main reason for high speedups is the reduced number of data transfers between FUs.", [["Evaluation", "TEST", 27, 37], ["high speedups", "PROBLEM", 57, 70]]], ["They are decreased by a factor of 2.98 in average as shown in Fig. 10 .", [["decreased", "OBSERVATION_MODIFIER", 9, 18]]], ["On the other hand, code size grows by a factor of 4.25 in average, which is caused by an increased size and number of instructions.EvaluationAll benchmarks require less than 10 s for code creation from class files, with the exception of SIMD512 (40 s) and RIPEMD160 (15 s).", [["an increased size", "PROBLEM", 86, 103], ["Evaluation", "TEST", 131, 141], ["size", "OBSERVATION_MODIFIER", 24, 28], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["size", "OBSERVATION_MODIFIER", 99, 103]]], ["In this benchmark set a substantial number of methods from the Java standard library has to be included in the binary file.", [["substantial", "OBSERVATION_MODIFIER", 24, 35], ["number", "OBSERVATION_MODIFIER", 36, 42]]], ["Measurement has been carried out on an Intel Core i7-6700 CPU with 16 GB RAM and a Java 1.8 HotSpot JVM on Ubuntu 16.04.Related WorkAMIDAR processors use principles from dataflow machines [4] .", [["Ubuntu", "TEST", 107, 113], ["WorkAMIDAR processors", "TREATMENT", 128, 149], ["dataflow machines", "TREATMENT", 170, 187]]], ["Thus, often a comparison is made with such processors.", [["such processors", "TREATMENT", 38, 53]]], ["In contrast to such machines, AMI-DAR avoids the known issues with typical dataflow machines [7] :Related Work-Broadcasting of tokens is done only for a handful of FUs.", [["AMI", "CHEMICAL", 30, 33], ["FUs", "CANCER", 164, 167], ["FUs", "PROTEIN", 164, 167], ["AMI", "PROBLEM", 30, 33]]], ["Thus, handling of tokens is not a problem. -In a dataflow machine, the availability of input data must be checked for a huge set of operations concurrently.", [["a dataflow machine", "TREATMENT", 47, 65], ["input data", "TEST", 87, 97], ["a huge set of operations", "TREATMENT", 118, 142]]], ["In AMIDAR, the availability of input data needs to be checked only localy inside of a functional unit.", [["AMIDAR", "PROTEIN", 3, 9], ["input data", "TEST", 31, 41]]], ["Thus, it can be implemented much more efficiently. -Dataflow machines can suffer from deadlocks, if the program is not composed in a proper way.", [["Dataflow machines", "TREATMENT", 52, 69]]], ["Such situations are not easy to detect and thus greatly complicate the compiler.Related WorkEven if dedicated dataflow processors are not longer researched due to the mentioned problems, dataflow is still used in scientific computing approaches.", [["dedicated dataflow processors", "TREATMENT", 100, 129]]], ["Maxeler uses a Java-like language to generate dataflow graphs and a compiler maps those graphs onto a set of field programmable gate arrays [2] .", [["a compiler maps", "TREATMENT", 66, 81], ["a set of field programmable gate arrays", "TREATMENT", 100, 139]]], ["The big drawback of this approach is its inability to execute regular code.", [["this approach", "TREATMENT", 20, 33]]], ["It is only efficient in high-throughput computing.Related WorkIn AMIDAR, FUs synchronize with each other by the exchange of data.", [["WorkIn AMIDAR", "PROTEIN", 58, 71], ["FUs", "DNA", 73, 76], ["efficient", "OBSERVATION_MODIFIER", 11, 20], ["high", "OBSERVATION_MODIFIER", 24, 28]]], ["In a similar manor, Transport Triggered Architectures (TTA) [1] use the transport of data to start new operations.", [["new operations", "TREATMENT", 99, 113]]], ["Nevertheless, AMIDAR provides more elasticity, since it allows arbitrary execution time for an FU without the need to adjust the microinstructions.", [["FU", "SIMPLE_CHEMICAL", 95, 97], ["AMIDAR", "PROTEIN", 14, 20], ["AMIDAR", "TREATMENT", 14, 20], ["an FU", "TREATMENT", 92, 97], ["the microinstructions", "TREATMENT", 125, 146]]], ["In contrast, TTAs require exact knowledge of the FU timing, since the result of an operation must be moved to its destination at the proper time.", [["FU", "SIMPLE_CHEMICAL", 49, 51], ["an operation", "TREATMENT", 80, 92], ["operation", "OBSERVATION", 83, 92]]], ["Even worse is the problem of the huge code memory of TTAs.", [["TTAs", "CANCER", 53, 57]]], ["In order to provide a high degree of parallelism, TTAs must be able to control as many independent data transports as possible.", [["TTAs", "SIMPLE_CHEMICAL", 50, 54], ["a high degree of parallelism", "PROBLEM", 20, 48], ["TTAs", "TREATMENT", 50, 54]]], ["Approaches have been published that reduce this memory size by means of compression [5] .", [["size", "OBSERVATION_MODIFIER", 55, 59], ["compression", "OBSERVATION", 72, 83]]], ["AMIDAR avoids the huge code memory in a different way by generating the token sets on the fly from a more abstract instruction set.Related WorkFinally, one could think about other instruction set architectures than Java Bytecode.", [["AMIDAR", "PROTEIN", 0, 6], ["huge", "OBSERVATION_MODIFIER", 18, 22], ["code memory", "OBSERVATION", 23, 34]]], ["Yet, it turns out that both come with severe drawbacks compared to the Java Bytecode.", [["severe drawbacks", "PROBLEM", 38, 54]]], ["Thus, the required type of operation (int, float, double) has to be reconstructed from the sources of the data.", [["operation", "TREATMENT", 27, 36]]], ["In the worst case, they need to be combined with type conversions at runtime.Conclusion and Future WorkIn this work, a promising novel ISA for AMIDAR processors has been presented.", [["AMIDAR processors", "TREATMENT", 143, 160]]], ["It borrows ideas from data flow architectures and in simulation shows significant speedups compared to Java Bytecode as ISA.", [["data flow architectures", "TEST", 22, 45], ["simulation", "TEST", 53, 63], ["significant speedups", "PROBLEM", 70, 90], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["speedups", "OBSERVATION", 82, 90]]], ["Only code size leaves room for improvement.", [["size", "OBSERVATION_MODIFIER", 10, 14]]]]}